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THE IMPACT OF IMPRECISION IN HCV VIRAL LOAD TEST RESULTS ON 
CLINICIANS’ THERAPEUTIC MANAGEMENT DECISIONS AND ON THE ECONOMIC 
VALUE OF THE TEST 
By Roberta Marie Madej, MS, MBA 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2013 
 
Major Director: William J. Korzun, Ph.D., Associate Professor 
Department of Clinical Laboratory Sciences 
 
 
 
     Clinical laboratory test results are integral to patient management.  Important aspects of 
laboratory tests’ contributions are the use of the test information and the role they have in 
facilitating efficient and effective use of healthcare resources.  Methods of measuring those 
contributions were examined using quantitative HCV RNA test results (HCV VL) in therapeutic 
management decisions as a model.  Test precision is important in those decisions; therefore, the 
clinical use was evaluated by studying the impact that knowledge of inherent assay imprecision 
had on clinicians’ decisions.  
     A survey describing a simulated patient at a decision point for HCV triple-combination 
therapy management was sent to 1491 hepatology clinicians. Participants saw HCV RNA results 
at five different levels and were asked to choose to: continue therapy, discontinue therapy, or 
repeat the test.  Test results were presented both with and without the 95% confidence intervals 
 (CIs).  Three of the VLs had CIs that overlapped the therapeutic decision level.  Participants saw 
both sets of results in random order. Demographics and practice preferences were also surveyed.  
     One-hundred-thirty-eight responses were received.  Adherence to clinical guidelines was 
demonstrated in self-reported behaviors and in most decisions. However, participants chose to 
repeat the test up to 37% of the time. The impact of the knowledge of assay imprecision did not 
have a statistically significant effect on clinicians’ decisions. 
     To determine economic value, an analytic decision-tree model was developed.  Transition 
probabilities, costs, and Quality of Life values were derived from published literature. Survey 
respondents’ decisions were used as model inputs. Across all HCV VL levels, the calculated test 
value was approximately $2600, with up to $17,000 in treatment-related cost savings per patient 
at higher HCV VLs.  The test value prevailed regardless of the presence or absence of CIs, and 
despite repeat testing. 
      The calculated value in cost savings/patient was up to 100 times the investment for HCV VL 
testing.  Laboratory tests are investments in efficient uses of healthcare resources.  Proper 
interpretation and use of their information is integral to that value.  This type of analysis can 
inform institutional decisions and higher level policy discussions.  
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Chapter One: Introduction  
 
 
 
     Clinical laboratory test results are integral to patient care and management. At times the 
information provided by test results is pivotal in the choice or evaluation of a clinical strategy.  
Laboratory results are also used in developing, implementing and measuring the outcomes of 
clinical practice and evidence based medicine.  Whether a clinician is screening individuals to 
determine disease risk, testing to inform diagnosis or prognosis, monitoring disease states, 
managing chronic health conditions, or individualizing therapeutic interventions, laboratory test 
information contributes to shaping the utilization of other medical services.  Laboratory test 
results are used in quality measures of healthcare, objective clinical outcome measures, pay-for-
performance measures, and as factual evidence in therapeutic clinical trials (The Lewin Group, 
2005, 2008).  While those who use laboratory test information may consider test results 
unconditionally robust, laboratory professionals understand that they are produced by assays, 
instruments, processes and people, all of which contribute to imprecision in that information. 
Clinicians and policy makers may not recognize the limitations of test results that can arise from 
the variability in the three phases of laboratory testing (pre-examination, examination and post-
examination phases). These limitations should be considered when interpreting the results. 
Furthermore, they may not appreciate the strategies laboratory professionals develop to mitigate 
test result variability.  Even for tests where little imprecision exists, research shows that 
laboratory test information is not always interpreted or used correctly. The concepts of disease 
probability are difficult, and management plans derived from test results may not be followed 
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optimally (Bramwell, West, & Salmon, 2006; Cahan, Gilon, Manor, & Paltiel, 2003; Gosh, 
Gosh, & Erwin, 2003; Steurer, Fischer, Bachmann. Koller & der Reit, 2002). This adds another 
facet to the quality and consistency of laboratory tests; the quality of the outcome of test 
information is dependent on the correct and optimal use of the results. 
     Conversely, laboratory professionals, whose customary focus are implementing the strategies 
to produce the most precise and accurate result, may not be aware of the broadest use of the test 
information by clinicians and policy makers.  Evaluations of clinical laboratory tests have 
traditionally centered on the analytical characteristics of assay methods.  The conventional 
laboratory test implementation plan includes verification or validation of sensitivity, specificity, 
precision, accuracy, reproducibility, and reportable range of the examination phase by best 
practice (Clinical and laboratory Standards Institute [CLSI] EP5A2, 2004; CLSI EP15A2, 2005) 
and in the United States, by law (Clinical Laboratory Improvement Act, 2003; Medical Device 
Quality Systems Regulation, 2008).  The adoption of broader quality systems practices now 
necessitate consideration of the pre and post examination phases as part of the total testing 
process (CLSI GP26A3, 2004).  In the fullest scope of practice, laboratory professionals are 
moving beyond the focused analytical evaluations to consider the applicability of the measurand 
to the disease process.  However, there is little formal work assessing how the information 
generated from laboratory testing is interpreted and incorporated into the medical decision-
making process.  This is becoming more necessary as the field of companion diagnostics grows, 
and constraints in healthcare resources demand that the most effective, informative and efficient 
services and interventions be used. 
     Medical providers have the responsibility to evaluate and employ those interventions and 
services that will provide the best outcome for their patients and for the healthcare system 
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(Huninck et al., 2006; Price & Christenson, 2007).  Clinical laboratory tests can be valuable tools 
in this effort, and are also subject to the same standard.  The ultimate value of a laboratory test is 
more completely determined by its informative impact in medical decisions.  The proper test 
must be ordered, and the information interpreted in context of the limitations of the tests and of 
the specific characteristics of the patient (Lundberg, 1998; Price & Christenson, 2007; Van 
Walraven & Naylor, 1998).  The analytical characteristics of the test, the implementation of the 
test, and the actual performance of the test, added to its interpretation and application by the 
medical decision maker, define the utility and value of the results. It is important then as part of 
an assessment of a laboratory test’s clinical utility, to understand the uses of that test’s 
information, particularly when those uses are integrated in clinical practice guidelines. 
     With the increasing scrutiny on the most effective use of healthcare resources, it is also 
important to understand the economic value that laboratory tests have in the healthcare system.  
In most cases, they are used as information to reduce the uncertainty in medical decisions.  
Growing demands on expanding technological choices and resources require prudent utilization 
of healthcare dollars, and provoke increasing demands for evidence-based information as well as 
for the evaluation of how that information is used (Drummond & Sculpher, 2006; Tunis, 2004).  
Health economics has been employed for nearly two decades in some countries for the selection, 
pricing and reimbursement of therapeutics, and it is now being applied to a broader scope of 
health care services and programs (Drummond & Sculpher, 2006).  In the United Kingdom, the 
National Health Service’s (NHS) National Institute for Clinical Excellence (NICE)  describes the 
process for evaluating healthcare technologies in three guidance documents:  Updated guide to 
the Methods of Technology Appraisals (NICE, 2008), Guide to Single Technology Appraisal 
Process (NICE, 2010) and Guide to the Multiple Technology Appraisal Process (NICE, 2010).  
 4 
 
Clinical effectiveness and cost effectiveness are aspects of the appraisals for those technologies 
approved by the NHS.  An important aspect of technology assessment in the United Kingdom 
now includes the projected financial impact on healthcare resources.  It is incumbent on the 
sponsor of a drug, intervention or device to demonstrate its cost effectiveness.  There are now 
various types of Health Technology Assessment (HTA) requirements, which include clinical and 
economic evaluations in over 30 countries.  A European collaborative project, the European 
Network for HTA (EUnetHTA) has been established in response to the need for developing a 
sustainable network to define and refine practices in this area (Minshall, 2008; Kristensen, 2008).  
The United States is also playing a role in these developments.  The Agency for Healthcare 
Research and Quality (AHRQ) is a partner organization to EUnetHTA and guidelines for 
submission of economic assessments of therapeutics are already established (Fry, Avery, & 
Sullivan, 2003).  As a part of the American Recovery and Reinvestment Act, the United States 
committed billions of dollars for comparative effectiveness research (CER), measuring costs and 
clinical utility of interventions, technologies, and services (Gaba, 2009).  As one of the 12 
agencies within the U.S. Department of Health and Human Services, the Agency for Health 
Research and Quality funds and disseminates comparative effectiveness and technology 
assessment research (http://www.ahrq.gov/about/). 
     Clinical laboratory testing, which has provided benchmark and experimental endpoint data to 
many health economic studies of therapeutics, devices and services, is now becoming the subject 
of these types of analyses; and its importance is growing.  For example, while concerned with 
providing broader access to the appropriate use of genetic test results, the Secretary’s Advisory 
Committee on Genetics Health and Society (SACGHS) made its first recommendation that 
evidence based information to drive coverage policies for that access (SACGHS, 2006). 
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Pharmacoeconomic experts criticize the lack of utility and value evidence for diagnostics 
(Ramsey et al., 2006).  Because non-laboratory clinical interventions are different from 
laboratory information services, it is essential that methods to evaluate the clinical and economic 
utility of laboratory tests be appropriate to in vitro diagnostics.  
HCV Viral Load Testing: A Model 
     The laboratory tests that drive the decisions for Hepatitis C disease management provide one 
model to examine the value of those tests in the decision-making process.  Hepatitis C viral load 
assays (HCV VL) quantitatively measure the amount of HCV RNA in patients’ plasma by 
nucleic acid testing (NAT), and the test results are a surrogate marker for the disease burden.  
HCV VL was integral to research on the natural history of the disease and is used in the clinical 
trials of therapeutics to treat it.  The test now has a role in determining the management path of 
HCV patients.  The American Association for Liver Diseases (AASLD) Clinical Practice 
guidelines and the American Gastroenterological Association recommend quantitative HCV 
RNA testing for viral load at several points during the diagnosis and management of the disease 
(Dienstag & McHutchinson, 2006; Ghany, Strader, Thomas, & Seeff , 2009; Ghany, Nelson, 
Strader, Thomas, & Seeff,  2011).  HCV Viral load is considered one of the main sources of 
information for tailoring therapy and monitoring compliance (Chevaliez & Pawlotsky, 2009; 
Mangia et al., 2008; Paxton, 2011; Terrault et al., 2005; Zeuzem et al., 2003).  The latest triple 
combination therapies for HCV genotype 1 patients include specific treatment recommendations 
based on absolute values of HCV VL (Ghany et al., 2011; Merck Sharp & Dohme Corporation, 
2011; Vertex Corporation, 2011).  Though HCV VL results are used as absolute values or 
relative value changes, there is little discussion of the inherent variability in viral load results 
except the published recommendations that patients be monitored with the same test throughout 
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their course.  Global proficiency test assessments and shared-sample studies have demonstrated 
the variability in NAT (Best, Gust, Johnson, McGavin, & Dax, 2000; Schirm, van Loon, 
Valentine-Thon, Klapper, Reid, & Cleator, 2002; Yen-Lieberman et al., 1996).  Practicing 
clinicians and laboratory professionals have published their observations regarding the variability 
of the assays and their possible impact on the decisions being made (Laperche et al., 2007, 
Pawlotsky, 1997).  There are few professionals who serve in both capacities, and as VL testing 
becomes more mainstream, clinicians’ understanding of this variability and its resulting impact 
on their decisions have not been studied. 
Statement of Problem 
     Conventional assessments of diagnostic tests are technically oriented and focus on the 
performance characteristics of the analytical process and technologies.  Diagnostic tests, 
however, are tools that produce information which is used in medical decisions.  As it informs a 
decision, there are two significant variables to the contribution of a diagnostic test: 1) the overall 
test performance and 2) the use of the information.  These are interdependent and contribute to 
the assessment of the utility and resulting value of a clinical laboratory test.  An example of this 
is found in HCV VL testing to determine and direct treatment strategies.  The test and methods 
have been technically validated and clinical trials support the basic utility of the results. 
Understanding the limitations, the use of the information resulting from these tests by clinicians, 
and the influence that knowledge of the limitations may have on their decisions have not been 
evaluated.  Additionally, the value that the test information brings to specific healthcare 
situations and, if this value changes with the quality of the test, have not been assessed.  
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Research Questions 
     Will knowledge of the imprecision in quantitative laboratory test results affect clinicians’ use 
of the information in managing patients?  Can this be measured? 
     Can health economic tools (decision analytic models) be used to determine the value of 
laboratory test information? 
     Will changes in the use of test information result in changes in the value of the laboratory 
test? 
Research Hypotheses and Objectives 
     This research studied the decisions made by clinicians using the viral load results from 
quantitative HCV RNA tests, with and without knowledge of the test imprecision (expressed as 
the 95% confidence intervals).  In addition to determining if there were changes in decisions 
associated with the knowledge, the value of the test information was calculated using a decision 
analytic model. The overall objective was to determine if the clinical utility (CU), measured as 
patient management decisions of clinicians using the results and the value of the laboratory test 
information measured by cost savings, will change if clinicians are aware of  the imprecision of 
the results. 
Null Hypotheses 
     The hypotheses for this research were:     
     H1 null hypothesis: The presentation of HCV VL results with 95% confidence intervals will 
have no impact on the treatment decision for HCV genotype 1 patients. 
     H2 null hypothesis.  There is no difference in the impact of awareness of CIs on the treatment 
decisions between different levels of HCV VL. 
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     H3 null hypothesis. Clinicians’ experience and demographics will have no impact on 
treatment decisions using HCV VL results presented with and without confidence intervals. 
The Value of Clinical Laboratory Test Information in Healthcare 
     In addition to testing the hypotheses, the impact of these decisions on the economic value of 
the test information was evaluated through the use of decision analytic model outcomes.  
Study Design 
     A non-experimental design using a survey targeted to a specific cohort of decision makers 
was employed.  The survey was developed for clinicians who use HCV VL test results in the 
management of their chronic HCV patients.  A defined clinical scenario was used describing a 
simulated HCV genotype 1 patient who had just completed 12 weeks of triple combination 
therapy with telaprevir, pegylated interferon-alpha and ribavirin. Different levels of quantitative 
HCV RNA results for the patient were presented to survey participants in the traditional manner, 
without confidence intervals, and also with the range of results that represent the 95% confidence 
intervals, which is an expression of the imprecision of the test.  The order of presentation of 
these two sets of results was randomized.  Participants were asked to decide whether to continue 
the patient onto double combination therapy, to discontinue therapy, or to repeat the test.  The 
distribution of responses was analyzed for differences in the likelihood of using the test 
information (not repeating the test) as well as differences in the ultimate therapy decision made 
by those who used the test result.  Further, the proportions of clinicians selecting each of the 
possible options were used to populate a decision analytic model of the case. Through the model, 
the expected value of the test results at each VL level and in a population of mixed VL levels, 
with and without corresponding confidence intervals was calculated.  
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Rationale for this Study 
      This research evaluated some of the interrelated factors in the provision and use of quality 
laboratory test results.  In order for laboratory test information to be effective, the result must be 
robust and it must be interpreted and used appropriately in the correct context.  As information 
providers, laboratory professionals make assumptions about the understanding and application of 
the information by the receivers of it without really knowing if those assumptions are accurate. 
This research examined whether the knowledge of the inherent imprecision of VL assays 
changes the decisions clinicians will make from those test results. There are recommendations to 
routinely report or make available on request the imprecision budgets with laboratory test results 
(CLSI C51A, 2011); yet there is no research to show that this addition would provide quality 
information to the clinician or to the patient. In addition, because the survey in this study was 
based on a well-defined clinical path where the use of the test is recommended to drive a specific 
treatment management decision, intended adherence to these guidelines was also evaluated. 
     The quality of a laboratory test result and its use in practice influences its value.  Current 
health economic publications use clinical pathways and decision analytic models, assuming that 
clinicians invariably make the most suitable patient management choice based on the information 
received. Research has shown that this presumption is simplistic (Bramwell et al., 2006; Steurer 
et al., 2002), and that the consequences of misinterpretation and misuse of test results are not 
well understood or appreciated (Gandhi et al., 2006).  Additionally, the actual use of information 
by clinicians, is rarely considered in health economic analyses.  
     In addition to patient diagnosis, prognosis, and medical management, the results of laboratory 
tests are inputs and endpoints in clinical trials and shape health economic assessment models; 
however, the value of the test information itself is not routinely measured or discussed.  When 
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economic analyses of laboratory tests are undertaken, tools commonly used such as cost-benefit, 
cost-effectiveness and cost-utility analyses may not fully define the true impact of the 
information.  Therefore, exploring the use of value calculations and clinical utility measures to 
evaluate the contributions of laboratory tests is important to the field of clinical laboratory 
science, health economics research, and healthcare resource assessment.  
     This study examined elements of the assumptions in current clinical research: the 
development of clinical decisions based on laboratory test information, compliance with 
guidelines in the face of test limitations, and the appropriateness of current methodologies to 
study laboratory test contributions to healthcare.  The objective is that the outcome of this work 
provides insight, strategies, and tools specific to the assessment of laboratory test information’s 
utility and value. If successful, these tools could be applied to other value analyses of laboratory 
tests in diverse healthcare situations. 
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Clinical Laboratory Testing in Healthcare 
     Clinical laboratory testing is pervasive in most aspects of healthcare.  Approximately 6.8 
billion laboratory tests are performed annually in the United States. Over 4,000 different tests are 
available for clinical use, and approximately 500 of the over 1,162 tests reimbursed by Medicare 
are performed on a regular basis.  In addition to being used as indicators of wellness, disease and 
patient treatment management, the results from testing are used in public health surveillance, in 
clinical trials, and in research. (The Lewin Group, 2008.) 
     Laboratory testing contributes to health management decisions from birth.  Approximately 
four million newborns are screened by tests for congenital and metabolic disorders annually 
(Little & Lewis, 2008).  For the 5,000 infants with severe disorders, more specific testing, and 
for some, life-long monitoring by laboratory tests will follow.  Adults are accustomed to periodic 
screening tests such as cholesterol, fasting blood glucose, fecal occult blood, urinalysis, 
Papanicolaou (Pap) testing and prostate specific antigen (PSA) tests.  Not only are test results 
incorporated into specific guidelines (America Diabetes Association [ADA], 2010; Nelson, 
Moser, Gaffey, & Waldron, 2009), but a majority of adults expect and desire these as part of 
their routine physical examinations (Oboler, Prochazka, Gonzales, Xu, & Anderson, 2002). 
     Advancements in treatment modalities, technological progress, and easy access to rapidly 
disseminated research information have facilitated the implementation of a growing number of 
new applications for medical laboratory testing.  A relevant example of this is the establishment 
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of molecular tests to direct, monitor and manage patients with serious viral infections such as 
human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV).  
The role of quantitative molecular assays for viral load testing has been the subject of 
investigation and debate in several viral diseases since technological improvements made this 
type of measurement feasible and more robust.  The precision and reproducibility of these tests 
continues to be discussed, particularly as they are integral to therapeutic management decisions 
(Chevaliez & Pawlotsky, 2009; Pisani et al., 2009). 
     Nucleic acid quantification for viral load was first applied in AIDS research to estimate the 
extent of HIV infection by measuring the number of RNA genome copies in the plasma (Ho, 
1996).  As molecular techniques were further refined, greater understanding of the pathogenicity 
of the virus, disease prognosis, and treatment success indicators developed (Mellors et al., 1996).  
Viral load measurements became surrogate markers of disease clearance in therapeutic trials; and 
the data gathered from those trials were applied to patient management guidelines when the 
agents were approved for therapy.  Quantitative HIV RNA testing used with CD4+ counts for 
therapy initiation and serial quantitative HIV RNA tests for monitoring viral load during therapy 
are now part of standard practice in the management of AIDS (Hammer et al., 2008).  Similar 
strategies have been applied to other viral diseases and several quantitative molecular assays 
have become integrated into patient management protocols. Examples include quantitative HBV 
DNA with genotyping assays which are integral to the selection of appropriate therapeutic 
regimens for hepatitis patients (Valsamakis, 2007).  Quantitative HCV RNA tests are used to 
monitor patients on therapy, detect drug resistance, and follow patient compliance (Ghany et al., 
2009; Paxton, 2011).  Further, human cytomegalovirus (HCMV) viral load results distinguish 
between viral disease and organ rejection in transplant patients, facilitating the appropriate 
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choice between conflicting management strategies (Griffiths, Whitley, Snydman, Singh, & 
Boeckh, 2008). 
     The adoption of molecular viral load markers is one example of similar scenarios utilizing test 
results as evidence in clinical practice guideline development and in patient management 
decisions.  The expanding recognition of companion diagnostics and the utilization of laboratory 
test results in all aspects of healthcare present the medical community with the challenge of 
determining their most effective and efficient applications.  Consequently, when evaluating new 
laboratory tests, investigations of clinical utility and economic value will become as necessary as 
assessing analytical performance and clinical outcomes (Ramsey et al., 2006).  
Clinical Utility: How Clinicians Use and Value Laboratory Test Information 
     Today the comprehensive assessment of necessary medical services includes an evaluation of 
clinical utility.  The term clinical utility is used throughout healthcare but remains subjectively 
interpreted.  First appearing in medical literature in 1961, its use has increased steadily, though a 
single consensus definition has not been developed (Smart, 2006).  The characterization of 
clinical utility often reflects the perspective of the stakeholder; and the outcomes measured 
delineate the scope.  For a laboratory test, clinical utility encompasses more than just the ability 
of the result to define a clinical state or disease.  It is a multidimensional parameter in which the 
stakeholders are patients, clinicians, and others in healthcare.  Evidence that a test result 
facilitates improved patient outcomes or that it is useful to those making medical decisions have 
been offered as definitions (The Lewin Group, 2009).  Broader descriptions include economic 
and social outcomes (Grosse & Khoury, 2006).  
     A search of the term clinical utility in the medical literature identified several common 
attributes synonymous with clinical effectiveness.  From the clinician’s perspective, four main 
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characteristics are considered: appropriateness, acceptability, practicability and accessibility.  For 
a service or an intervention to be appropriate, clinical evidence should demonstrate its impact on 
treatment and its importance to clinical decision making.  To be acceptable, the effect on a 
patient’s course, quality of life, and on the clinician’s practice, are considered.  The training and 
knowledge needed to implement the service and to maintain the functionality of using it are 
characteristics of practicability.  Accessibility incorporates availability, costs, cost effectiveness 
and resources (Smart, 2006).   
     For laboratory tests, characteristics of appropriateness and acceptability, as defined here, are 
normally assessed when new tests are established.  By regulation, manufacturers who sell in vitro 
diagnostic tests in the United States must submit data supporting the safety and effectiveness of 
their tests, either by showing substantial equivalence to pre-existing tests or demonstrating it 
through studies.  The intended use of the test in question, the relative risk of the test and its 
placement in the healthcare system all impact the type of submission and the data needed to 
support it (USFDA 21CFR807, 21CRF814, 21CFR860).  This is accomplished through clinical 
trials, where the new tests are validated analytically and evaluated according to clinical 
outcomes, or compared to other tests for which clinical outcomes have been established. 
Depending on the test and the scientific environment, intended use statements, clinical and 
professional guidelines, and marketing or post-market studies may incorporate the medical 
decisions to be made and the impact the test may have on patient care.  Less well studied are the 
practicability and accessibility characteristics of clinical utility, those that incorporate clinician 
behaviors and economic effectiveness.  
     Clinicians are the gatekeepers to medical care and are the predominant prescribers and users 
of laboratory tests. It is appropriate then, to evaluate clinical utility from their perspective. 
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Clinicians interpret and utilize laboratory test results as one of their criteria in tailoring available 
treatment strategies to the medical and quality-of-life needs of their patients.  The clinical utility 
of a laboratory test depends on the clinician’s ability to prescribe it appropriately and to use the 
information derived from it effectively and correctly.  This in turn depends on their 
understanding of the clinical information provided by the test and the limitations of the method. 
These are elements of the practicability aspect of clinical utility. 
     There is some published research regarding clinicians’ understanding and use of diagnostic 
information, but less on the specific subject of laboratory test information interpretation and use. 
Because laboratory test results inform varied clinical states and stages, it is difficult to generalize 
the depth and breadth of understanding needed to apply them with only a few studies.  Some test 
applications are a one-to-one correlation of result and disease state, while others demand a 
working knowledge of probability and risk, and still others require interpretation along a 
quantitative continuum.  What has been demonstrated, though, is that many clinicians have 
difficulty with the practical applications of the concepts used to fully apply diagnostic 
information.  Some examples follow. 
     Fifty practitioners in Australia completed self-assessment questionnaires where they rated 
their ability to understand and describe evidence-based medicine terms such as relative risk, 
absolute risk, sensitivity, specificity and positive predictive value (PPV).  For each of the terms, 
there were only 14-30% positive responses to the question of whether they could understand and 
explain the term to others.  In post-survey assessment interviews where the same physicians were 
asked to explain the terms, only three of the practitioners met some of description criteria: two 
partially explained the term, numbers needed to treat (NNT), and one satisfactorily explained 
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sensitivity. This study illustrated the practitioners’ difficulty with the terms and also their 
inability to realistically assess their shortcomings (Young, Glasziou, & Ward, 2002). 
     In another study, researchers in Switzerland surveyed 263 general practice physicians to 
evaluate which types of additional test information would most effectively aid physicians’ in 
correctly determining the probability of a patient having a disease. Their study also gave insight 
to physicians’ ability to practically apply sensitivity and predictive values (Streurer et al., 2002).  
They designed a two-part survey, the first part consisting of multiple choice selections of 
definitions for sensitivity and PPV.  In addition to answering the multiple choice questions, 
subjects were asked to calculate the probability of disease in a patient with a positive test. They 
were given the test characteristics of 95% sensitivity, 95% specificity, a population prevalence of 
1%, and a range of choices for answers.  Though 76% and 61% of the physicians chose the 
correct definitions for sensitivity and PPV, respectively, only 22% made the correct selection of 
less than or equal to 25% for the probability of disease in the presence of a positive test result 
(56% selected the choice of “nearly 100 %”).  On first examination, the results seem more 
encouraging than the Australian group’s findings, even with a large proportion of subjects 
selecting the grossly wrong PPV of near 100%.  However, there are key differences.  In this 
study, the participants were given a choice of definitions, as opposed to having their own 
definition scored against expected terms.  Also, answers for the probability calculation were split 
into ranges and presented as selections.  The large difference in percent correct for the definitions 
versus the percent correct for the PPV calculation illustrates a deficit in the ability to apply the 
information, even though the definitions could be memorized or reasoned. 
     In the second part of the survey, the participants were asked to estimate the probability of 
endometrial cancer in a 65 year old woman with abnormal uterine bleeding and were given 10% 
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as the prevalence of endometrial cancer in women with abnormal bleeding.  The original group 
was split into three sub groups and each third received the results of a positive transvaginal 
ultrasound test in a different manner.  One sub group received only the result (“pathological 
result compatible with cancer”).  The second group received the result plus the sensitivity and 
specificity of the test; and the third received the result plus simple wording of the likelihood ratio 
of a positive test: “A positive test is obtained twice as frequently in women with an endometrial 
cancer than in those without the disease.”  In this phase of the study, the group that had only the 
positive test result grossly overestimated the probability of disease; those given numerical values 
for sensitivity and specificity gave a significantly lower estimate; and those for whom the test 
characteristics were described in simple words, gave an estimate of likelihood closest to that 
found in literature based groups.  However, in a later analysis of the data, it was determined that 
the “simplified language” approach may have provided an opportunity to incorrectly apply a 
mathematical calculation that coincidently resulted in a number close to the correct one.  In the 
amended analysis, it was still concluded that the added quantitative information regarding the 
test characteristics moderated the physicians’ tendencies to overestimate the probability of 
disease (group one vs. group two plus group three).  However, the comparison between the type 
of information provided, or comparing group three alone with group one in a stricter analysis 
were no longer statistically significant (Bachmann, Steurer, & ter Reit, 2003).  The impact to the 
patient of overestimating or underestimating the probability of disease is specific to each clinical 
case and was not addressed by this study.  It does raise the question of clinicians’ expectations of 
the diagnostic utility of tests and the possibility that prejudicial expectations could lead to the 
incorrect application of the information. Inaccurate high expectations of utility can lead to 
inappropriate overuse of tests. 
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     Of concern is that physicians’ over-estimation of the pre-test probabilities of medical 
conditions in their patients could lead to improper test usage and bias of interpretations test 
results in support of the original assessments.  To understand clinicians’ ability to ration the 
probabilities of possible clinical conditions for a single patient, physicians and residents in 
another study were presented with a patient scenario and five possible clinical conditions for the 
symptomology and evidence.  They were asked to estimate the probabilities of each condition for 
the patient in the scenario.  Of the 84 physicians tested, 65% of them determined probabilities for 
each condition such that the total exceeded 100% (Cahan et al., 2003).  This finding is not 
uncommon.  Misapplying pre-test probabilities and baseline risks, as well as incorrect PPV 
calculations were recurrent findings in several other studies on this topic (Bramwell et al., 2006; 
Ghosh & Ghosh, 2004; Heller, Sandars, Patterson & McElduff, 2004).   
     The research discussed thus far focuses on qualitative tests, pre-and post-test probabilities and 
analysis of patient risk.  There are few studies focused on the topic of the impact that clinicians’ 
awareness of quantitative test imprecision will have on their decisions. A rare number of clinical 
guidelines exist that specify the use of tests with defined criteria for precision, such as those for 
cholesterol in lipid management and troponin in the assessment of cardiac arrest (National 
Cholesterol Education Program Laboratory Standardization Panel, 1988; Thygessen et al., 2012).  
Clinical specialists and physicians associated with laboratory practice have published their 
observations of test variability, examining analytical and biological sources; discussed the 
possible impacts, and have made recommendations for mitigation in laboratory practice, but not 
in medical practice (Fraser, 2003; Plebani, 2004).  One example is an examination of the 
variability of creatinine measurements on the calculations of estimated glomerular filtration rate 
(eGFR) and the impact it has on the classification of renal disease (Klee, Schryver, Saenger, & 
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Larsen, 2007).  Consecutive blood samples from patients were used to analyze the within-subject 
variance of creatinine testing, and mathematical simulation was used to create scenarios of 
different creatinine levels with varied levels of imprecision.  It was determined that a 20 µmol/L 
negative shift in creatinine nearly doubled the percentage of patients classified as having 
decreased renal function, and the same positive shift nearly halved the percent.  
Recommendations for stringent control of the laboratory methods were made, but there was no 
mention of the need to understand or mitigate the influence of the variation on physicians’ 
interpretations. In addition there was no recommendation to assess what physicians’ actual 
interpretation would be for results very near the decision breakpoints. 
     Observations of imprecision in molecular viral load assays have led some practicing 
specialists to question patient monitoring results and recommend further comparative studies 
(Pawlotsky, 1997).   However, no studies such as those described previously, addressing 
practicing clinicians’ understanding of pre and post-test probability, PPV and likelihood ratios, 
or their understanding of the variation in the quantitative test results could be found in the 
literature, nor were they recommended by any of the researchers. 
    The clinical laboratory and regulatory communities have recognized the importance of the 
variability surrounding quantitative results and the possible implication this could have on the 
clinical utility of laboratory tests.  This is most evident in the International Standards 
Organization’s (ISO) requirements for determining and reporting the uncertainty for test methods 
in the 2012 standards for quality and competence in medical laboratories, and in guidelines 
developed to help laboratories provide this information (ISO, 2012 ; CLSI C51A, 2011). Studies 
of clinicians’ understanding and application of these potentially confusing issues are necessary.  
 20 
 
The provision of such information, along with quantitative results and reference ranges, could 
impact the clinical utility of current and future laboratory tests. 
     Optimal use of laboratory tests depends intrinsically on physicians’ abilities to correctly apply 
the information derived from them in practice.  This requires that they understand more than the 
results, the reference ranges, and the diagnostic conditions supported, but also the limitations of 
the test producing the results, and the robustness of that result in the context of clinical practice. 
When developing tests, calibrating the result with clinical outcomes may provide correct answers 
and have analytic value, making the test appropriate and acceptable; but it may not have 
complete clinical utility as used in routine practice. Studies measuring clinicians’ interpretation, 
understanding, and use of quantitative information (i.e., the practicability aspect of clinical 
utility) are necessary.  
Health Economics and the Assessment of Value 
     Growing demands for healthcare resources, escalating utilization and expanding technology 
options, require judicious allocation of those resources.  Choosing appropriate services and 
interventions amid technology abundance and resource constraints is difficult.  Yet physicians in 
their role as gatekeepers to healthcare services, must consider the most efficient and effective use 
of interventions and tools.  Policy leaders also need clear, concise, and commutable data to 
inform their debates and decisions as they determine standard practice protocols and 
reimbursement strategies.  To evaluate laboratory tests in this environment, the accessibility 
aspect of clinical utility must be considered in addition to analytical and clinical performance 
characteristics. This includes how the test augments or replaces conventional practices, the costs 
to the system, the benefits generated, and the resources needed to maintain the testing services.  
Laboratory tests are vehicles that provide information to reduce uncertainty in medical decisions. 
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New tests can be categorized as those that provide completely new information (as in a new 
analyte), refine existing diagnostic information, or provide similar information to what is 
available through the use of new technology.  When evaluating the accessibility of a test, the 
information provided by the test as well as the resources needed to establish, maintain and 
effectively utilize the results from the test should be considered. 
     Evaluating the accessibility of a health care intervention or service includes demonstrating its 
value to the system in communicable terms.  Led by the Australians in the 1990s, several 
countries have adopted a range of methods in the field of health economics (HE) to substantiate 
the utilization and reimbursement of therapeutics (Drummond & Sculpher, 2006).  These 
methods are now incorporated into more expansive Health Technology Assessments (HTA) and 
are being applied to a broader scope of health care services and programs. HTA covers an 
expanded analysis of health technologies using the information from technical and clinical cost-
effectiveness research and evidence based medicine (EBM) to evaluate where to place the 
technology relative to current practice and resources.  In a global survey by the HTA principles 
working group of the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR), the term is defined as “the careful evaluation of a medical or health technology for 
evidence of its safety, efficacy, cost, cost-effectiveness and ethical and legal implications, both in 
absolute terms and in comparison with other competing technologies.” (Stephens, Handke, & 
Doshi, 2010).  
     In the United Kingdom, the National Health Service’s (NHS) National Institute for Clinical 
Excellence (NICE) lays out the process for evaluating healthcare technologies in three guidance 
documents:  Updated Guide to the Methods of Technology Appraisals (NICE, 2008), Guide to 
Single Technology Appraisal Process (NICE, 2010) and Guide to the Multiple Technology 
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Appraisal Process (NICE, 2010).  Clinical effectiveness and cost effectiveness are key parts of 
the submissions for approval by the NHS. The assessment includes the projected financial impact 
of the new technology on national healthcare resources.  It is incumbent on the sponsor of a drug, 
intervention or device to demonstrate its cost effectiveness.  Over 30 countries now employ some 
type of HTA.  The majority of stated purposes for these HTAs are for coverage decisions and 
clinical guidance.  Though the evaluation of costs is unpopular in many jurisdictions, a little over 
half of HTAs formally include cost and cost effectiveness (Stephens et al., 2010). 
     In response to the rapid adoption of HTA, a European collaborative project, the European 
Network for HTA (EUnetHTA) was established to develop a sustainable network defining and 
refining practices in this area (Kristensen, 2008; Minshall, 2008).  Though HTAs vary among 
countries and even within countries, guiding principles to improve their conduct have been 
published by key experts in the field.  The principles cover the structure of HTAs, the methods 
used, the processes for conduct, and the use of the HTA in healthcare decisions.  The common 
threads in all the principles are: defining specificity in purpose, equal application to all health 
care goods and services and establishing processes for maintaining objectivity and transparency 
(Drummond et al., 2008). 
     The United States is active in the global debate and in forming its own policies.  The Agency 
for Healthcare Research and Quality (AHRQ) is a partner organization in EUnetHTA.  As a part 
of the American Recovery and Reinvestment Act, the United States committed billions of dollars 
for comparative effectiveness research (CER), measuring costs and clinical utility of 
interventions, technologies, and services (Gaba, 2009).  As one of the 12 agencies within the 
U.S. Department of Health and Human Services, the Agency for Health Research and Quality 
(AHRQ) funds and disseminates comparative effectiveness and technology assessment research 
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(http://www.ahrq.gov/about/).  The importance of these evaluations is growing and discussions 
continue to develop the structure, methods, and metrics of these programs (Avron, 2009; Garber 
& Tunis, 2009; Naik & Petersen, 2009).  CER and HTAs are included in coverage with evidence 
development (CED) programs that are used by the Centers for Medicare and Medicaid Services 
(CMS) and large insurers for coverage and reimbursement decisions (Drummond et al., 2008). 
With respect to testing, the Secretary’s Advisory Committee on Genetics Health and Society 
(SACGHS), while concerned with providing broader access to the appropriate use of genetic test 
results, listed as its first recommendation that evidence-based information drive coverage 
policies to ensure access (SACGHS, 2006).  Since guidelines for the submission of economic 
assessments for therapeutics have already been established (Fry et al., 2003), health economists 
criticize the lack of utility and value evidence for diagnostics and recommend the same standards 
be applied to this field (Drummond et al., 2008; Ramsey et al., 2006).  
    New discoveries and rapid dispersion of information provide more options in a field of limited 
resources.  It is important then to assess the impact of applying economic methods developed for 
pharmaceutical interventions on valuing diagnostic tests.  These tools have not been used to 
appraise laboratory tests in the past, so there are few specific guidelines with which to compare 
the clinical and economic value of new tests and technologies.  Pharmaceuticals are 
interventions; their delivery, function and outcomes are essentially different from laboratory 
tests, which supply information.  From a laboratory test, there is usually an indirect and 
interdependent path leading to the final patient outcome.  The laboratory test result must be 
recognized, understood, and used correctly in an intervention decision.  The medical intervention 
must then be applied (or not) to the patient, and must work as predicted to produce the intended 
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outcome.  It is essential to understand how current health economic methods can be suitably 
applied to isolate the value of the laboratory test in this complex relationship. 
Economic Assessments in Healthcare 
     Three elemental types of economic analyses permeate the literature for the appraisal of 
therapeutics and interventions and are now being applied to evaluate laboratory tests: Cost-
benefit analyses (CBA), Cost-effectiveness analyses (CEA), and a specific type of CEA: Cost-
utility analyses (CUA) (Bloom, 2004; Neumann, Greenberg, Olchanski, Stone, & Rosen, 2005; 
Tunis, 2004).  These assessments can provide information for decision making, but like 
diagnostic tests in patient management, they should not be the sole source of the decision.  The 
elements of CBA, CEA and CUA are categorized in Table 1. Further detail is described in the 
following sections.  
Table 1 
 
Types of Health Economic Analyses 
 
Type of 
Analysis 
What is it 
asking? 
Identification 
of Outcomes 
Costs  Benefits Report Considerations 
Cost Benefit 
Analysis 
(CBA) 
What is the 
added cost 
for an added 
benefit? 
Single or 
multiple 
outcomes. 
Monetary  Monetary  Benefit 
/Cost 
ratio 
or NPV 
Determine 
monetary value 
of intangibles 
 
 
Cost 
Effectiveness 
Analysis 
(CEA) 
 
What is the 
cost per unit 
of outcome?  
 
Single and 
common 
outcome. 
Varying 
degrees. 
 
Monetary  
 
Natural 
units 
 
Cost / 
natural 
unit 
selected 
 
Determine the 
threshold value 
of the natural 
units 
 
Cost Utility 
Analysis 
(CUA) 
 
What is the 
cost per 
desired unit 
of outcome? 
 
Single or 
multiple 
outcomes. 
Varying 
degrees. 
 
Monetary  
 
Value:  
combination 
of quant and 
qual of life 
 
Cost/ 
QALY 
or 
DALY 
 
Threshold 
values for cost 
per QALY/ 
DALY 
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     Cost-benefit analysis.  In CBA all the costs and the benefits from the programs being 
evaluated are converted to monetary terms.  This method is employed in situations where market 
indicators are not useful or they are non-existent (such as health care policy); and where 
decisions must be made on projected future benefits.  An investment can be considered favorable 
if the money derived from benefits exceeds that of the costs.  Many times this is expressed as a 
ratio between the discounted net benefits (B) over the discounted net costs (C); if the benefit to 
cost ratio (BCR) is greater than one, a test or medical intervention has value (Folland, Goodman, 
& Stano, 1997).  In theory, this statement is simple. However in reality, determining all costs, 
sourcing appropriate data for them, and quantifying the benefits in monetary terms from the 
proper perspective are challenges. 
     In CBA for clinical laboratory diagnostics, the costs include more than just the reagents and 
personnel, or as often presented in pharmacoeconomic studies, the list price or reimbursement 
price of the tests.  The perspective of the analysis is an important issue in all health economic 
studies; in CBA this will determine the inputs used. If the study perspective for a CBA is at the 
institutional level, the costs to the institution beyond the clinical laboratory service, as well as the 
benefits gained by the whole institution are quantified.  For example, if analyzing the 
introduction of a new test from the sole perspective of the laboratory, reagents, personnel, 
training, and comparisons to the charges for sending the test to reference labs might be made.  
The opportunity costs of using the space and resources for other laboratory tests might also be 
considered.  But when assessing the impact at the institutional level, inputs to the costs and the 
benefits extend beyond the horizon of the laboratory and parameters such as patient length-of-
stay, patient level of service, or physician utilization would be considered. CBA can be useful in 
different scenarios such as decisions whether or not to order a test, methodology comparisons, 
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and testing site comparisons (main laboratory vs. satellite or point-of-care service).  The direct 
and indirect costs and benefits, and opportunity costs are relatively tangible and straightforward 
to measure in these narrowly focused CBAs. 
     Challenges emerge when clinical laboratory tests are discussed in the realm of total health 
care services and where competing, non-test intervention options might exist.  For example, 
policy makers may compare the option of implementing a laboratory test or a different method of 
diagnosis to direct patients to specific types of care; or compare the implementation of a test-
and-treat strategy to population vaccination for an infectious disease.  In these situations, the 
societal perspective is used; the scope is broadened and other types of costs, unfamiliar to 
clinical laboratory professionals must be considered. In addition to capturing a broader scope of 
direct and indirect costs and benefits, some may be intangible, requiring a transformation to 
monetary value.  This can be particularly challenging when intangibles, such as the value of a 
service or the value of a life, must be determined.  Methods to derive the willingness to pay can 
be used for services, and several methods to estimate the value of an individual life are 
continually assessed and calibrated (Johansson, 2003; Messonnier & Meltzer, 2003). 
     CBA for diagnostic testing should carry further considerations based on the performance 
characteristics of the tests.  Many past economic analyses of clinical programs assume that 
testing is 100% correct.  This may be appropriate when the test information is a small part of a 
very large and complex study and its role is minimal.  In more recent studies, where diagnostics 
are the central focus of the analysis, or the test information is pivotal in determining or assessing 
patient outcomes, the test performance characteristics play a key role in assessing the BCR.   
Costs associated with false negative and with false positive results must be added to the 
equations.  
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     CBA facilitates the comparison of different types of programs because it strips them down to 
monetary measures, and when the net present value (NPV) of the BCR is calculated, CBA can 
provide data to compare options with different time horizons.  When deciding to implement 
laboratory tests or programs surrounding the implementation of tests, when confronted with a 
choice between different options, or when ranking priorities within a set budget, CBA can be 
useful.  Distilling options down to identical monetary units is in contrast to the other two 
common tools used in health economics, Cost-effective analysis and Cost-utility analysis, where 
the options compared are presented in terms of costs per unit of health outcome (Messonnier & 
Meltzer, 2003). 
     Cost-effectiveness analysis.  Cost-effectiveness analyses systematically consider alternative 
approaches to an issue by comparing the costs and the consequences of each approach as they 
impact an appropriately selected health-related outcome unit.  What distinguishes CEA is that the 
outcomes of all the alternatives are measured in the same unit and must be relevant to the clinical 
objective (Berger, Bingefors, Hedblom, Pashos, & Torrance, 2003).  Examples are life-years, 
symptom free-days, and cases prevented. These are described as “natural units” (Drummond & 
Sculpher, 2006). Compared to CBA, which assesses programs with different objectives (and 
perhaps different outcomes); CEA evaluates programs with different approaches to the same 
objective.  The costs to obtain that objective are compared.  Therefore, a single, measurable, 
natural-unit outcome must be selected (Fos & Fine 2003). 
     CEAs are growing in popularity and are becoming the predominant method for evaluating the 
costs and effects of alternative strategies in health care (Messonnier & Meltzer, 2003).  The 
programs and interventions being compared can be ranked, or several interventions can be 
studied, each for their incremental cost effectiveness. The perspective in CEA is usually from a 
 28 
 
patient or public health view; and in CEA this perspective determines the outcomes measured. 
When a laboratory test is being evaluated, the impact that the test has on extending patients’ 
lives, averting disease, or changing a specific state of health of patients is considered.  The 
challenge for laboratory testing is to demonstrate the direct impact of the test on the patient state. 
An example of this is a new or more sensitive marker that informs the definitive treatment of 
patients, such as a marker for stroke or acute myocardial infarction.  By using the new marker, 
the number of appropriately treated cases may increase.  For this example, calculating the 
positive or negative balance of all the costs and consequences, as in CBA, may not be useful.  A 
cost-effectiveness ratio (CER), the cost per life saved or the cost per complication averted, more 
appropriately conveys the value of the outcome.  When compared against the standard test, or no 
test at all, an Incremental Cost Effectiveness Ratio (ICER) can be calculated illustrating the 
incremental cost per life saved (or other natural outcome) of the program under consideration. 
An issue for interpretation is assessing whether the value of the CER or the ICER is acceptable. 
Few countries and jurisdictions have established thresholds for cost effectiveness.  
     Cost-utility analysis.  Because CEA expresses costs per a specific biological unit, 
interventions with different natural outcomes cannot be compared.  In addition, there can be a 
range of interpretations that decision makers may have regarding the comparative value of the 
outcomes (e.g. determining the relative priority of blood pressure control compared to 
cholesterol management or to a year of life).  A further refinement in CEA is the Cost-utility 
analysis. In CUA, the benefits or outcomes are expressed in parameters that account for quality 
as well as the quantity of the benefit in Quality Adjusted Life Years (QALY) or Disability 
Adjusted Life Years (DALY).  QALYs are measures of mortality and the quality of life. The 
quality of life is measured on a scale from 0 (death) to 1 (full health) and the time gained in the 
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CEA is adjusted by the quality weight depending on the state of health (Gold et al., 1996 p. 88). 
The QALY has become a standard currency in health economic evaluations. QALYs are most 
useful when evaluating individual benefits in longer term outcomes.  The values for QALYs 
encompass the preferences of individuals for specific states of health, and they can be 
determined in several ways.  The important characteristic of these methods is that preference 
weights are not subjectively assigned but are determined through individual surveys and are 
published for use by researchers.  
     Less often used is the DALY.  A DALY is defined as one year of healthy life lost due to death 
or disability from the disease or condition in question.  It is the sum of the years of life lost 
(YLL) and the years of life with a disability (YLD) and thus, incorporates the time lost to death 
at each age, disability weights, age weights and time preference (Fos & Fine, 2005).  DALYs 
provide a relative scale to compare different diseases and conditions, both physical and mental. 
Since DALYs are calculated from a theoretical maximum life span, that maximum must be 
carefully ascertained. For every subject studied, an individual life span should be calculated 
based on health and risk factors for each (minus the condition in question).  Because this is 
impractical, actuarial data for specific populations are utilized. This makes the DALY a gross 
measurement at best and comparable among studies only when all the conditions used in the 
DALY calculation are transparent and pertinent.  In addition to actuarial-determined life spans, 
the quality of life ratings are assigned by health professionals, not the individuals suffering with 
the disability.  For these reasons, the DALY is considered less relevant. 
     CUA facilitates the comparison of programs producing different outcomes, as each is 
translated into directly comparable QALYs or DALYs.  For example, if policy makers are 
deciding whether to institute a community smoking cessation or weight loss program, outcomes 
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from a CUA would be presented as the cost per QALY for each option.  For laboratory services, 
a clinic might utilize CUA to decide between establishing a point-of-care cholesterol or a 
prothrombin-time testing service for their outpatient community.  The question being addressed 
by CUA does not necessarily have to be a direct comparison of one or more options.  Some 
jurisdictions have explicit or implicit values for the reasonable cost of a QALY or DALY.  In 
those cases, if the analysis of a single option results in the cost/QALY less than the threshold, the 
program can be considered economically viable. 
     An example of interpreting the relevance of a CER derived from a CUA is in an analysis of 
Chlamydia trachomatis testing performed in The Netherlands. The impact of a systematic 
screening-treatment program that included partner treatment for young Dutch adults was 
evaluated for its impact on preventing the serious sequelae associated with the infection, pelvic 
inflammatory disease (PID) and sterility (de Vries, van Bergen, de Jong-van den Berg, & 
Postma, 2006). The calculated CER was €373 per major outcome averted (MOA).  The only 
benchmark available in The Netherlands at the time was a threshold of €20,000 /life-year gained 
or QALY.  In order to discuss the comparative relevance of their numbers, the researchers 
applied recently published quality adjusted weights from the United States to each of the disease 
states into their mathematical model to convert the events averted into QALYs.  By this method, 
the calculated overall cost was €1000 per QALY.  Since this was far below the policy threshold, 
they concluded that the program was cost effective.  
     Decision analysis and mathematical models.  Health economic evaluations are commonly 
performed by constructing and populating mathematical models.  The models may extrapolate 
data from clinical trials, or extract data from several sources including literature and public 
records.  As models, they cannot duplicate life situations, so this limits applicability to the 
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assumptions made in building them.  However, it can also be argued, that randomized clinical 
trials, considered the gold standard scientific in evidence gathering, also can have limitations in 
scope and applicability.  In clinical trials, well-controlled patient selection criteria, strict 
operational management, and finite timelines, result in a representative sample and conditions 
that may not necessarily be generalize able to an entire population for a longer horizon. 
Mathematical models can incorporate the results from several trials, meta-analyses of 
publications, and numerous databases and can represent many scenarios.  The assumptions in 
models, though limited, are transparent, and the impact of key assumptions can be tested in 
sensitivity analyses.  Neither represents the total solution in healthcare policy analysis. Both 
should be used alone or in combination, with knowledge of the limitations and as appropriate for 
the situation analyzed (Cohen & Reynolds, 2008; Lang, Lopert, & Hill, 2003; Weinstein et al., 
2001).  
     A framework for these analyses that is useful to health economics is decision analysis. Prior 
to use in healthcare, analytic modeling had demonstrated its utility in situations when investment 
choices had to be made in uncertain situations and the major downstream decisions and 
outcomes were considerations in the decision (Gallant, Kieffel, & Chatwin, 1997; Weinstein et 
al., 2001).  Designing models for decision analysis gives structure to the question and the 
options, demands evidence, provides a format to evaluate uncertainty and variability within the 
assumptions, and can reveal a path to future research (Drummond, Sculpher, Torrance, O’Brien, 
& Stoddart, 2005).  The nature of this discipline is a systematic approach to outline and quantify 
the options in decisions to be made under conditions of uncertainty (Goldie & Corso, 2003; Scott 
& Rafferty, 2007).  A primary purpose of diagnostic testing is to provide information that 
reduces uncertainty in healthcare decisions; in some situations, a single diagnostic test can be 
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placed directly in the clinical decision path. In these cases, decision analytic modeling could be 
used to quantify the role of that test.  Decision analysis can be particularly useful in healthcare 
because the expected value of different strategies can be compared after recording the relevant 
events with their probabilities and associated costs.  When enough information exists, the 
modeling can be performed before resources are invested in long term trials. In 
pharmacoeconomics, decision modeling, first described for use in healthcare in 1980 (Fineberg, 
1980; Weinstein & Fineberg, 1980) has become useful for analyzing data from many sources to 
better inform decisions in actual practice (Sanchez & Lee, 2000).  The elements of a simple 
analytic decision model are shown in Figure 1.  The first point in the tree is the decision node, 
represented by the square.  A decision informed by a laboratory test will stratify the patients to 
different management schemes based on the results of the test.  The next point of dispersion is 
the chance node (filled circle) that illustrates which of the several events beyond the control of 
the decision maker may occur.  There may be several different branches; but, symmetry around 
each node is not required.  The branches represent the natural sequence of consequent events, 
and each must be mutually exclusive.  Collectively they must exhaust all possibilities.  Two are 
shown in the figure for simplicity.  The probabilities of each of these chance events are recorded 
along the branches.  The final nodes are the terminal nodes which represent the end of each 
sequence along with the outcome of the events (life years/ QALYS/ length of stay).  Value is 
assigned to the outcomes.  The expected value of each branch can be compared by calculating 
from right to left, multiplying the probabilities by the cost of the outcomes for each decision 
alternative.  
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Figure 1. Example of a simple decision tree analytic model. This example describes a laboratory 
test informing patient management strategy (adapted from Weinstein & Fineberg, 1980). 
      
     The purpose of decision analytic modeling, according to an International Society for 
Pharmacoeconomics Outcomes Research (ISPOR) guideline, is to “structure evidence on clinical 
and economic outcomes in a form that can help to inform decisions about clinical practices and 
health-care resource allocations” (Weinstein et al., 2003).  It is important that models are not 
mistaken for truth but instead used as tools to facilitate information gathering for disciplined 
analyses. Because a model has the ability to reveal logical connections between inputs and 
outputs in the form of valued consequences and costs, the model should be transparent and 
follow commonly accepted practice guidelines (Weinstein et al. 2001; Weinstein et al., 2003).   
     Technological advancements expand the options in healthcare services, and increase the 
utility of analytic modeling to inform research, clinical practice and policy decisions.  Placing a 
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laboratory test in the clinical decision path and illustrating its impact on succeeding events, may 
be particularly suitable for the evaluation of pharmacogenomics and companion diagnostics, 
where test information is the gating item that guides therapy choices.  The value of making the 
therapeutic decision with and without the test information can be calculated.  An example is in 
the management of warfarin therapy, where genetic variants in metabolic enzymes have been 
associated with variations in the efficacy of the drug.   
     Researchers evaluating the use of genetic test information to modify doses of warfarin therapy 
have used decision modeling and cost effectiveness in their assessments.  In one such study, 
You, Chan, Wong and Cheng (2004) employed decision analytic modeling to assess the cost-
benefit of pharmacogenomics-oriented management of warfarin dosing.  Their goal was to 
evaluate the potential clinical and economic outcomes of using CYP2C9 genotype data for 
patients receiving anticoagulant therapy.  Patients with CYP2C9 polymorphisms are associated 
with reduced warfarin dosing requirements and higher risk of a major bleeding event from 
warfarin overdosing during the first three months of therapy. Using CYP2C9 polymorphism 
prevalence, event rates, and cost data from clinical trials and provider data, they constructed a 
decision tree to simulate the events of two theoretical cohorts initiating warfarin therapy: one 
with genotyping data prior to the institution of therapy and one without genotyping.  Patients 
with at least one CYP2C9 variant (in the genotyped group) received intensified anticoagulation 
service while those without the significant polymorphisms and those not genotyped received 
standard care.  Through the model outputs, it was determined that major bleeding events would 
be averted in the genotyped group; however, the total costs of care for this group would also be 
greater.  The incremental cost of averting a bleeding event was $5778 per event. Using the CER 
benchmark of less than $50,000 per QALY as a goal (from Panel on Cost Effectiveness in Health 
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in Medicine), they converted their outcomes to this measure by estimating one month of illness 
at a utility score of 0.39 for events averted, resulting in 0.05 QALY.  For those patients who 
hypothetically averted death from a major bleed, they conservatively estimated a life expectancy 
of one year and calculated one QALY.  To be cost effective by the benchmark, they calculated 
that the genotyping scheme would have to show a gain of greater than 0.1 QALY per event 
averted ($5778/ $50,000); their results were between 0.05 and 1 QALY.  One of the difficulties 
in the interpretation of this study is the projected infrequency of bleeding events.  Though 
potentially devastating, the number of events in these patients was small, approximately eight per 
100 patient years.  This is weighed against the risk of delaying therapy (to wait for genotyping) 
and risking stroke; approximately two events per 100 patient years.  Another issue is the 12-
month time horizon of the model, appraising an intervention that is most useful in the initial 
three months.  Specific to testing, a third challenge is measuring the impact of the laboratory test 
using conventional health economic tools.  It is hard to prove that the test alone has a direct 
effect on the patient outcome.  As in this study, the test result can lead to a more expensive 
health management path.  However, the CUA and the information from this model are useful. 
Since the infrequency of the bleeding events is prohibitive to the trials needed to prospectively 
demonstrate the utility of the intervention, recommendations for more focused clinical trials can 
be made.  In this case, limiting prospective clinical trials to the induction period of three months 
and examining the costs of the intensified anticoagulation service, perhaps as standard of care, 
could be pursued.    
     Analytic models can also be used to understand how best to focus technology investments to 
optimize patient outcome. Meyers et al. (2000) utilized a Markov model for the analysis of cost 
effectiveness of specific improvements in tests for cervical cancer screening.  Figure 2 illustrates 
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a simple Markov model; an analytic tool used to represent disease progression states and events 
that recur over a specified period of time (Lang et al., 2003).  In Figure 2, each mutually 
exclusive health state is in a circle, and the transitions between each of the states are represented 
by arrows (state transitions).  The probabilities of moving from one state to another or staying in 
the same health state are assigned. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Example of a simple Markov model (adapted from Goldie & Corso, 2003). 
 
     In the Meyers study, researchers were able to provide insight into the marginal cost of 
performance specification improvements for new cervical cancer screening tests.  Using the 
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they increased levels of sensitivity in the hypothetical test, they only altered the specificity by 
making it equal or poorer than the base case, assuming that a new technology would increase 
sensitivity at the expense of maintaining or decreasing specificity.  They also examined different 
screening frequencies of the new versus hypothetical test.  Improved sensitivity led to 
substantially greater costs than the health benefits obtained, mainly due to the magnified number 
of low grade lesions with the consequent increased resources needed to evaluate them.  Findings 
such as these can help policy makers focus on the attributes that new technologies should present 
as they assess them. They can also influence the direction of future development of new tests.  
New screening tests for cervical cancer might only be viable if, in addition to sensitivity 
improvements, specificity is also improved or if the downstream procedures for evaluating all 
patients with positive test results became less expensive.  
     The optimal placement of a new test among conventional tests for hereditary 
hemochromatosis (HH) has been studied through analytic modeling in Canada (Gagne, Reihnarz, 
Laflamme, Adams, & Rousseau, 2007).  Researchers built a modular simulation program to 
generate a virtual population of one million people with demographic, genetic and phenotypic 
characteristics specific for HH.  They used this “population” to evaluate all screening algorithms 
that were practically possible using the available biochemical and genetic tests.  In addition, they 
altered the population by varying HFE gene frequencies and penetrance.  Using their model they 
were able to analyze the outcomes of 165 different screening algorithms in 91 different virtual 
populations.  Among the top cost-effective strategies for most permutations of prevalence and 
penetrance was a combination of conventional biochemical tests: unbound iron-binding capacity 
plus transferrin saturation.  The genetic test was optimally cost-effective as a confirmatory test. 
Additionally, analysis of population screening was also performed and was shown not to be cost-
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effective when only hepatic complications were considered.  This analytic model can be 
continually refined and used to provide insight on several research and policy questions 
regarding effective HH management.  
     For viral molecular tests, economic studies have focused on screening strategies for blood 
borne viruses such as HIV, HCV and HBV.  In blood-donor screening, HE analyses have 
forecasted costs of up to $11.2 million per QALY using the combination of HCV, HIV and HBV 
NAT tests to avert infection and subsequent disease in blood-product recipients.  Despite the 
high cost /QALY, the outcomes have not influenced policy makers to recommend against their 
adoption.  However, the information has helped support the discontinuance of other non-essential 
or repetitive tests, such as anti-hepatitis B core and p24 antigen testing (Jackson, Busch, Stramer, 
& AuBuchon, 2003).   
     For individual diagnosis and patient management of these viral diseases, there is a paucity of 
health economic literature.  Most work has focused on assessing the cost effectiveness of 
screening populations for the early detection and early intervention of HCV disease.  The United 
Kingdom’s National Health Service (NHS) published an HTA report on the cost effectiveness of 
actively screening former injecting drug users (IDUs) for HCV.  They built a decision analytic 
model to evaluate the impact of case-finding (a proactive search of a targeted population) and 
treatment on a hypothetical cohort of 1000 IDUs.  They compared the targeted, screened and 
treated cohort to one that spontaneously presented for testing.  Clinical and epidemiological 
experts were used to inform the structure of the model and parameter estimates were populated 
through literature and electronic database searches.  Their model consisted of a simple decision 
tree for the testing schemes, with a Markov model for the treatment and outcomes.  The model 
ran for the life of the cohort cases; all entered at 37 years of age.  For each 1,000 subjects in the 
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case-finding cohort, three cases of decompensated cirrhosis, three deaths (from HCV disease), 
and one case of hepatocellular carcinoma were averted.  One liver transplant for each 10,000 
cases would also be averted.  Twenty-five more subjects in the case-finding cohort than in the 
spontaneous testing cohort would be prescribed combination therapy.  In terms of cost-utility, 
£16,514 per QALY would be invested, below the £30,000 per QALY benchmark used by NHS 
policy makers.  Though it resulted in higher absolute costs, £760,000 due to targeting, testing 
and treatment resources, the case-finding strategy in this scenario was within the acceptable NHS 
criteria (Castelnuovo et al., 2006).  This type of study is used by NHS commissioners to adopt 
strategies, set policy or design further research. 
     An Italian group evaluated the cost effectiveness of screening in IDUs and patients who 
received major and minor surgery (potential exposure risk) for the Veneto region, using the 
demographic and public health records from this population of 4,750,000.  They hypothesized 
that the socioeconomic burden of disease could be reduced by screening and early intervention in 
asymptomatic, at-risk groups.  They further stratified the analysis by HCV genotype, which 
impacts treatment success.  Both IDU and surgery patients’ analyses were very sensitive to the 
prevalence of the more difficult to treat genotypes 1 and 4.  However, only the IDU population 
screening was shown to be below the cost per QALY threshold of €30,000.  Screening IDUs 
actually had a negative cost per QALY in those with genotypes 1 and 4 (€ -5.14).  For cases with 
genotypes 2 and 3, the cost per QALY was €9,659.  In the surgery patients, all costs per QALY 
were far above the threshold: €699,991 for genotypes 1and 4 and €2,324,471 for genotypes 2 and 
3 (Tramarin et al, 2008).  These outcomes could reflect the relative risks of these two 
populations.  The surgery patients were not limited to only those that would receive blood 
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products.  Even so, the adoption of HCV screening of blood products has significantly reduced 
the risk of infection for recipients. 
     The type of population, the risk of developing disease, and the prevalence of disease have 
been important modifiers in other studies.  The results of an analysis in France showed that 
screening for HCV was the dominant (more-cost effective) strategy only in IDUs, when that 
group, transfusion patients, and the general population were compared (Loubiere, Rotily, & 
Moatti, 2003).  An earlier US study using the prevalence of the 3.8% for the general population, 
also found that screening the average risk group in a relatively low prevalence setting was not 
cost effective as a general health policy (Singer & Younossi, 2001). 
     These examples illustrate some of the opportunities and difficulties in applying traditional 
economic analyses to studying the cost effectiveness of laboratory tests.  Diagnostics are usually 
a new cost, unless one is replacing another.  Understanding how to structure an analysis in 
specific populations with differing prevalence rates, or states of health and with different test 
performance characteristics is challenging. 
     Another way to consider the value of diagnostic tests is to regard the costs of laboratory tests 
as investments in information which will reduce uncertainty in specific medical decisions. 
Directing resources and investments towards developing and refining tests that provide the most 
clinically valuable information could result from these analyses.  Value of information (VOI) 
analytical tools are becoming useful in clinical trial design to identify and evaluate the benefit of 
proposed additional research. Reducing uncertainty and the calculated clinical and economic 
value of that reduction are instructive in determining clinical trial strategy (Yokota & Thompson, 
2004).  Laboratory tests provide information which reduces uncertainty in health and patient 
management.  In this regard, VOI might be applied to ascertain the value of diagnostic tests.   
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     This idea is not new.  In 1988, Phelps and Mushlin suggested methods to calculate the 
Expected Value of Diagnostic Information (EVDI) and the Expected Value of Clinical 
Information (EVCI) using CUA and decision analytic models as the analytical foundation.  The 
probabilities of a patient being sick or well, and being treated or not in each of those states, with 
and without the diagnostic information to guide the treatment decisions, were illustrated in 
models that look very much like current analytical decision trees.  While the publication was a 
theoretical description, it presented several principles.  The most important was the view that 
diagnostic tests are information and their value should be measured in that regard.  The base case 
analysis is then a specific clinical path without the diagnostic information, and it is compared to 
the clinical path utilizing the test results.  The importance of understanding that diagnostic tests 
do not deliver perfect information and the costs and consequences of choosing the “incorrect 
path” based on that imperfect information were also described.  Several applications for this type 
of analysis were proposed, including determining the range of disease probabilities over which 
devices may be used, and comparing one device against another without the expense of 
randomized controlled trials. 
     Methods calculating VOI have rarely been applied to analyses of laboratory tests.  Recent 
work to determine the value of epidermal growth factor receptor (EGFR) in non-small-cell lung 
cancer (NSCLC) second-line treatment with (EGFR) tyrosine kinase inhibitors (TKI’s) illustrates 
some of the challenges in measuring the value of laboratory testing and provides one use of VOI 
(Carlson, Garrison, Ramsey, & Veenstra, 2009).  Two different test methods, a protein 
expression and a gene copy number test were evaluated.  Sensitivity analyses of the model 
revealed that effectiveness was most sensitive to changes in disease-progression free and overall 
survival states.  The CUA of pathways with and without the test results demonstrated that the 
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pathway without the testing was more “cost-effective” up to a threshold of $150,000 cost per 
QALY, after which, the gene copy number test was more cost effective.  Testing for EGFR by 
gene copy number produced an added three weeks quality-adjusted life expectancy and a 1.4 
month overall survival difference at the cost of $9200.  (Test costs were $320; most of the 
additional costs were treatment costs associated with extended survival). The ICER of adding the 
test, and the outcomes associated with the testing was $162,000. It is not surprising that a test 
providing information that extends life by only a few weeks would produce a costly outcome. In 
addition to the CE analyses, the Expected Value of Perfect Information (EVPI) at a threshold of 
$US 100,000/ QALY was calculated.  Over a five-year period, the EVPI was $31.4 million, 
representing the upper bound of opportunity costs that the added test information would 
contribute in appropriately triaging patients during that time.  Currently, there is no agreed upon 
benchmark for information investment; therefore, the EVPI merely supports recommendations 
for further study into the role of this test, particularly if the efficacy of the treatment is improved. 
     The expense of NSCL cancer treatment, the increased response of those testing positive for 
EGFR, and the necessity of selecting only those patients that could respond provided a rationale 
to demonstrate the clinical and economic utility for a test to select these patients.  However, the 
benefit of the intervention in the population was marginal, and the benefit added further health 
care costs to the economic outcome.  Calculating the EVPI, however, demonstrated the value 
that the information itself could impart in the clinical scenario.  While investing in healthcare 
costs and services, is it worth investing up to $31.4 million over five years to decrease the 
uncertainty with which patients are chosen for this therapy?  Though there are no policy 
thresholds at this time, it is conceivable that clinicians and patients might be able to use this type 
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of information at the individual level or a cost per test basis if there was enough research around 
the VOI parameter.  
     The EGFR study calculated the VOI assuming the results derived from the tests were always 
correct; therefore, the value calculated was the upper limit of any contribution by the test. 
Combining more realistic technical characteristics of tests with the VOI derived from them, is 
the basis of a synthesis of analytical tools proposed in “ROTS analysis” (Laking, Lord, & 
Fischer, 2006).  ROTS analysis combines two linear schools of thought: the ROC or Receiver –
Operator Curve analysts and the VOI analysts. This multidimensional model links changing test 
thresholds and the cost-effectiveness of different interventions.  Within the stated changing 
parameters, ROTS analysis provides a method to answer questions regarding the justification for 
doing a test, a test’s optimum operating point, and comparison to competing tests or 
methodologies.  However, the graphical representation and interpretation in ROTS may be 
beyond the current scope of CE discussions, particularly since the current HE methods were not 
specifically optimized to analyze laboratory tests.  A subset of the conclusions in ROTS could be 
obtained by appropriate sensitivity analyses of more standard CE evaluations, though ROTS 
provides more interpolation and dimension.  ROTS seems to be optimized for qualitative results, 
utilizing sensitivity and specificity as principle parameters.  The results of quantitative tests 
would have to be translated into clinical sensitivity and specificity for the intended outcome, if 
the method were to be employed to assess quantitative results. 
     Among the methods surveyed, cost-benefit and cost-effective analyses are being applied to 
diagnostic testing, and used by policy makers and academics.  Laboratory professionals utilize 
CB to justify new tests, methods, or instruments for their particular organization, but usually do 
not initiate more strategic CEA and CUA analyses.  Conversely, health economists rarely 
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represent the performance characteristics of diagnostic tests in their analytical models.  For 
laboratory professionals, the reasons may be that the analyses are too complex, require too much 
input, or have received too little exposure.  Because of discreet institutional budgets, the 
relevance of developing CE models for health policy may have little perceived relevance to the 
operations of clinical laboratories.  For academics and health economists, including test 
performance characteristics and their subsequent impact on the clinical pathways modeled may 
be too complex, or may be considered trivial in the scheme of the larger analyses.  Most of the 
examples of HE analyses for laboratory tests in the research discussed here have been focused on 
diagnostics with a yes/ no result of disease states carrying different probabilities, which is only 
one use of laboratory test results. There is no work examining the value impact of the variation in 
quantitative tests which are used to monitor and adjust clinical therapies.  Viral disease 
management depends on quantitative viral load test information for triaging patients to the 
proper therapy, for monitoring patients on therapy, and for determining clearance of the virus. 
For HCV, where a change in quantitative test results can catalyze an alteration in therapy, it is 
relevant to examine the clinical and economic value of those results and the impact that 
imprecision has on the decisions made by them. 
Hepatitis C and Viral Load Testing 
     Hepatitis C imposes a major disease burden on the world (Sy & Jamal, 2006).  The global 
prevalence of HCV has been estimated by WHO to be approximately 3%, affecting 170 million 
people (http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index3.html ).  This is 
considered an underestimate due to reporting inefficiencies, underreporting, and the fact that 
many of the rates are derived from disease prevalence in the blood donor population. Depending 
on the country and area surveyed, the prevalence of HCV can range from below 1% to above 
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20%. In the United States, underreporting and asymptomatic infections add to the recording 
challenges. Approximately 3.2 million people in the US have chronic HCV 
(http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm#section1).  The National Institutes of Health 
project 35,000 new cases per year and cautions that since most chronic infections have not yet 
been diagnosed, a fourfold increase in the number of infected adults is predicted from 1990 to 
2015 (NIH, 2002). 
     HCV is the leading cause of liver transplantation in the United States, one of the principal 
causes of cirrhosis, and a common cause of hepatocellular carcinoma.  It is the primary reason 
for death from liver disease in the United States.  Between 1999 and 2007, HCV related deaths 
outpaced HIV and HBV related deaths and accounted for approximately 4.58 deaths per 100,000 
persons per year (Ly et al., 2012). With an estimated prevalence of at least 1.8%, HCV is the 
most common chronic blood-borne infection in the United States (NIH, 2002).  
     The virus, transmission and course of disease.  The hepatitis C virus is a small enveloped 
RNA virus constituting its own genus within the Flaviviridae family (Op De Beeck & 
Dubuisson, 2003).  There are six genotypes of HCV, each having implications on viral 
persistence and patient management (Simmonds et al., 2005).  Genotype 1 is predominant in the 
US, accounting for 70– 75% of all HCV infections. It is also associated with a lower response to 
current treatment regimens (NIH, 2002). 
    HCV is transmitted primarily through contact with infected blood or blood products.  This is 
the main source of infection in several countries.  In the US, the blood supply has been routinely 
tested for HCV antibody since 1992.  For those who received transfusions, blood products or 
organ transplants prior to 1992 the risk is high. Since then, the risk from this source has been 
minimized and injection drug users currently have the highest risk.  Other possible sources of 
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infection include exposure to an infected sexual partner, perinatal exposure, and occupational 
exposure to infected blood by healthcare workers (Ghany et al., 2009; & NIH, 2002; Sy et al., 
2006). 
     Many individuals infected with HCV remain symptomless.  For those that do develop clinical 
symptoms, the incubation period ranges from 15-150 days.  Approximately 15-25% of infected 
individuals will spontaneously clear the virus.  The remaining 75-85% will maintain chronic 
infections.  These individuals are at risk for further, serious sequelae.  Approximately 60-70% of 
those chronically infected will develop chronic liver disease.  Of these, 5-10% are expected to 
develop cirrhosis and 1-5% will die from the consequences of the cirrhosis which includes 
hepatocellular carcinoma (Ghany et al., 2009; Seeff, 1999).  A review of several natural history 
studies in the 1990s concluded that approximately 20% of infected individuals progress to 
cirrhosis, fibrosis and serious end-stage liver disease.  The serious consequences of HCV 
infection usually manifest after approximately 20 years (Seeff, 1999).  Figure 3 provides an 
illustration of HCV disease pathways. 
     Treatment and patient management.  Because the symptoms of HCV infection can be 
inconspicuous while the virus remains transmissible, diagnosis is important. In addition, because 
the disease manifests slowly, early diagnosis provides a window of opportunity to intervene and 
prevent the more serious consequences associated with progression.  For genotypes 2-6, the most 
common treatment strategies for chronic HCV infection employ combinations of long-acting 
pegylated interferon-alpha, and ribavirin (Ghany et al., 2009; Sulkowski, 2008).  While there are 
several treatment protocols approved by the US Food and Drug Administration (FDA), the 
strategy that has demonstrated the highest rates of sustained viral response (SVR) and is the  
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Figure 3. The natural course of HCV infection. Adapted from Seeff, 1999; Ghany et al., 2009; 
and CDC.gov 2012. 
 
current standard of care, is a combination of peginterferon-alpha administered in weekly 
subcutaneous injections with daily oral ribavirin (Ghany et al., 2009).  Besides the treatment 
inconvenience, the side effects of this combination therapy are not trivial.  The management of 
the side effects is particularly frustrating for non-symptomatic individuals diagnosed with HCV.  
Adverse effects include profound fatigue, headache and other pain, neutropenia, 
thrombocytopenia, hypothyroidism and hyperthyroidism, visual disturbances, nausea, fever, 
depression, irritability, suicidal tendencies, and cognitive impairment.  Other complaints include 
insomnia, inability to exercise, and the loss of motivation.  The addition of concomitant 
medications and interventions to manage these adverse events impact patients’ quality of life and 
productivity (Ghany et al., 2009; Hopwood, Treloar, & Redsull, 2006).  
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     In 2011, a new class of therapeutics was added to the dual therapy for the treatment of HCV 
genotype 1, the most common and difficult to treat of the HCV viruses in the US.  The use of one 
of the protease inhibitors, telaprevir (Incivek ™) or boceprevir (Victrelis™), with the dual 
combination therapy, increases the  response rate, but rates of anemia are also increased and 
hemoglobin levels must be monitored closely (Ghany et al., 2011; Merck Sharp & Dohme 
Corporation, 2011; Vertex Corporation, 2011).  There are several other therapeutics for HCV in 
development and for which HCV VL measurements will be critical in the assessment of their 
success (Cox, 2013). 
     Adverse events and inconvenience can also impact patients’ compliance to therapy.  Because 
of the associated debilitating events and the observation that not all infections are eliminated by 
therapeutics, a goal of many clinical research studies has been to find the most effective and 
shortest regimen.  HCV viral load (VL) testing has played a key role in these studies; and as 
therapeutic strategies are individualized to patients, VL testing utilization will increase.  Current 
treatment protocols require administration of therapy for a minimum of 12 weeks up to 72 
weeks, depending on viral genotype, and the HCV VL test results at specified intervals during 
the treatment.  The goal is to treat the patient aggressively, but humanely, to eradicate the virus.  
Through research, opportunities to remove patients from further therapeutic discomfort when VL 
results indicate therapy is not effective have been identified (Chevaliez & Pawlotsky, 2009; 
Ghany et al., 2009; Ghany et al., 2011). 
     Chronic HCV disease management and laboratory testing.  Laboratory testing is 
integrated into all phases of hepatitis C patient care: diagnosis, therapy selection and 
management, and the determination of failure or sustained cure.  Patients are usually first 
diagnosed by means of positive HCV antibody tests that are confirmed by qualitative or 
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quantitative (viral load) HCV RNA tests.  Serum aminotranferase levels and liver biopsy 
histology help establish the severity of the disease and any sequelae present.  Quantitative HCV 
RNA and HCV genotype tests along with biopsy results and patient data are used to plan the 
most appropriate and potentially effective treatment strategy (Chevaliez & Pawlotsky 2009; 
Ghany et al., 2009; Ghany et al., 2011; Sulkowski, 2008).  A newer biomarker, IL28B has been 
added to the testing menu.  Knowledge of mutations in this gene provides a probability of 
successful response for therapies using interferon in HCV genotype 1 infected patients.  
However, HCV VL reduction and clearance are still the definitive targets. (Ge et al., 2009; 
Sharifi & Alavian, 2011).  
     The goal of therapy is to avoid the future complications of HCV, which can only be achieved 
with certainty if the virus is eradicated.  The most powerful predictor of treatment response and 
the definitive indicator of treatment outcome is HCV VL.  When treatment begins, a viral load 
determination is made.  Depending on the genotype, the severity of liver disease, the likelihood 
of a sustainable response to treatment, the probability of adverse events, and the presence of 
comorbid conditions, the length of treatment is individualized.  The key information for 
adjusting the length of treatment is the succeeding HCV VL results.  The best evidence of the 
eradication of the virus is provided by quantitative HCV RNA nucleic acid testing (NAT) of 
patients’ blood throughout the course of therapy and continuing after therapy (Ghany et al., 
2009; Sulkowski, 2008).  
     The American Association for the Study of Liver Diseases (AASLD) publishes data-
supported recommendations for the diagnosis, treatment, and management of patients with 
hepatitis C disease.  In the newly revised guidelines for HCV genotype 1, the predominant 
genotype in the United States and the most refractive to therapy, clinicians are recommended to 
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initiate their treatment-naïve HCV patients with one of the new protease inhibitors plus the 
standard dual combination therapy.  After the initial treatment period using the three 
therapeutics, quantitative HCV RNA testing is performed to determine the viral load.  If the 
HCV RNA level is not below a specified number (100 IU/ml for boceprevir or 1000 IU/ml for 
telaprevir) therapy can be discontinued (Ghany et.al, 2011).  Clinical studies have demonstrated 
that there is virtually no probability of a sustained viral response (SVR) for patients that do not 
achieve this milestone (Chevaliez & Pawlotsky 2009; Ghany et al., 2011, Terrault et al., 2005; 
Zeuzem et al., 2003).  For patients where the initial phase of therapy has been successful, 
treatment should continue with interferon-alpha and ribavirin for 12 to 36 additional weeks, 
depending on HCV VL results within that period.  At the end of therapy, another viral load 
measurement is taken with the anticipation that the patient has achieved a “less than detectable” 
value.  Twenty four weeks after therapy completion, an HCV VL test is performed to confirm the 
patients SVR status.  AASLD guidelines also differentiate the treatment management for patients 
with genotype 2 or 3.  These patients receive an HCV VL test at the beginning of their treatment 
and are scheduled for 24 weeks of interferon-alpha and ribavirin therapy.  At the end of 24 weeks 
another viral load determination is made and then again at 48 weeks to determine the 
sustainability of the response (Ghany et al., 2009).  Figure 4 illustrates these clinical pathways.  
     Clinical management guidelines illustrate the integral and essential role of quantitative HCV 
testing in HCV patient care.  Considering the length of treatment, potential morbidity, and costs 
associated with current therapy, studies continue to focus on altering regimens specific to patient 
and disease characteristics.  Newer clinical studies are exploring even more individualized 
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treatment strategies, from shortening treatment based on the first time HCV is undetectable, to 
lengthening it in other situations.  The results of these studies are proposals that recommend 
shortening therapy when a rapid viral response (RVR) is established, halting therapy when it has 
been demonstrated to be ineffective, or lengthening it when prolonged therapy increases the 
chance of SVR (Chevaliez & Pawlotsky, 2009; Mangia et al., 2007; Poordad, Reddy, & Martin, 
2008;  Zeuzem et al., 2005).  In all cases, the decisions are predicated on the HCV VL 
measurement.  Establishing SVR by means of HCV VL was the surrogate endpoint for the 
clinical trials that led to the approval of the two new protease inhibitors for HCV genotype 1 
patients (Jacobson et al., 2011).  While the dependence on this measurement is essential, there is 
little technical discussion in the clinical literature on the imprecision of the assays and the 
clinical consequence of acting on such information, and no studies demonstrating how 
differences in the precision of the results will affect clinicians’ decisions. 
     Quantitative HCV RNA viral load testing.  The hepatitis C Virus was discovered in 1989; 
one of the first organisms to be linked to disease by molecular techniques alone (Choo et al., 
1989).  Establishing hepatitis C virus as the etiologic agent of one of the forms of non A/ non B 
hepatitis was accomplished by identifying and sequencing the viral RNA; without actually 
isolating or culturing the virus.  Despite the newness of the molecular techniques used to isolate 
and quantify the virus, by 1995 viral load testing for HCV was being used regularly for 
prognosis and disease therapy management (Gretch et al., 1995; Martinot-Peignoux et al., 1995).  
By 2001, it was considered one of the most common tests performed in many molecular 
laboratories (Podzorski, 2001). 
     Early researchers demonstrated the discrepancies within and between the different available 
commercial and laboratory developed assays.  There were no formal proficiency testing 
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programs for HCV VL at the time, so the discrepancies were observed by comparing the results 
of multi-center studies distributing shared samples.  The earliest of these compared qualitative 
results on undiluted samples and on dilution series of samples.  One early European study found 
that only five of the 31 participating laboratories from Europe, the US and Japan performed 
flawlessly on a panel of four HCV positive, six HCV negative and a dilution series with two 
samples (Zaaijer et al., 1993).  The earliest College of American Pathologist (CAP) proficiency 
test panels demonstrated 13 – 95% correct results on the HCV RNA qualitative samples 
distributed in the first year to approximately 50 laboratories in the United States (Gretch, 1997).  
The Quality Control for Molecular Diagnostics (QCMD), a European Union supported 
proficiency testing effort, was the first to provide globally available qualitative and quantitative 
HCV proficiency testing panels.  Two consecutive panels in 1999 and 2000 showed an 
improvement in qualitative testing where over 80% of global laboratories reported correct 
results.  For those laboratories reporting quantitative results on the first panel, 60% were within 
the acceptable range of the geometric mean +/- 0.5 log10 and for the second panel in 2000, 73% 
were within this range (Schirm et al., 2002). 
     In addition to the differences in technologies and asynchronous states of development for 
available assays, there were no globally accepted standard reference materials, primarily because 
the virus could not be propagated.  As a consequence, quantitative assays were developed with 
different reporting units: copies, genome equivalent units, and relative light units (Schirm et al., 
2002).  In 1996, the World Health Organization (WHO) in a global collaborative study with 22 
laboratories established the first WHO International Standard for HCV RNA, expressing the 
quantity in International Units (IU) (Saldanha, Heath, Lelie, & the WHO collaborative study 
group, 1999).  International units are assigned to biologic material WHO International Standards 
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and have no reference other than in relation to that standard material and the testing that 
quantified it (WHO, 2002).  The difference in quantification among the global laboratories that 
tested the first standard, using either quantitative tests or limiting dilutions with qualitative 
testing, was greater than 2 log10.  Although the inter laboratory imprecision was large, this was 
viewed as providing a step towards reducing the variability in the results of future tests. 
     Despite the establishment of the WHO International standard, assessment of proficiency 
testing for quantitative tests continued to be difficult.  Participating laboratories still reported 
historical units, so conversion factors were used for multi-assay comparisons (Pembrey et al., 
2003).  Adding to the complexity was a technology shift to real time polymerase chain reaction 
(RT-PCR) which expanded the reportable range span from barely 5 log10 IU/ml to greater than 6 
log10 IU/ ml (Barbeau, Goforth, Caliendo, & Nolte, 2004).  Bias continues to exist between 
methods and among the genotypes in HCV VL, to the extent that it could influence treatment 
decisions.  The recommendation to follow serial patient samples with one test method, and 
preferably through one laboratory, throughout the treatment experience of the patient, is still 
relevant (Caliendo et al., 2006; Laperche et al., 2007).  In practice, however, this 
recommendation may not be easy to follow, and there is no information regarding actual 
compliance.  
     Even if clinicians had the ability to direct patients’ serial samples to one laboratory using one 
method, there would still be reason for concern.  Depending on the technology and the laboratory 
used, the inherent imprecision may make it difficult to determine the changes in viral load 
necessary to guide treatment decisions.  At the time when therapy management decisions were 
made based on the detection of a 2 log10 reduction in viral load, the Instituto Superiore di Sanità 
in Italy conducted a multi-center study with 58 laboratories and two manufacturers using a panel 
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of samples designed to reflect the performance of this intended use.  In addition to one panel 
sample at the sensitivity limit, six samples of the eight member panel were designed to test the 
ability of the tests to accurately detect a 2 log10 change.  Three replicates each of two samples 
that were at 5.68 log10 and 3.61 log10 were distributed to the participants in each of two panel 
sets.  In the data analysis, all combinations of the results between these two samples were 
calculated and the percent of unacceptable result-combinations was reported.  The range of 
unacceptable results (less than 2 log10 IU/ml difference between the two samples) among the four 
methods tested was 30% to 66% with an overall rate of 40% of all the results.  It was calculated 
that this could have led to the unnecessary discontinuation of therapy in up to 40% of patients.  
The researchers noted that if an uncertainty of 2 SD was considered in the evaluation of the 
results, the hypothetical incorrect decisions would have been reduced to 2% (Pisani et al., 2009).  
With the exception of the HCV VL results from the laboratories, the work that determined these 
conclusions was accomplished by mathematical modeling.  The new therapeutic regimens for 
HCV genotype 1 incorporate the achievement of absolute reduction of viral load for the therapy 
management decision; the 2 log10 IU/ml change is no longer used.  Though the limit of detection 
for the acceptable assays to determine the VL are specified in pharmaceutical labeling and 
clinical guidelines, the precision specifications are not, and there is variance around those 
absolute values in even the most reproducible tests.  Whether or not physicians consider the 
imprecision in HCV VL tests as they are making therapeutic management decisions with these 
quantitative results is untested.  
Justification for the Research  
     HCV Viral load testing is essential to the diagnosis and management of patients infected with 
the virus.  The previous section discussed the recommendations for using HCV VL in clinical 
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decisions and some of the clinical research that demonstrated its utility.  Based on research, the 
collective opinions of experts, and FDA submissions for therapeutics, HCV VL testing is 
standard practice to inform decisions in treatment of the disease.  The efforts to understand and 
decrease the imprecision in HCV quantitative testing has also been discussed, as well as opinion 
leaders’ views of the residual variation and the impact that could have on patient care.  The 
research and discussion of these complex issues have been conducted among experts in 
laboratory testing, virology and hepatology.  It is unknown if all treating physicians have 
integrated this knowledge into their practice.  As new treatment regimens are introduced, it is 
important to understand where indecision, confusion, or non-adherence to recommended 
practices exist. 
     The current research regarding physicians’ integration of test results in medical decision 
making illustrates a broad, inconsistent, and sometimes incorrect understanding of the precise 
meaning and application of the intended information supplied by laboratory testing.  The types of 
laboratory tests that have been addressed in the studies discussed are primarily those informing 
the physician of the probable presence or absence of disease.  There are no studies measuring 
physicians’ understanding of continuous quantitative information, nor are there studies 
addressing the impact of integrating the knowledge of the imprecision in quantitative testing in 
their decisions. 
      It is appropriate to use HCV disease management as a model to study the implications of 
quantitative test variation on clinicians’ decisions.  The global impact of the morbidity and 
mortality on society has been discussed; but added to that is a growing body of publications 
outlining the costs of chronic HCV disease, cost-benefit impacts of intervention, and cost 
effectiveness of specific therapies.  In the United States, the direct costs of HCV infection in 
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1998 were calculated to be one billion dollars (Wong, 2006).  The extended incubation time 
before complications manifest will result in a calculated economic burden of $US 86.2 billion of 
direct and indirect medical expenses during 2010-2019.  Adding quality of life, productivity and 
societal costs increases the estimate to $US 184 billion (Shah & Wong, 2006).  The seriousness 
of the economic impact and the possibility of reducing that impact with suboptimal interventions 
drive studies to demonstrate the cost effectiveness of specific and comparative therapeutic 
regimens (Hornberger et al., 2006; Rajenrda & Wong, 2007).  Paired with those studies and 
subsequent disease management strategies are the HCV VL tests that direct patients into the most 
effective therapeutic plan, but the monetary value of those tests is rarely studied.  For example, 
the ability to cease treatment at 12 weeks for non-responding patients was calculated to save $US 
15,000 per patient (Wong, 2006).  Though HCV VL results drive the decision, there is no 
analysis of the contribution to savings the test may have.  Further, there is no discussion of  how 
the variation in the results might impact the decision and alter the utility and value of the pivotal 
determinant.  
     In the research presented here, these two important questions were studied.  Referring to 
Smart’s proposed model of clinical utility (2006), this study first examined the practicability, the 
knowledge and training needed to support HCV VL testing, by evaluating the understanding and 
impact the test results presented with imprecision information  have on clinicians’ use of the 
information.  A survey presenting a specific scenario of a simulated patient completing 12 weeks 
of therapy and that patient’s initial and 12 week HCV VL results at different levels was offered 
to clinicians (survey participants) who treat patients with chronic hepatitis C.  In random order, 
each participant saw the test results with and without disclosing the imprecision, expressed as the 
95% confidence intervals.  The participants were asked to choose their course of action based on 
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the two different types of reports.  The accessibility, or the economic and cost effectiveness 
consequences of using HCV VL results as “perfect” information, and as information with 
imprecision were then evaluated using decision analytic modeling and value of information 
calculations. 
     The purpose of this study was to test the hypothesis that clinician awareness of the expected 
imprecision in pivotal test results will impact their medical management decisions.  The data 
from their responses were also used in decision analytic models to measure the changes in the 
value of the information provided by laboratory tests as clinicians alter their use of them.  The 
work consisted of an observational study utilizing a clinician survey that presented a scenario 
where laboratory results provide the determining factor for the subsequent step in a patient’s 
medical care. 
      The treatment of chronic hepatitis C using quantitative HCV RNA results was chosen for this 
study for several reasons: AASLD practice guidelines recommend the consideration of an action 
based on the results of the quantitative HCV RNA molecular tests.  The guidelines and several 
publications recommend the use of a single test methodology by a single manufacturer 
throughout the care of the patient.  It is unknown if clinicians comply with this recommendation 
and purposefully choose the same laboratory and method for their patient testing.  Finally, there 
is an increasing reliance on both absolute and relative values derived from molecular viral load 
testing in the personalization of therapy regimes for several viral diseases.  It is important to 
investigate the clinician mitigation and responses to the variation in this type of testing. 
     Contribution of the research.  The hypothetical impact that the variation in VL testing could 
have on the ability to assess a 2 log10 reduction of HCV for patients on therapy was 
mathematically demonstrated (Pisani et al., 2009).  However, whether or not clinicians would 
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have acted on the information as predicted in the European study was not tested.  The new 
therapeutics and new guidelines for HCV genotype 1 patient management present an opportunity 
to analyze what physicians will do given the imprecision of the test results when making a 
decision around an absolute threshold.  Physicians’ abilities to appropriately utilize test results 
impact the value of those results, and consequently the tests from which the results are produced.  
Appraising the value of tests as information with realistic performance characteristics, as well as 
with data on the use of the information, is an approach not commonly employed in clinical utility 
discussions of laboratory tests.  Additionally, the value of information as a measure of laboratory 
test value has not been published.  It may provide additional information for the assessment, 
development and direction of future investment in clinical laboratory tests. 
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Chapter Three: Methods   
 
 
 
     The purpose of this research was to study if presenting imprecision information with 
laboratory test results impacts patient management decisions and the use of healthcare resources. 
The study utilized the quantitative test for HCV viral load (HCV VL), a pivotal test in clinical 
practice, as a model.  The impact that knowing the imprecision, an inherent characteristic of the 
test, has on the decisions of those who use HCV VL for therapeutic management was measured 
in this study.  Further, the test’s economic value and the changes to that value based on the 
recorded decisions were calculated.  For the first part of this research, a survey was developed to 
evaluate decisions made when the HCV RNA (HCV VL) results were provided with and without 
the 95% confidence intervals (CIs) that describe the imprecision.  Using HCV VL results for a 
simulated HCV genotype 1 infected patient on triple-combination therapy, the survey was 
designed to compare the responses to VL results reported in the customary manner, without 
imprecision information, to responses to the same results reported with their 95% confidence 
intervals.  Each survey participant was presented with both types of HCV VL presentations (with 
and without CI), but in random order.  The characteristics of the simulated patient and the 
expected confidence intervals for the HCV RNA levels were derived from literature.  It was 
expected that responses made viewing results with imprecision information would be different 
from the responses made viewing results in the conventional presentation. 
     Survey data were analyzed for differences in responses to the HCV VL results with CI and 
those without CI. The respondents’ patient management decisions were then used as inputs to a 
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decision analytic model developed to calculate the value in cost savings and changes to that 
value based on changes in responses from the different presentations. 
Survey Design 
     The survey was designed to focus on the decision made after 12 weeks of triple combination 
therapy for patients infected with HCV genotype 1 virus: telaprevir (Incivek™), alpha interferon 
and ribavirin.  The selection of the decision point for the survey was based on information in the 
labeling of  Incivek (Vertex Pharmaceuticals, 2011) and the updated American Association for 
the Study of Liver Diseases (AASLD) guidelines that incorporate treatment and evaluation 
guidelines for these therapeutic regimens (Ghany et al., 2011).  
     For treatment naïve patients without cirrhosis (the simulated patient in the survey), the 
following treatment recommendations are stated in the AASLD guidelines. (Class and levels 
refer to the strength of evidence supporting the recommendation): 
    “ The recommended dose of telaprevir is 750 mg administered with food (not 
low-fat) three times per day (every 7-9 hours) together with peginterferon alpha 
and weight-based ribavirin for 12 weeks followed by an additional 12-36 weeks 
of peginterferon alpha and ribavirin (Class 1, Level A). 
     Patients without cirrhosis treated with telaprevir, peginterferon, and ribavirin, 
whose HCV RNA level at weeks 4 and 12 is undetectable should be considered 
for a shortened duration of therapy of 24 weeks (Class 2a, Level A). 
     Treatment with all three drugs (telaprevir, peginterferon alpha, and ribavirin) 
should be stopped if the HCV RNA level is >1,000 IU/ml at treatment weeks 4 or 
12 and/or detectable at treatment week 24 (Class 2a, Level B).” 
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     The survey was designed according to the clinical path in Figure 5.  The decisions that 
participants made based upon the HCV VL results after 12 weeks of therapy, with and without 
confidence intervals, were recorded and analyzed. 
     Participants were presented with a description of a simulated patient with HCV genotype 1 
disease who had been on triple combination therapy for 12 weeks.  The initial HCV VL for this 
patient, as well the description of that patient’s tolerance to the therapy over the 12 week course 
were also described.  Five different levels of HCV VL results were presented to the survey 
participants with and without the 95% confidence interval for each result. The order in which 
these were presented was randomized.  The HCV VL levels in the survey included results for 
which the patient management choice made according to practice guidelines would be relatively 
clear, as well as results for which the choice could be equivocal.  Participants were asked to 
consider each result individually and choose one of three patient management decisions: to 
continue therapy, to discontinue therapy, or to repeat the HCV VL test.  The survey was hosted 
on Survey Monkey
®
, an internet based, secure survey service. (Appendix A contains the 
complete survey text.) 
     Although the HCV VL result can be pivotal in the 12-week treatment management decision 
for HCV patients on triple combination therapy, other patient variables are considered by 
clinicians, such as age, weight, sex, degree of cirrhosis, and tolerance to therapy (Ghany et al., 
2009; Sulkowski, 2008).  The survey was designed to reduce as many of these variables as 
possible by presenting one patient with average demographics and a moderate set of adverse 
events.  Since professional practice, judgment, and experience can also influence the decisions, 
questions relating to the participants’ demographics and practice were incorporated into the 
 
  
 
 
 
 
 
Figure 5. Clinical path for HCV genotype 1 patients after 12 weeks of triple combination therapy. The three shaded boxes represent 
the choices following the presentation of different HCV VL results with and without confidence intervals in the survey.
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survey.  These included professional credentials, the number of years the participant has been 
treating HCV, the average number of HCV patients seen per month, the area of practice specialty 
and the geographic region in which the participant practiced. Other items in the survey queried 
preferences regarding the prescription and use of laboratory tests, such as the ability to direct 
patient testing to a single testing laboratory or method, the desire to have confidence intervals 
reported with results, and the preferred guidelines used for managing patients with HCV disease.   
     Selection of HCV VL test results and imprecision ranges.  One set of quantitative HCV 
RNA test results presented to the participants represented typical HCV VL results.  From most 
laboratories these results are reported without information regarding the imprecision of the 
assays. The other set of results reported the identical test values, but with the 95% confidence 
intervals for those values, as well. 
     The 95% confidence intervals for the HCV VL results in the survey were based on published 
literature.  Imprecision statistics are published from multi-site trials, assay studies and 
proficiency test summaries, and they provide insight to the expected confidence intervals within 
a laboratory.  However, these are usually focused experiments, sometimes with artificial or 
pooled samples (Caliendo et al., 2006; La Perche et al., 2007; Pisani et al., 2009).  The 
confidence intervals used in the survey for this research were calculated according to a 
recommendation by the Virology Quality Assurance Laboratory Program (VQA).  The VQA 
program, formed by the virology committee of the AIDS Clinical Trials Group uses an intra-
laboratory SD criterion of 0.15 log10 SD for viral load assays (Yen-Lieberman et al., 1996).  It 
was first established for HIV assays, however, laboratory directors producing results for other 
VL assays recognize it as a goal (Caliendo et al., 2006).  Though the recommendation was made 
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in 1996, later published studies either refer to this recommendation or their data demonstrates 
that 0.15 log10 = 1SD is still a reasonable estimate (Table 2). 
Table 2  
Three Studies with Published Intra-laboratory Reproducibility Statistics  
  
Study Year  Replicates VL ranges: 
   0-2.9 log10 3-4.9 log10 > 5 log10 
   SD log10 SD log10 SD log10 
      
Foreman 
&Valsamakis 
2004 20 0.2 0.2 0.1 
      
Caliendo et al. 2006 7 Approx. 
0.15 
Approx. 
0.15 
Approx. 
0.15 
      
Chevaliez et al. 2009 6 0.8 .04 0.21 
 
     For the imprecision budget of 1SD = 0.15 log10 used for the HCV VL results in the survey, 
the calculated 95% CI ranges were determined as shown in Table 3.  They were rounded for the 
survey presentation. 
Table 3  
95% CIs for HCV VL Results in Survey. Based on 0.15 log10 =1SD 
 
 HCV VL IU/ml 
Test Result Low 95% High 95% 
562,000 286,000 1,107,000 
31,620 16,060 62,230 
1,950 991 3,837 
1,000 508 1,968 
562 286 1,107 
100 51 197 
 
     Using the information in Table 3, if patients are managed according to absolute test values 
and clinical guidelines alone, without consideration of test imprecision and other factors, the 
responses in Table 4 could be predicted at each HCV VL level for the 12-week result. 
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Table 4 
Predicted Decisions Based on HCV VL Test Result and Clinical Guidelines 
Baseline 
(IU/ml) 
Post 12 wk Rx 
HCV VL (IU/ml) 
Decision according to guidelines 
562,000   
 31,620 Discontinue therapy 
 1,950 Discontinue therapy 
 1,000 Continue/Discontinue therapy 
 562 Continue therapy 
 100 Continue therapy 
 
 
Selection of the Study Sample 
     Clinicians who treat patients with chronic HCV disease were the intended population for this 
survey. Access to these clinicians was through the member directory of the AASLD-American 
Association for the Study of Liver Diseases. Members with physician (MD or DO), physician’s 
assistant (PA), nurse practitioner (NP) or nurse (RN) credentials who did not indicate a pediatric 
specialty were invited to participate through a personally addressed e-mail containing a link to 
the survey. 
     Sample size.  To compare the decisions made with and without the presentation of confidence 
intervals, it was determined that a sample size of 99 would be needed for an effect size of .1 
(showing a 10% difference in responses across the three decisions) with 2 predictors (the level of 
the viral load and the presence/ absence of confidence intervals) an alpha of .05 and power of .8. 
(On-line sample size calculator (http://www.danielsoper.com/statcalc/calc01.aspx). Adding 
demographic and clinician practice variables, with up to 12 predictors, a sample size of 184 
would be required for the same power and alpha.  Invitations to join the survey with an enclosed 
link were sent by the primary researcher to 1491 selected AASLD members.  The first page of 
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the survey contained an explanation and consent form.  The study received approval by Virginia 
Commonwealth University IRB #HM14538. 
Variables in the Survey 
     The decision to continue or discontinue treatment (therapy decision) is a function of the 
information presented to the clinician (patient and test result information), clinicians’ judgment 
and experience (clinician variables), and standard or accepted clinical practices. The survey was 
designed to test many of these variables.  The variables are listed in Table 5. 
Testing a Draft Version of the Survey 
     Prior to the release of the final survey, a draft version of survey (HCVVL Survey- Draft 3) 
was sent via e-mail link to three physicians, one laboratory director and a clinical trials manager.  
Instructions to review the survey and send comments were provided in the e-mail with the 
internet link and PDF attachment of the survey. Some recipients of the e-mail chose to complete 
the survey and in addition to their comments, their survey responses were recorded. 
     For those that actually completed the survey, the responses were “analyzed” as a test of the 
survey and the internet hosted service. There were four recorded responses: two from physicians 
and two from clinical research managers (one was also a medical student). Three of the four 
respondents stated they managed HCV patients.  The time to complete the survey was less than 
11 minutes for all respondents. 
     All respondents chose integer values for the test results but one of three that answered the 
question stated that their laboratory reports are provided results both in integer and log values. 
     For the four that answered the main question, there was a difference in the decision choices 
made using the test values without the confidence intervals (No CI) and those results with the 
confidence intervals (with CI).  The pairs where the decision was different between the two 
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Table 5 
Variables in the Survey 
 
Variable Variable 
Type  
Source Analytical 
type 
All participants    
Retest Dependent Survey Categorical 
Discontinue Therapy Dependent Survey Categorical 
Continue Therapy Dependent Survey Categorical 
Result presentation with or without 
95% CI (intervention) 
Independent Provided Categorical  
HCV VL Independent Provided Categorical 
Contribution of CI results Independent Survey Categorical 
Desire to have CI results Independent Survey Categorical 
HCV Pt management professionals    
Years of experience Independent Survey Continuous 
No. of patients per month Independent Survey Continuous 
Guidelines used for managing HCV 
patients 
Independent Survey Categorical 
Use of HCV VL for Rx management Independent Survey Categorical 
HCV Pt management professionals utilizing 
HCV VL 
   
Send tests to same testing lab Independent Survey Categorical 
HCV VL test method specified Independent Survey Categorical 
Type of VL test results received from 
testing lab 
Independent Survey Categorical 
Guidelines used in treating HCV 
patients 
Independent Survey Categorical 
Physicians    
Field of practice Independent Survey Categorical 
 
presentations are highlighted in yellow in Table 6.  The survey instrument appeared to be able to 
elicit and record responses and the data was retrievable in a manner that could be used for the 
planned analyses.  
Final Survey Version 
     The final version of the survey distributed for the study was changed based on the reviews by 
this pilot group, and research committee members. Changes included: 
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Table 6 
Responses to Patient Management Questions from Draft HCV VL Survey 
 
Test  Result 
(IU/ml) 
% Response 
 Continue Rx with Dual 
Therapy   
DC Rx Retest 
 No CI With CI No CI With CI No CI With CI 
100,000  0 0 100 100 0 0 
5,623 0 0 100 100 0 0 
1,950 0 0 100 75 0 25 
1000 25 0 0 0 75 100 
562 100 75 0 0 0 25 
100 100 100 0 0 0 0 
 
1)  The order of presentation of the HCV VL results with and without CIs was 
randomized.  (In the pilot version, the order was constant: without CI presented first, 
with CI presented second.)  
2)  HCV RNA test result numbers were only presented as integers in the final survey.  In 
the pilot survey, participants were given a choice between integer and log10 values. 
This choice was sacrificed on the final survey for the ability to randomize the 
question order.  All those participants completing the pilot survey chose integers, and 
in discussions with laboratory directors on the subject, integer presentation was the 
predominant form for laboratories not providing both.  
3)  The pilot version included a question about the importance of other non- HCV VL test 
considerations for therapy management.  All participants rated each of items at least 
moderately important.  In view of the length of the survey and consideration that this 
did not contribute to the aim of the survey, this question was eliminated. 
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     Other feedback from participants included questions regarding the drug of choice, suggestions 
to randomize the presentation of results with and without CIs and a request to simplify the 
survey.  The three adjustments described above were made in response to their feedback.  
The Decision Analytic Model 
     The treatment decision responses from the survey were used in an economic model to assess 
if changes in the treatment decisions influenced the value of the test.  A development decision 
analytical model was constructed in Microsoft Excel 2007 to calculate the changes in test value 
as the use of the information changed.  
The key assumptions in the development model were: 
 The entry point in the model was at the HCV VL test following 12 weeks of triple 
combination therapy (Incivek, interferon –alpha and ribavirin); the point where AASLD 
guidelines recommend patients with HCV VL above 1000 IU/ml be removed from 
further treatment. 
 The initial choice of decisions at the entry point was: Discontinue therapy, Continue 
therapy or to Repeat the test. (The same decisions as in the survey). 
 Parameters and disease states were for HCV genotype 1 patients.  For the development 
model, the health states were: Response, SVR, Chronic HCV, Cirrhosis, Hepatocellular 
Carcinoma, and Death. 
 The time horizon of the development model was 72 weeks.  This encompasses the length 
of influence of the HCV VL test in this clinical pathway, allowing the possibility of  two 
weeks delay for re-testing, an additional 36 weeks of continuing therapy plus 24 weeks 
post therapy and testing to evaluate an SVR (SVR is defined as undetectable HCV RNA 
24 weeks post the completion of therapy.)  Sixty two weeks were needed to 
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accommodate the two week repeat-test decision, but since the model was in 12-week 
cycles, 72 weeks were used. 
 The development model employed Markov chains to map the probabilities of moving 
through health states after the treatment management decisions had been made and 
entered. 
 With the exception of the first two cycles, each time cycle was 12 weeks.   
 In the first cycle, the population of patients entered in the “repeat test” decision remained 
in a chronic HCV state on dual combination therapy for two weeks and then were “re-
entered” back into the population for 10 weeks based on the percent decision to 
discontinue or continue therapy from those that did not choose to re-test.  This was 
designed to simulate the time for a new sample to be drawn, tested, and reported with 
subsequent clinician interpretation and decision. 
 There were no Quality of Life (QoL) values calculated in the development model. 
     Parameters for the development model.  The purpose of the development model was to test 
functionality and sensitivity to inputs. For the development model, transition probabilities and 
cost parameter values were derived from literature and bureau of statistics tables where 
accessible, however, estimations were made for several of the parameters. After testing the 
development model for functionality, all parameter values were sourced from literature and 
documented for the final model. 
     Testing the development model.  The model was checked for mathematical accuracy by 
visually checking each equation, assuring all populations were 100% at each state, and after 
running the model, by analyzing the outputs for consistency with expected results. 
     A minimum of 235 scenarios were tested in the development model.  Included were: 
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• All patients continuing on therapy (as if there were no test) 
• All patients removed from therapy (therapy failure with no test) 
• Using the response/ no-response population percentages cited in the clinical trials for 
Incivek (telaprevir) 
• All combinations of the three decisions: Repeat the test/ Discontinue therapy and 
Continue therapy in 5% increments. (Simulating increased indecision based on test 
imprecision.) 
     The model output for a patient without therapy costs and without testing was $4,917 per 
person during this period. These patients continued on a path of chronic HCV and subsequent 
disease management cost consequences for the entire 72 weeks. 
     The total costs for remaining on therapy in the development model were $14,474 per patient. 
This represented the costs if there was no HCV VL testing at week 12 and therapy was continued 
for all patients, including those patients with VL greater than 1000 IU/ml (who should be 
removed from therapy).  HCV VL testing saves medical costs and quality of life loss due to 
medication adverse events.  The value of perfect test information was calculated to be the value 
of the savings from discontinuing a therapy regimen that was not appropriate (up to $9557) for 
the individual patient with a true HCV VL above 1000 IU/ml.  However, the development model 
had no consideration of penalties for incorrectly removing a patient from therapy.  There were no 
quality of life values for health states, and the costs of disease progression were not fully 
developed. 
     To test a scenario duplicating the expected population response rates in the clinical trials for 
telaprevir, inferences from the clinical trial literature were made.  Though a cutoff of <1000 
IU/ml for continuing therapy is given in literature and guidelines, there is no data in the studies 
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showing the percent of patients with HCV VLs greater than 1000 IU/ml at week 12.  The 
telaprevir clinical trial reported that 58% of patients had an extended Rapid Virological 
Response (eRVR), defined as an undetectable HCV VL at week 4 and 12.  Among the 42% of 
patients who did not have an eRVR, a Sustained Virological Response (SVR), which is the 
treatment goal, was achieved in 60%.  Therefore, it was assumed that approximately 17% (42% x 
.40) of total patients starting therapy could be expected to have an HCV VL at week 12 that 
would indicate that they are non-responsive to the therapy. 
     In a population where approximately 17% would have an HCV VL that would dictate 
removal from therapy at week 12, the average per-patient cost would be $6542.  Therefore, 
testing on a population basis, and removing patients with HCV VL’s > 1000 IU/ml from 
unproductive therapy, should save approximately $7932 (14,474-6542) per patient, provided the 
test is reliable, and not repeated. 
     To model the consequences of imprecision, increasing retest rates were used as a surrogate.  
The percent retest population was started at 0% (completely accurate, precise and reliable 
information) and was increased up to 100% in 5% increments.  Each of these were tested with all 
combinations of decisions to continue or discontinue therapy; also varied in 5% increments.  The 
relative changes in total costs as the percent of decisions to repeat the test increased, were plotted 
from the model outputs and are shown in Figure 6. 
    Conclusion of development model testing and final model.  Through the development 
model studies, it was concluded that mechanistically, the outputs from the model produced 
changes in total costs as a result of different percentages of each decision entered.  For the final 
model used in the research, values for transition probabilities, costs and QoL were sourced from  
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Figure 6. Percent change in costs as a function of percent retest rate. 
 
 
literature. The dual therapy costs were adjusted for inflation. Table 7 lists the parameters used in 
the model and their source. 
     Costs for health states were derived from Pyenson, Fitch, and Iwasaki (2009).  Commercial 
and Medicare costs (for those above and below 65years of age) were provided in their analysis.  
From that publication, the Medicare costs for those less than 65 years of age were used in the 
final version of the model. For several of the health states, they were more conservative than the 
commercial costs.  The health state costs derived from Pyenson et al. were not inflation-adjusted. 
In the review of other literature, including an analysis of a large managed care organization 
claims database from July 2001 to March 2010, the variability of reporting costs of each health 
state for HCV disease was revealed (McAdam-Marx et al., 2011).  Monthly costs at published 
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Table 7  
Decision Analytic Model Parameters  
Parameter (12 weeks) Value Source 
Triple combination therapy responses   
 Undetectable HCV VL  p 12 wks 
dual Rx 
0.58 Jacobson et al., 2011 
 Undetectable HCV RNA at Rx end 0.87 Jacobson et al., 2011 
 Continued Response  0.75 Jacobson et al.,2011 
Health state transition probabilities   
 Progression: Chronic HCV  to 
cirrhosis  
.006 Pyenson et al., 2009 
 Progression: Cirrhosis to 
Decompensated Cirrhosis 
.010 Pyenson et al., 2009 
 Progression: Decompensated 
Cirrhosis to HepCA  
.010 Pyenson et al., 2009 
Costs   
 Cost of HCV viral load test $58.88 CMS, Laboratory  Fee Schedule, 
April 2013 
 Cost of  12 wks dual therapy 
(interferon and ribavirin) 
$5,721 Piwko et al, 2005 
Adj to 2013 via 
http://www.bls.gov/cpi/cpicalc.htm 
 12 week period costs for patients 
with SVR
1 
$0  
 12 week costs for patients with 
Chronic HCV
1 
$1545 Pyenson et al., 2009 
 12 week costs for patients with 
Cirrhosis
1 
$2345 Pyenson et al., 2009 
 12 week costs for patients with 
Decompensated Cirrhosis
1 
$21,300 Pyenson et al., 2009 
 12 week period costs for patients 
with Hepatocellular Ca
1 
$7200 Pyenson et al., 2009 
QoL Values   
 Chronic hepatitis 0.82 Australian Government, Dept of 
Health and Aging, 2002 
 Cirrhosis – diagnosed 0.74 Australian Government, Dept of 
Health and Aging, 2002 
 Decompensated cirrhosis 0.32 Australian Government, Dept of 
Health and Aging, 2002 
 Hepatocellular carcinoma 0.10 Australian Government, Dept of 
Health and Aging, 2002 
 
1Excludes HCV dual therapy and HCV test 
costs. Includes other medical costs associated 
with health state 
  
 
 
 
 76 
 
and inflation adjusted values were compared (Table 8).  The values as published in Pyenson et al. 
were higher in some cases than McAdam-Marx et al. and lower in others.  Therefore, the values 
as published in Pyenson et al. were used in the model as published (first column of costs in Table 
8).  A sensitivity analysis of the impact of cost variation was performed with the model and is 
reported in the results section.   
Table 8 
Comparison of Published and Inflation Adjusted Costs for HCV Health States 
 
 
 
     Other changes made to the final version of the model used in this research were: removal of 
death as a health state, removal of SVR as a separate health state from Response, and reduction 
of the time from 72 to 60 weeks (more appropriately reflecting the time span over which the test 
has influence; that needed to evaluate SVR).  In addition, the health state “Decompensated 
cirrhosis” was added and Quality of Life (QoL) values were accumulated at each state.    
     In addition, because the clinically prescribed decisions are not identical for all VL levels, 
different inputs and patient flow strategies were used for each VL level when testing the inputs 
from the survey at each distinct VL level.  
     For each viral load level, the model was run with at least three separate sets of inputs.   
 
 Monthly Costs ($)
HCV Health State Pyenson et al.,  2009
Pyenson et al. 
adjusted* 
McAdam-Marx et al., 
2011
McAdam-Marx et al.
adjusted*
Chronic HCV 515 556 488 529
Compensated 
Cirrhosis
772 833 437 474
Decompensated 
Cirrhosis
4200 4536 2295 2488
HCC 2400 2592 3616 3919
* Adjusted for inflation to 2013 costs per http://www.bls.gov/cpi/cpicalc.htm
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1. Inputs reflecting all patients on therapy for the duration of therapy, reflecting a situation 
where no test is available to guide removal of non-responders.  (For this situation the 
model had to be adjusted to remove the 24-week HCV test cost and subsequent routing 
based on the results.) 
2. Inputs according to AASLD guideline-directed decisions (e.g. no repeats and using the 
percent distribution of the population VLs at that level, based on the imprecision used in 
the survey 1SD =0.15 log10) 
3. Inputs according to the proportion of decision choices by respondents in the survey.  
Only data from the first presentation of HCV results to the respondents were used.  These 
data were used, as opposed to combining all responses, because clinicians normally are 
provided with a single presentation of results to review.   
     The decision proportions were entered into health states at time zero (review of HCV results 
post completion of 12 weeks of triple combination therapy) according to the following strategies: 
1. For the Discontinue therapy arm, all decision proportions were entered in the Chronic 
HCV health state as no further therapy would be given. 
2. For the Continue therapy arm of the model: 
a. The Repeat test decisions were combined with the Continue therapy decisions for 
entry. After a cycle of two weeks, this proportion of responses was re-distributed 
among the discontinue therapy and continue therapy arms according to the percent at 
in the original entry. 
b. For decisions recorded at a HCV VL=1950 IU/ml, proportions were entered into the 
health states based on the distribution of the VL, using the CIs in the survey.  At an 
HCV VL =1950 IU/ml, the lower 95% confidence limit is 990 IU/ml.  Approximately 
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2.7% of the HCV VL values would be at 1000 IU/ml or below. Therefore, in the 
Continue therapy arm, 2.7% of the decisions were entered in the Response health 
state and 97.3% were entered in the Chronic HCV health state.  For guideline-
directed decisions, the proportions used for each arm were: 0% Repeat test/97.3% 
Discontinue therapy/ 2.7% Continue therapy. 
c. For decision choices recorded at HCV VL1000 IU/ml proportions in the Continue 
therapy arm were split equally between the Chronic HCV state and the Response 
state.  For guideline-directed decisions, the proportions used for each arm were: 0% 
Repeat test/50% Discontinue therapy/ 50% Continue therapy. 
d. For decision choices recorded at HCV VL 560 IU/ml proportions were entered into 
the health states based on the distribution of the VL using the CIs in the survey.  At 
an HCV VL of 560 IU/ml the upper 95% confidence limit is 1110 IU/ml.  If 97.5% is 
at 1110 IU/ml or below, then 95.2% is at 1000 IU/ml or below. Therefore, in the 
Continue therapy arm 95.2% of the decisions were entered in the Response state and 
4.8% in the Chronic HCV health state. For guideline-directed decisions, the 
proportions used for each arm were: 0% Repeat test/4.8% Discontinue therapy/ 
95.2% Continue therapy. 
e. For decision choices recorded at HCV VL 100 IU/ml decisions for the Continue 
therapy arm were entered in the Response health state. For guideline-directed 
decisions, the proportions used for each arm were: 0% Repeat therapy/0% 
Discontinue therapy/100% Continue therapy. 
     As with the development model analyses, inputs representing a population of diverse HCV 
VL levels were also analyzed. The decision inputs were designed so that the therapy response 
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outcomes of the model reflected the telaprevir trial outcomes as closely as possible.  The inputs 
are described in the results section.  
     Each decision set (proportions for Continue therapy, Discontinue therapy or Repeat test) was 
used for the initial inputs to a model run. The resulting total costs and the average QoL ratio 
from all branches of the model, each time the model was run, were recorded and compared.  The 
total costs of the survey-recorded decision choices with and without CI were compared against 
the total costs of the guideline-directed decisions at each VL level.  In addition, the total costs 
resulting from the removal of non-responders from therapy were subtracted from the total costs 
of keeping all patients on therapy for a determination of the value of the quantitative HCV RNA 
test information.  Sensitivity analyses of the model to costs, QoL values and retest rates were 
also performed.  
Hypothesis Testing 
     The recorded responses from the survey were analyzed using Chi-square, bivariate and 
multinomial logistic regression techniques to test the first three hypotheses defined for this 
research. 
     H1 null hypothesis: The presentation of HCV VL results with 95% confidence intervals will 
have no impact on the treatment decision for HCV Genotype 1 patients. 
     It was presumed that the presentation of results with CI would result in different decisions 
when compared to the decisions made with results presented in the conventional manner. For the 
HCV VL load levels immediately below the threshold, at the threshold, and immediately above 
the threshold it was expected that there would be increased ambiguity between the Discontinue 
and Continue therapy choices, and higher repeat testing decisions for the results presented with 
CI.  Since the CI’s for the HCV VL immediately above the threshold crossed slightly below the 
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threshold, it was also thought that there might be an increased proportion of clinicians deciding 
to continue therapy when compared to decisions made viewing the same HCV VL result without 
CI.  Anticipating these findings, the second hypothesis was formed to further characterize the 
differences in decisions that might be observed. 
     H2 null hypothesis.  There is no difference in the impact of awareness of CIs on the treatment 
decisions between different HCV VL levels. 
   H3 null hypothesis. Clinicians’ experience and demographics will have no impact on treatment 
decisions using HCV VL results presented with and without confidence intervals.  If there were 
differences in the decisions made viewing results with and without the presentation of CI, it was 
thought that differences in experience and practice might correlate with the ability to apply the 
information correctly. 
     In addition to testing these hypotheses, the recorded responses from the survey were used as 
inputs to the decision analytic model to evaluate the economic impact of the clinicians’ 
decisions.  It was proposed that the value of the HCV VL test at the 12- week decision point in 
therapy could be determined by calculating the cost of treatment and disease progression, leaving 
all patients on therapy throughout the course and comparing them to the costs in the scenario 
where patients who would fail therapy, revealed by the HCV VL test results, did not continue the 
dual-combination treatment. 
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Chapter Four: Results   
 
 
 
      The purpose of this research was to examine methods of measuring the contribution of 
laboratory tests to healthcare.  Important aspects of a laboratory test’s contribution are the 
clinical utility of the test information, and the role of that information in facilitating efficient and 
effective use of patient management resources. The use of quantitative HCV RNA test results 
(HCV VL) to decide whether to continue or discontinue antiviral therapy after 12 weeks of 
treatment was used as a model for this research.  For the clinical utility of the HCV VL test, 
precision is crucial; therefore, the clinical utility was evaluated by studying the impact that the 
knowledge of the inherent assay imprecision might have on patient management decisions.  To 
measure the test’s economic contribution, a Markov decision-tree model was developed to 
determine the cost differences in leaving all patients on therapy versus removing those who 
would not respond given their HCV VL result.  Further, the cost differences resulting from 
removing patients from therapy as directed solely by clinical guidelines and those resulting from 
removing patients according to the clinicians’ decisions from the survey were determined and 
compared.  
Impact of Test Imprecision on Clinician Decisions 
     A survey was designed to elicit clinicians’ decisions when HCV VL results were provided 
with the 95% confidence intervals around five different levels of HCV viral load results.  An 
invitation e-mail with the survey link was sent by the primary researcher to 1491 members of the 
American Association for the Study of Liver Diseases.  At the close of the survey, 138 responses 
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were recorded (9.3%).  Of those responding, 14 accepted only the consent and progressed no 
further, six of the respondents answered only one of the two questions with the HCL VL results, 
and the remaining 118 answered both. Though respondents could exit the survey at any point, 
114 answered demographic and clinician preferences questions as well.  Respondents used an 
average of 8.3 minutes to complete the survey.  Recorded times greater than 60 minutes were 
removed from the data.  It was assumed that these respondents had been interrupted or left their 
computers with the survey open and that the elapsed time was not reflective of time spent 
answering the questions.  
     Sample.  The sample of respondents consisted of health care professionals who would utilize 
HCV VL results in their clinical practice.  Physicians comprised 89% of respondents and 92% of 
respondents answered that they managed the treatment of hepatitis C patients.  Responders were 
in practice an average of 20.5 years and saw an average of 47 patients per month.  Ninety-one 
percent claimed their field as hepatology, gastroenterology or both.  All respondents indicated 
they use HCV RNA results in the management of their patients with hepatitis C.  Of those, 
84.2% indicated they send their samples to the same testing lab for the pre-treatment and the 12-
week test points most of the time.  The remaining 15.8% responded it was not within their 
control.  Sixty-one percent specified that the identical test method be used for the pre-treatment 
and the 12 week test points; while 28.9% responded it was not within their control.  Of the 114 
respondents to the question of practice guidelines used, 96% indicated the use of the AASLD 
guidelines.  EASL guidelines were utilized by 15.8%, and information from pharmaceutical 
companies was utilized by 13.2%.  These responses indicate knowledge of the current clinical 
practice guidelines for the management of hepatitis C disease, and the intent to comply.  Table 9 
contains the responses to the questions regarding practice preferences and logistics. 
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Table 9  
 
Respondent Preferences and Patient Management Practices 
____________________________________________________________________ 
 
Preferences and Practices      Percent of Responses  
 
Preferences regarding presentation of CI:         
  
The results with CI    n=118   
      Neither added to nor detracted from the test result  44.9  
  Provided relevant added information to the test result 38.1  
  Detracted from or confused the test result   16.9  
              
 Desire to receive the 95% CI with patient results?  n=114      
  No        46.5  
  Yes        43  
  Not decided         7.9  
  Already do receive them       2.6  
         
Practices regarding HCV RNA testing:         
  
Send tests to the same lab for Pretreatment and 12-wk HCV RNA. n=114    
  Yes        84.2  
  Not within respondents control    15.8  
  No          0  
         
 Specify that identical methods be used for pre-treatment and 12-week HCV RNA.  n=114  
  Most of the time      61.4  
  Not within respondents control    28.9  
  Not at all         8.8  
  Sometimes            0.1  
         
 Type of VL results received from laboratory.  n= 114     
  Integers and Log10      71.9  
  Integers       20.2  
  Log10          6.1  
  Unsure          1.6  
         
Guidelines used for patient management. (Non-exclusive choices.) n=114    
  AASLD       96.5  
  EASL        15.8  
  Pharmaceutical Company     13.2  
  Institutional         7  
  Others        Less than 7  
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     Descriptive statistics of the sample demographics are in Table 10.  The responses were 
analyzed in total and then were split, based on whether the respondents saw the results presented 
without CI first (No CI) or with CI first (With CI).  For categorical data, the chi-square test was 
used to test the independence of the observed versus expected frequencies in each of the two 
population samples (Microsoft Excel 2007).  For continuous data, the TTEST function 
(Microsoft Excel 2007) was used to test for significance.  The two groups, separated by the order 
of the presentation of results with confidence intervals, were demographically similar; no 
statistical differences were determined.  They could be used be used as two separate sample 
groups for future comparisons. 
     Hypothesis testing.  Different groupings of the data were used in the following analyses for 
hypothesis testing.  Analyses of multiple decisions and variables employed Pearson’s chi-square, 
logistic regression, and multinomial logistic regression (IBM SPSS version 20).  Analyses at 
each VL level, comparing each of the three decisions made without CI (NoCI) and with CI (With 
CI) were performed by chi-square tests (Microsoft Excel 2007).  Figure 7 outlines the different 
data groupings. 
     H1 null hypothesis. The presentation of HCV VL results with 95% confidence intervals will 
have no impact on the treatment decision for HCV Genotype 1 patients.  
     H2 null hypothesis.  There is no difference in the impact of awareness of CIs on the treatment 
decisions between different levels of HCV VL. 
     These two hypotheses are interdependent.  In a thorough analysis of H01, H02 is included as 
the data was analyzed for the impact of CI on the three decisions in total and separately at each 
VL level. 
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Table 10  
 
Sample Population Demographics 
 
 
 
Seen First
No CI With CI
Total Percent Number Percent Number Percent p
Participants* 124 65 52.4 59 47.6
Location of practice
US 101 81.5 52 80.0 49 83.1 0.98
Europe 6 4.8 3 4.6 3 5.1 0.99
Canada 5 4.0 4 6.2 1 1.7 0.66
AUS/NZ 2 1.6 2 3.1 0 0.0 0.61
LATAM 2 1.6 1 1.5 1 1.7 0.99
No response 8 6.5 3 4.6 5 8.5 0.58
Profession
Physician 110 88.7 59 90.8 51 86.4 0.97
Nurse Practitioner 1 0.8 0 0.0 1 1.7 0.77
Nurse 1 0.8 1 1.5 0 0.0 0.82
Physician's Assistant 1 0.8 0 0.0 1 1.7 0.78
Other 1 0.8 1 1.5 0 0.0 0.82
No response 10 8.1 4 6.2 6 10.2 0.87
Manage hepatitis C patients
Yes 114 91.9 61 93.8 53 89.8 0.88
No 4 3.2 2 3.1 2 3.4 0.99
No response 6 4.8 2 3.1 4 6.8 0.82
Number of patients per month
Responses 114 91.9 61 93.8 53 89.8
Range 0-300 2-300 0-300
Median 30 35 30
Avg 47.0 54.1 38.8
SD 56.6 61.4 49.8 0.15
Number of years in practice
Responses 114 91.9 61 93.8 53 89.8
Range 1-45 1-40 4-45
Median 20 20 20
Avg 20.5 20.7 20.3
SD 10.0 9.8 10.3 0.82
Field of practice (Non-exclusive multiple choice)
Responses 114 91.9 61 93.8 53 89.8
Hepatology 88 71.0 47 72.3 41 69.5 0.99
Gastroenterology 34 27.4 18 27.7 16 27.1 0.99
Infectious diseases 9 7.3 5 7.7 4 6.8 0.99
Internal Medicine 4 3.2 2 3.1 2 3.4 0.99
Pediatric Hepatology 1 0.8 0 0.0 1 1.7 0.77
Virology 1 0.8 1 1.5 0 0.0 0.82
Pathology 1 0.8 0 0.0 1 1.7 0.77
Research 1 0.8 0 0.0 1 1.7 0.77
Blanks 10 8.1 4 6.2 6 10.2 0.88
*Answering at least one question
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Figure 7.  Groupings of data for analysis of survey responses.  
     The strategies used to analyze the responses in relation to the presentation of results with and 
without CI were (Figure 7): 
 Analysis of the decisions from all respondents as one group. 
 Analysis of the decisions between two groups, based upon whether the respondents saw 
HCV VL results with CI first or without CI first. 
 Analysis of the impact of the presentation order of results with and without CI on the 
decisions made. 
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n=118   
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n=24   
  
Analyzed all   responses ,  
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seen:   
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n=124   
  
Analyzed all   responses  ,  
split population on first  
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n=124   
NoCI  results : n=65   
WithCI   results: n=58 - 59   
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 Analysis of the impact of the presentation order of CI on individuals whose decisions 
were different between the first and second questions.  
     Analysis of decisions from all respondents independent of order seen.  Data from 124 
respondents were used, and decisions based upon the results with CI and the results without CI 
were compared. 
     Multinomial logistic regression was used to analyze the impact of CI on choosing one of the 
three possible decisions: Discontinue therapy, Continue therapy or Repeat the test.  Through 
logistic regression methods (bivariate and multinomial) the probability of an outcome can be 
predicted based on the known values or frequencies of occurrence of the predictor variables.  For 
the first analysis, the sole predictor variable was the presence or absence of CI with the 
quantitative HCV VL results. Table 11 lists the impact of the variable CI on the decision 
outcomes. Multinomial logistic regression uses one of the outcomes as a reference and returns 
one less than the number of outcomes as models.  In this research, there were three outcomes so 
two models in relation to the reference are returned.  The Repeat test outcome was the reference 
in these regressions. Separate analyses of the likelihood of repeating the test was performed by 
binomial logistic regression and is presented later.  In logistic regression, the coefficients for 
each variable (B) are selected through maximum likelihood estimation, fitting the parameters to 
the observed data. They represent the change in the logit of the outcome variable (the natural 
logarithm of the odds of the outcome happening) associated with a one-unit change in the 
predictor variable. The Wald statistic denotes whether the coefficient is significantly different 
from zero, the strength of that predictor variable.  It is a z-statistic with a chi-square distribution; 
therefore its significance can be reported.  Exp B is the exponential of the predictor coefficient, B 
(natural logarithm) and as such indicates the change in odds based on a unit change of the  
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Table 11 
Multinomial Regression Statistics with Variable CI.  All Responses 
 
 
predictor; or the odds ratio.  Numbers greater than one are associated with increasing odds and 
numbers less than one are associated with decreasing odds of the outcome.  In Table 11, the 
analysis shows that the presentation of CI as a variable has no significant strength as a predictor 
(p=.419 to Discontinue therapy vs. Repeat test, and p= .281 to Continue therapy vs. Repeat test). 
     Since CI made no significant impact on the decision outcomes, the variable Viral load level 
was added.  Predictor variables in this multinomial regression were, Viral load level (VL), 
whether the respondents saw results with CI (WCI) and the interaction of the two variables, 
(VL* WCI).  The final model contained only the VL levels as a significant predictor (model chi-
square 792.6, p<0.05, df=8).  Addition of the variable CI, or the interaction of the two variables, 
CI and VL provided no additional model strength.  In fact, the addition of CI as a variable 
detracted from model strength (p=.481). Therefore, the presence or absence of CI with the result 
Lower 
Bound Exp (B)
Upper 
Bound
Discontinue therapy
Intercept 1.213 .119 103.157 1 .000
Without CI .141 .174 .654 1 .419 .818 1.151 1.620
With CI 0
b 0
Continue therapy
Intercept .841 .125 44.968 1 .000
Without CI .196 .182 1.160 1 .281 .852 1.216 1.738
With CI 0
b 0
VL= Viral Load  CI= Confidence Intervals
95% Confidence Interval for Exp(B)
Odds ratio
a. The reference category is: Repeat test
b. This parameter is set to zero because it is redundant.
Decision at all HCV VL 
levels
a
B Std. Error Wald df p
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did not impact the decision outcomes in this data set.  Table 12 lists the impact of the variable 
VL and WCI on the decision outcomes. 
Table 12 
Multinomial Regression Statistics with Viral Load and the Presence or Absence of CI Variables.  
All Responses 
 
 
     Each VL level was then examined separately using all responses.  Chi-square was used to test 
the independence of the observed versus expected frequencies of the decisions made at each VL, 
using HCV VL results with or without CI.  A value of p< 0.05 for the CHISQ.TEST indicates a 
very low probability that differences are due to random error, therefore the data sets would be 
considered different.  As shown in Table 13, no statistically significant probabilities were 
obtained for the any of the three possible decisions made from results with CI or without CI at  
Lower Bound Exp (B) Upper Bound
Discontinue therapy
Intercept 21.313 .527 1635.543 1 0.000
100 IU/ml -21.378 .588 1320.312 1 .000 1.639E-10 5.193E-10 1.645E-09
560 IU/ml -20.760 .569 1329.446 1 .000 3.158E-10 9.641E-10 2.943E-09
1000 IU/ml -21.273 .539 1555.018 1 0.000 2.005E-10 5.770E-10 1.661E-09
1950 IU/ml -19.430 .488 1582.955 1 0.000 1.399E-09 3.644E-09 9.489E-09
31620 IU/ml 0
b 0
Without CI .141 .196 .513 1 .474 .784 1.151 1.690
With CI 0
b 0
Continue therapy
Intercept 17.590 .329 2865.757 1 0.000
100 IU/ml -15.716 .377 1737.393 1 0.000 7.140E-08 1.495E-07 3.130E-07
560 IU/ml -15.950 .375 1813.406 1 0.000 5.677E-08 1.183E-07 2.465E-07
1000 IU/ml -18.134 .357 2581.260 1 0.000 6.620E-09 1.332E-08 2.682E-08
1950 IU/ml -18.269 0.000 1 1.163E-08 1.163E-08 1.163E-08
31620 IU/ml 0
b 0
Without CI .241 .199 1.458 1 .227 .861 1.272 1.881
With CI 0
b 0
VL= Viral Load level.  WCI= With Confidence Intervals
a. The reference category is: "Repeat Test"
b. This parameter is set to zero because it is redundant.
Decision at all HCV VLs
a
B Std. Error Wald df p
95% Confidence Interval for Exp(B)
Odds Ratio
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Table 13 
All Data: Any Order Seen. Chi-square Analysis at Each VL Level 
 
 
NoCI= Without Confidence Intervals.  With CI= With Confidence Intervals 
any of the viral load levels, indicating no difference in response at any level based on 
presentation of HCV VL results with or without CI. 
     To further verify the paired analyses performed for each single decision, all three decisions at 
each VL were further analyzed, utilizing Pearson’s chi-square statistic to test for the 
independence of two variables.  The variables were: HCV VL results presented with CI, and 
HCV VL results presented without CI.  With a low significance value (p <0.05) the hypothesis 
that the variables are independent would be rejected and the confidence that they are related is 
increased.  Table 14 contains the output of each of the five analyses.  Pearson’s chi-square 
statistic was significant at all VLs, indicating a strong relationship between decisions made using 
results with CI and those without CI, with little to no impact of the presentation of CI.  Cramer’s 
V, a measure of association that can be used for nominal variables was greater than 0.8 for each 
level tested, supporting the chi-square findings. 
     Analysis of responses between two groups based on the order of the presentation of results 
with and without CI.  In practice, HCV VL results are presented to a clinician only once, 
currently without the CI.  Therefore, respondents were split into two groups based on whether 
Discontinue Therapy Continue Therapy Repeat Test
Question with Question with Question with
No CI With CI No CI With CI No CI With CI
Viral Load
IU/ml #  (% resp) #  (% resp) p #  (% resp) #  (% resp) p #  (% resp) #  (% resp) p
31620 117 (97.5) 119 (97.5) 1.00 3 (2.5) 3 (2.5) 1.00 0 0
1950 99 (82.5) 98 (81.0) 0.99 8 (6.7) 8 (6.6) 1.00 13 (10.8) 15 (12.4) 0.99
1000 49 (40.8) 48 (39.7) 1.00 29 (24.2) 28 (23.1) 1.00 42 (35.0) 45 (37.2) 0.99
560 25 (20.8) 27 (22.1) 1.00 85 (70.8) 77  (63.1) 0.65 10 (8.3) 18 (14.8) 0.49
100 12 (10.0) 14 (11.5) 0.99 95 (79.2) 95 (77.9) 1.00 13 (10.8) 13 (10.7) 1.00
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Table 14 
Results of Pearson’s Chi-square Test. All Three Decisions 
 
 
 
they saw results with CI first or without CI first.  For each respondent, only the decisions 
recorded from the first question were analyzed (one answer-set of decisions from each 
respondent).  Sixty-five respondents (53.4%) saw the results presented with no CI first, and 59 
(47.6%) saw results with CI first. The data presented earlier in Table 10 demonstrate that the two 
groups were demographically similar.  
     To determine if there was a significant impact of confidence intervals or viral load level on 
the decisions based upon how the respondents saw the results first, multinomial logistic 
regression was used with the three decisions as outcomes for the dependent variable.  As with the 
analysis using all responses, predictor variables were: VL (Viral load level), whether the 
respondents saw results with CI (Saw CI) and the interaction of the two variables, (VL* Saw CI).  
Again, the final model contained the two predictor variables independently; addition of the 
interaction provided no additional model strength (model chi-square 497.4, p< .05, df=8).  Viral 
load level was the only significant predictor variable. The significance of the Wald statistic for 
the variable CI was p= .539 for Discontinue therapy and p= .128 for Continue therapy. The 
addition of CI detracted from overall model strength in this analysis (p= .051) but to a lesser 
Viral Load
IU/ml
Contingency 
Table
Pearson's  
X
2
df p
Cramers 
V
31,620 NoCIxWCI* 118 1 0.00 1
1950 NoCIxWCI 174.8 4 0.00 0.86
1000 NoCIxWCI 162.9 4 0.00 0.83
560 NoCIxWCI 158.5 4 0.00 0.82
100 NoCIxWCI 199.9 4 0.00 0.921
*NoCI= results without CI.  WCI= results with CI
 92 
 
extent than in the analysis with all responses.  Table 15 displays the regression statistics with the 
variables viral load level and the presentation of CI. 
Table 15 
Multinomial Regression Statistics: Two Populations Based on Responses to the First 
Presentation of HCV VL Only 
 
 
RL= Viral load level.  CI = Confidence Intervals 
     As with the analysis of all responses, chi-square tests were used for this grouping to test for a 
probable correlation of decision with the presentation of CI at each VL (Table 16).  Though no 
statistically significant correlations were found, some interesting observations were made.  When 
presented with HCV VL with CI just above the decision threshold [1950 (990-3800 IU/ml)], 7% 
more respondents chose the decision to continue therapy, and approximately 11% fewer chose to 
discontinue therapy than those presented with results without CI. A small percent more (2%) 
 
Lower Bound Exp (B) Upper Bound
Discontinue therapy
Intercept 21.317 .747 814.283 1 .000
100 IU/ml -21.506 .837 659.641 1 .000 8.858E-11 4.572E-10 2.360E-09
560 IU/ml -20.769 .811 656.122 1 .000 1.949E-10 9.548E-10 4.679E-09
1000 IU/ml -21.393 .763 785.394 1 .000 1.146E-10 5.118E-10 2.285E-09
1950 IU/ml -19.432 .691 789.913 1 .000 9.381E-10 3.637E-09 1.410E-08
31620 IU/ml 0
b 0
Without CI .173 .281 .378 1 .539 .685 1.189 2.063
With CI 0
b 0
Continue therapy
Intercept 17.898 .463 1495.535 1 0.000
100 IU/ml -15.626 .535 853.550 1 .000 5.735E-08 1.636E-07 4.667E-07
560 IU/ml -15.773 .536 866.571 1 .000 4.940E-08 1.412E-07 4.035E-07
1000 IU/ml -18.113 .502 1299.566 1 .000 5.083E-09 1.361E-08 3.643E-08
1950 IU/ml -18.261 0.000 1 1.173E-08 1.173E-08 1.173E-08
31620 IU/ml 0
b 0
Without CI -.432 .284 2.315 1 .128 .372 .649 1.132
With CI 0
b 0
a. The reference category is: Repeat Test
b. This parameter is set to zero because it is redundant.
Decision at all HCV 
VL's
a
B Std. Error Wald df p
95% Confidence Interval for Exp(B)
Odds Ratio
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Table 16 
Respondents’ Decisions Split by Presentation of Results for First Question 
 
 NoCI= Without Confidence Intervals.  With CI= With Confidence Intervals 
 
chose the Repeat test option. When presented with results just below the decision point and with 
CI [560 (290-1,110) IU/ml], 13%  more respondents chose the decision to continue therapy, 5% 
less chose to discontinue therapy, and 7% fewer chose to repeat the test. With the exception of 
the repeat testing at this level, these decision differences were more pronounced with the 
responses split into two groups based on the first presentation seen, than those observed when all 
responses were analyzed as one group.  At the decision threshold of 1000 IU/ml, 11% fewer who 
saw the results with CI (510- 1,970 IU/ml) chose to discontinue therapy than those who saw 
results without CI, and 7% more repeated the test.  The percentage of respondents who chose to 
continue therapy was the same between these two groups at this level.  Since the confidence 
intervals presented with the HCV VL results immediately above and below the threshold showed 
the VL crossing the decision threshold, these results reveal some impact on the decision 
outcomes.  However the impact was not statistically significant by chi-square tests. 
     To determine if there were differences in response to CI between VLs, the number and 
percent responses for each decision were analyzed by two-tailed T tests.  No statistical 
significance was found for any of the response differences (p= .66 - .91). 
Discontinue Therapy Continue Therapy Repeat Test
"Survey with" "Survey with" "Survey with"
No CI With CI No CI With CI No CI With CI
Viral Load
IU/ml #  (% resp) #  (% resp) p #  (% resp) #  (% resp) p #  (% resp) #  (% resp) p
31620 64 (98.5) 57 (95.0) 0.93 1 (1.5) 2 (5.0) 0.93 0 0
1950 56 (86.2) 45 (77.6) 0.67 2 (3.1) 6 (10.3) 0.45 7 (10.8) 7 (12.1) 1.00
1000 28 (43.1) 19 (32.8) 0.71 16 (24.6) 14 (24.1) 1.00 21 (32.3) 25 (43.1) 0.68
560 15 (23.1) 10 (16.9) 0.87 41 (63.1) 45 (76.3) 0.47 9 (13.8) 4 (6.8) 0.65
100 7 (10.8) 5 (8.5) 0.98 48 (73.8) 51 (86.4) 0.38 10 (15.4) 3 (5.1) 0.32
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     Analysis based on order of the presentation of results, with or without CI.  The order of 
presentation of the HCV VL results, with or without CI, was randomized among the survey 
participants.  Therefore, responses could be analyzed based on the order in which they were seen. 
As with prior analyses, chi-square tests were used separately for each VL level.  There was only 
one decision outcome that was initially observed as statistically significant, the decision to 
continue therapy based on HCV VL results of 560 IU/ml with CI [560 (290-1,110) IU/ml].   For 
this case, the order in which the HCV VL results were seen, with or without CI, had an impact on 
the decision made.  If the respondents saw the HCV VL without CI first, fewer decided to 
continue therapy than those who saw the result with CI first (p = 0.04).  More decided to 
discontinue therapy than those who saw the CI first, and more decided to repeat the test than 
those who saw the CI first.  The latter two comparisons were not statistically significant by the 
original criterion of p<0.05.  However, even the one statistically significant effect by the original 
criterion may be a result of an inflated chance of a type I error due to the multiple tests 
performed (Field, 2013).  Applying the Bonferroni correction, using 28 as the number of tests, a 
more rigorous threshold for significance would be 0.002 (pcrit = α/κ).  In this case, no finding is 
statistically significant.  Table 17 shows all the pair wise chi-square tests for these analyses and 
the associated p-values with each pair. The first column labeled “Viral Load” is the item seen by 
the participant.  The decision choices are in the succeeding columns, but split by the type of 
presentation the respondents saw first. For example, for the first viral load presented (31,620 
IU/ml without CI), 117 respondents decided to discontinue therapy. Sixty-four of them answered 
this seeing this as the first presentation (NoCI), while 53 of the respondents had seen the results 
with CI before viewing this result.  
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Table 17 
Chi-square Test Result Based on Order Seen 
 
NoCI= Without Confidence Intervals.  With CI= With Confidence Intervals 
 
 
     Further analysis of the decision outcomes for a VL of 560 IU/ml with CI.  Though there were 
no statistically significant findings at the VL of 560 IU/ ml with CI, this result presented some of 
the more interesting observations and was used for further analysis. In the survey, respondents 
were asked if the results with CI provided relevant information, if it detracted from or confused 
the result, or if neither of these applied. This variable (Relevant) was used in a multinomial 
logistic regression with all three decisions as outcomes at the VL level of 560 IU/ml presented 
with CI.  The other predictor variable was which test results were seen first, those without CI or 
those with CI.  The only outcome having a significant predictor was the decision to continue 
therapy.  The significant predictor for Continue therapy was the order of the presentation of 
results: viewing the HCV VL results with no CI first.  The regression model and individual chi-
Discontinue Therapy Continue Therapy Repeat Test
Seen First Seen First Seen First
No CI With CI No CI With CI No CI With CI
Viral Load # (%resp) # (%resp) p # (%resp) # (%resp) p # (%resp) # (%resp) p
31620 64 (98.5) 53 (96.4) 0.91 1 (1.5) 2 (3.6) 0.91 0 0
1950 56 (86.2) 43 (78.2) 0.73 2 (3.1) 6 (10.9) 0.40 7 (10.8) 6 (10.9) 1.00
1000 28 (43.1) 21 (38.2) 0.96 16 (24.6) 13 (23.6) 1.00 21 (32.3) 21 (38.2) 0.93
560 15 (23.1) 10 (18.2) 0.93 41 (63.1) 44 (80.0) 0.25 9 (13.8) 1 (1.8) 0.13
100 7 (10.8) 5 (9.1) 0.99 48 (73.8) 47 (85.5) 0.49 10 (15.4) 3 (5.5) 0.39
31620  
(16,060 - 62,230)
62 (98.4) 57 (95.0) 0.77 1 (1.6) 3 (5.0) 0.77 0 0
1950 
(990- 3,800 )
53 (84.1) 45 (77.6) 0.84 2 (3.2) 6 (10.3) 0.47 8 (12.7) 7 (12.1) 1.00
1000  
(510 – 1,970 )
29 (46.0) 19 (32.8) 0.53 14 (22.2) 14 (24.1) 1.00 20 (31.7) 25 (43.1) 0.64
560
(290 - 1,110)
17 (27.0) 10 (16.9) 0.62 32 (50.8) 45 (76.3) 0.04 14 (22.2) 4 (6.8) 0.12
100 
(50 – 200) 9 (14.3) 5 (8.5) 0.80 44 (69.8) 51 (86.4) 0.18 10 (15.9) 3 (5.1) 0.29
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square tests had the same outcome.  However from the model it could be determined that if 
clinicians saw a VL of 560 IU/ml without CI first, they were 7.5 times less likely (odds ratio 
0.134) to decide to continue their patients on therapy than to repeat the test.  Table 18 displays 
the statistical data. 
Table 18 
Multinomial Regression of Decision Choices at 560 IU/ml 
 
 
     Narrowing the analysis further just to the decision to continue therapy with the presentation of 
results at 560 IU/ml, binomial logistic regression analyses could be used and other factors could 
be examined.  Predictor variables were: which test results were seen first, with or without CI 
(Seen first), and whether the respondent thought that the results with CI provided relevant 
information (Relevant).  The predictor variables were added in hierarchical progression: Seen 
first, Relevant and the interaction Seen first *Relevant.  The chi-square of each new model over 
Lower Bound Exp(B) Upper Bound
Discontinue Therapy
Intercept 1.441 .710 4.120 1 .042
No CI seen first -.982 .757 1.682 1 .195 .085 .375 1.652
With CI seen first 0
b 0
CI added to 
information
-.696 .665 1.097 1 .295 .136 .499 1.834
CI detracted from 
information
.112 1.305 .007 1 .932 .087 1.118 14.437
CI neither added or 
detracted 0
b 0
Continue Therapy
Intercept 2.418 .658 13.523 1 .000
No CI seen first -2.009 .692 8.436 1 .004 .035 .134 .520
With CI seen first 0
b 0
CI added to 
information
.169 .600 .079 1 .778 .366 1.184 3.833
CI detracted from 
information
2.017 1.132 3.178 1 .075 .818 7.519 69.104
CI neither added or 
detracted 0
b 0
a. The reference category is: Repeat Test
b. This parameter is set to zero because it is redundant.
560 IU/ml with CI
a
B Std. Error Wald df p
95% Confidence Interval for Exp(B)
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the previous was significant at p<0.05. The final model contained both predictors and the 
interaction of the two predictor variables. However, the model only correctly predicted 67.8% of 
the outcomes.  Of the predictor variables, the two parameters most informative (Wald statistic 
p<0.5) were: viewing HCV VL without CI first (from Seen first) and, if the CI detracted from or 
confused the result (from the variable Relevant).  At HCV VL of 560 IU/ml, clinicians who saw 
results without CI first were nearly four times less likely to choose to continue therapy (odds 
ratio 0.256)  than those who saw the results with CI first.  However, respondents who answered 
that the CIs detracted from the result were seven times more likely to choose the “continue with 
therapy” option at this level (odds ratio 7.12), than those who responded that the CI presentation 
did not add information or it detracted/ confused the result (the reference). Table 19 lists the 
variables with their corresponding statistics. 
Table 19  
Logistic Regression Statistics for Continue Therapy Decision at HCV VL 560IU/ml with CI 
 
     Prior analyses suggested that there were no interdependencies between the variables in the 
survey; however, to specifically illustrate this, a correlation matrix utilizing Pearson’s chi-square 
was developed.  Table 20 shows that the only statistically significant correlation is between the 
decision to continue therapy when the HCV VL = 560 IU/ml with CI and whether or not the CI 
was seen first.  This is consistent with the other findings. 
Lower Exp(B) Upper
No CI seen first -1.363 .429 10.073 1 .002 .110 .256 .594
Relevant 7.864 2 .020
CI added to 
information
.598 .442 1.834 1 .176 .765 1.819 4.322
CI detracted 
from information
1.963 .715 7.538 1 .006 1.754 7.121 28.915
Constant .794 .364 4.760 1 .029 2.213
95% C.I.for EXP(B)
Odds ratioContinue Therapy at 560 
IU/ml with CI B S.E. Wald df p
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Table 20 
Correlation Matrix for the Decision to Continue Therapy at 560 IU/ml 
 
     Impact of presentation order, with and without CI, on changes in decisions from the first to 
the second set of results.  Data from the 118 respondents who answered both questions were 
included in the data set. Twenty-four (20.3%) gave different decisions for the second question 
than they did for the first question.  Of those, 18 (75%) saw the test results without CIs first, 
while 6 (25%) saw the results with CIs first.  By the chi-square test, this difference was not 
significant: p= 0.13). 
     Binomial logistic regression was performed on the dependent variable Changed decision, 
using each decision at each level (31 changed decisions out of 588 individual decisions at all 
levels).  Predictor variables were VL and Seen first (whether the respondent saw the results 
without CI first or saw the results with CI first).  The predictor variables VL and Seen First were 
added in hierarchical progression: VL, Seen first and the interaction of VL*Seen first.  In a final 
560 IU/ml 
With CI 
Continue 
Seen first: 
With or 
Without CI
CI provided 
relevant 
information
Want to have 
CI with results
Pearson Correlation 1 .264
** -.116 .031
Sig. (2-tailed) .003 .211 .746
N 122 122 118 114
Pearson Correlation .264
** 1 .042 -.034
Sig. (2-tailed) .003 .648 .718
N 122 124 118 114
Pearson Correlation -.116 .042 1 -.143
Sig. (2-tailed) .211 .648 .130
N 118 118 118 114
Pearson Correlation .031 -.034 -.143 1
Sig. (2-tailed) .746 .718 .130
N 114 114 114 114
Correlations
560 IU/ml With CI 
Continue Therapy
Seen first: With or 
Without CI
CI provided 
relevant 
information
Want to have CI 
with results
**. Correlation is significant at the 0.01 level (2-tailed).
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model, excluding the interaction of the two variables, Seen first was significant (Wald = 3.176, 
p=0.001, df=1). For those who viewed results without CIs first, the odds of changing the 
response on the next result with CI were approximately five times more likely than the converse 
(95% CI of odds ratio: 1.11-13.39).  The addition of the interaction of VL*Seen first was not 
informative and masked the significance of the variable Seen First.   
     H1 and H2 null hypothesis findings. The H1 null hypothesis, that the presentation of CIs will 
have no impact on the clinicians’ therapy management decisions, cannot be rejected.  The 
presentation of HCV VL results with 95% confidence intervals had no statistically significant 
impact on the treatment decision for HCV genotype 1 patients.  There were no statistically 
significant findings at a significance threshold that corrected for the multiple analyses performed.  
The one finding with a p<.05 did continue to be seen when analyzed further, however, it 
describes a scenario that does not reflect clinical practice.  At 560 IU/ml, when respondents first 
saw results without CI and then were presented with results displaying the CI, they were less 
likely to choose to continue therapy than their counterparts who saw the results with CI first.  
Conversely, clinicians who stated the presentation of CIs detracted from or confused the results 
were more likely to continue therapy.  In addition, clinicians seeing results without CI first and 
then with CI were more likely to change their decision on the second question. Though these are 
interesting findings that could provide some insight to further research, they do not support the 
rejection of the null hypothesis. 
     The H2 null hypothesis is also not rejected.  H02, that there is no impact of CIs on the 
decisions at different VLs, depended on at least one finding in H01 at one of the VL levels. Viral 
load levels themselves, had the greatest impact on decision outcomes irrespective of whether the 
results were presented with or without CIs. 
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     H3 null hypothesis. Clinicians’ experience and demographics will have no impact on 
treatment decisions using HCV VL results presented with and without confidence intervals. 
     Multinomial logistic regression was used to evaluate possible correlations between physician 
demographics, clinical experience, practice preferences and the three outcome decisions.  
Predictors variables in the analysis were the five viral load levels (VL), presentation of HCV VL 
results with or without CI (With CI / NoCI), where the respondents practiced (Where practice), 
the respondents’ professions, field of medicine, whether they manage hepatitis C patients, use 
AASLD guidelines, the number of years in practice (Years practice), and the number of hepatitis 
C patients seen per month (Patients month).  Besides VL, only where the clinicians practiced, the 
number of years in practice and the number of patients seen per month demonstrated any 
significance to the outcome (Wald statistic at p< .05). The first two were significant in the 
decision to discontinue therapy and the third was significant in the decision to continue therapy.  
     To examine the role of clinicians’ practice preferences, the variables Relevant (whether the 
respondents thought the presentation of CIs added information to the result) and whether or not 
the respondent wanted to see CI with their results (Want CI), were added to the model with the 
variables HCV VL levels, With CI, Where practice, Years practice and Patients month. With 
addition of these variables, where clinicians practiced was no longer statistically significant in 
the overall model.  The Wald statistic for practicing in Europe went from p=0.031 to p=0.325 
and for practicing in Canada, it went from p=0.043 to p=0.43.  The number of respondents in 
these categories was small compared to those that practice in the United States (less than 10% 
combined).   
     Across all HCV VL levels, the number of years in practice had a negative influence on the 
decision to discontinue therapy (Exp B/ odds ratio 0.974).  However, the impact was slight.  For 
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each increasing year in practice the choice of discontinuing therapy at all VLs is 1.02 times less 
likely than repeating the test.  Responses indicating a desire to have CIs reported with results and 
those indicating the converse both had a negative association with this decision.  The odds ratios 
for both these responses were less than one and the frequency of these two choices was very 
close (42.0% wanted CI and 47.3% did not).  The other choices for this variable were “Don’t 
know” and “I already receive CI”, and the responses for these two variables together were 
approximately 10%.  Because there was no distinguishable difference in the responses of those 
that did and did not want CI, this variable was not considered useful in predicting the decision to 
discontinue therapy. 
     For the decision to continue therapy, the number of patients seen per month had a small 
negative impact.  However clinicians who thought the presentation of CI’s detracted from or 
confused the result, were 3.2 times more likely to choose this response at all VLs (odds ratio 
3.197) than to repeat the test.  This was a statistically significant finding and is similar to the 
findings at 560 IU/ml in the presentation of results with CI.    
     The decisions at each VL were further analyzed by multinomial logistic regression.  Only the 
number of years in practice and the number of hepatitis C patients seen per month were 
significantly associated with decisions at specific HCV VL levels (Wald statistics p<0.05), and 
those were only at HCV VLs of 1950 IU/ml and 100 IU/ml respectively. The effects were small. 
For example, at 1950 IU/ml, with each increasing year of practice, the respondents were 1.07 
times less likely to choose the decision to discontinue therapy versus repeating the test.  The 
significant effect of respondents who stated that the results with CI detracted/ confused the 
result, which was seen in the model with all decisions from all VLs, was not significant at any 
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single specific VL with or without CI.  All variables with statistical significance are listed in 
Table 21. 
     The H3 null hypothesis, that experience and demographics will have no impact on the therapy 
management decisions, is rejected.  Some respondent demographics and practice preferences did 
impact the HCV therapy decision outcomes.  Over all decision outcomes at any VL, the 
significant demographics and characteristics were: the years in practice, the number of patients 
seen per month, and whether or not the presentation of results detracted or confused the results.  
At 1950 IU/ml, the number of years in practice was significant in the Discontinue therapy 
decision; and at 100 IU/ml, the number of patients seen per month was significant to the 
Continue therapy decision. The presentation of results with or without CI made no impact. 
     Other analyses for clinical utility. The amount of repeat testing was notable at some VL 
levels.  Repeat testing delays the implementation of results and can add costs to a patient’s care.  
Analysis of the data to determine if any of the variables contributed to the likelihood of repeating 
the test was performed. 
     Decision to repeat the test. Respondents chose to repeat the test at all VLs except the highest 
one: 31,620 IU/ml.  The choice Repeat test was 17.5% of all decisions made at all levels.  For 
those respondents answering both HCV VL questions, the decision to repeat did not decrease 
with the second viewing of the HCV VLs: 8.2% of all first-question response decisions and 8.5% 
of all second-question response decisions were Repeat test decisions. The decision to repeat tests 
at the therapy decision threshold and the two immediately flanking levels (560, 1000, and 1950 
IU/ml) was 19.8% of all decisions made.  At the decision threshold (1000 IU/ml) Repeat test was 
36.1% of all decisions made.   
.
  
 
Table 21 
Respondent Demographic, Practice and Preference Variables Demonstrating Significance in Respondent Decision Choices 
 
 
 
 
 
 
95% Confidence Interval for Exp(B)
Dependant variable Variable parameter Variable Type p
Lower 
bound Exp (B)
Upper 
bound
Decisions at all VL Decicion to Discontinue Therapy *Where practice: Europe
Categorical
0.031
0.325
0.025
.075
0.144
.421
0.838
2.363
*Where practice :Canada
Categorical
0.043
0.433
0.013
0.081
0.112
0.488
0.937
2.932
Number of years in practice Continuous 0.025 0.952 0.974 0.997
Want CI with HCV VL results Categorical 0.011 0.026 0.127 0.625
Do NOT want CI with HCV VL results Categorical 0.001 0.014 0.067 0.332
Decision to Continue Therapy Number of patients per month 0.014 0.991 0.995 0.999
CI's detracted from or confused result Categorical 0.001 1.603 3.197 6.375
Decisions at VL 1950 IU/ml Decicion to Discontinue Therapy Number of years in practice
Continuous
0.026 0.868 0.928 0.991
Decisions at VL 100 IU/ml Decision to Continue Therapy Number of patients per month Continuous 0.01 0.974 0.985 0.996
*Statistical significance of parameters in Where_practice were only observed in model without Relevant and Want_CI: top p value for each. 
1
0
3
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     Table 22 lists the percent of decisions at all VLs presented with and without CI.  In the 
previous chi-square analyses of the decisions made at each VL the decision to repeat the test was 
not significantly influenced by the presentation of CI.  In the multinomial regression analyses, 
the repeat decision outcome was the reference and only the variables examined in H3 null 
hypothesis analyses showed any significance.  Using the Repeat test as the only dependant 
variable with a yes/no outcome, binomial logistic regression could be utilized for a specific 
analysis of this decision. 
     Binomial logistic regression analyses were performed on the decision of whether or not to 
repeat the test to further examine if there was any effect from viral load levels or the presentation 
of results with CI.  Data from all responses were used first.  Predictor variables were: VL and the 
presentation of CI.  The model chi-square was significant (p<0.05) and 86.4% of cases could be 
correctly classified.  The only significant variable however was the HCV VL level (Wald=33.12, 
p<0.5, df=4).  Whether or not the respondents thought the presentation of CI provided relevant 
information (predictor variable-Relevant) was added to the model.  There was no significant 
correlation (Wald = 3.18, p= 0.204, df=2).  
     Similarly, logistic regression analysis was performed using only the responses from the first 
question. VL and whether the respondent viewed results with CI (Saw CI) were predictor 
variables.  The presence or absence of CI was not significant in the decision to repeat tests either 
alone (p=0.663) or interacting with VL (p=0.196).  Viral Load level is the strongest predictor of 
the decision to repeat the test.  This is consistent with the visual examination of the data. 
     Summary of survey analyses. From the survey, 138 responses were received.  Strong 
clinical guideline adherence was demonstrated in self-reported behaviors and in decision choices 
recorded.  However, up to 37% of decisions were to repeat the test.  The impact of knowing the 
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Table 22  
Decisions Made at Each VL Level 
 
 
assay imprecision was not statistically significant to clinicians’ decision regarding the therapy 
management of the simulated patient.  There was no significant impact of clinician 
demographics, experience or practice preferences for the decisions made using the results with or 
without CI, however those who thought the CIs detracted from or confused the result were more 
likely to decide to continue therapy than repeat the test. Those who thought the CIs confused or 
Decisions
HCV VL 
Level 
IU/ml
Discontinue 
Therapy (%)
Continue 
Therapy 
(%)
Repeat test 
(%)
31620 Combined 97.5 2.5 0.0
NoCI 97.5 2.5 0.0
With CI 97.5 2.5 0.0
1950 Combined 81.7 6.6 11.6
NoCI 82.5 6.8 10.8
With CI 81.0 6.6 12.4
1000 Combined 40.2 23.7 36.1
NoCI 40.8 24.2 35.0
With CI 39.7 23.1 37.2
500 Combined 21.5 67.0 11.6
NoCI 20.8 70.8 8.3
With CI 22.1 63.1 14.8
100 Combined 10.7 78.5 10.7
NoCI 10.0 79.2 10.8
With CI 11.5 77.9 10.7
Combined:  All responses from Q1 and Q2 combined
NoCI:  Responses from all results reported without confidence intervals
With CI: Responses from all results reported with confidence intervals
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detracted from the result were only 16.9% of responses however.  Some associations were 
observed between demographics, practice preferences, and decisions regardless of the 
presentation of CI at each viral load level.  The most impactful variable on the decisions 
recorded for repeating the test was the level of viral load being reviewed.  
Determining Value and the Impact of Clinicians’ Use of Test Information on that Value 
     A Markov decision-tree model was developed as described in the Methods section. Changes 
from the pilot model were: removal of death as a health state, removal of SVR as a separate 
health state from the Response health state, and reduction of the time horizon from 72 to 60 
weeks (more appropriately reflecting the time span over which the test has influence; that needed 
to evaluate SVR).  In addition, the health state “Decompensated cirrhosis” was added and 
Quality of Life (QoL) values were accumulated at each state.  Transition probabilities, costs and 
QoL parameters for health states were populated from literature and older costs were inflation 
adjusted where appropriate (Table 7).  Decisions made by clinicians’ test use were represented 
by the survey data for initial model inputs. The circled boxes in Figure 8 illustrate where in the 
decision tree initial inputs were entered. 
     Analyses to evaluate the economic impact of the clinicians’ decisions.  The impact of 
decisions made from HCV VL results with and without CI on the value of the test was evaluated 
using the model described in the methods and the preceding paragraphs.  
     Because the clinically prescribed decisions are not identical for all VL levels, data for each 
VL in the survey was first evaluated separately, and different inputs and patient flow strategies 
were used for each level accordingly.  At each VL level, the analysis was run with all patients on 
therapy to determine treatment costs without the therapy management information provided by 
HCV VL, then with decision inputs according to established guidelines (AASLD, 2011; Vertex 
  
 
 
 
Figure 8. Decision path showing health states, costs, transition probabilities and QoL.  The circled boxes show the entry point for the 
three decisions: Continue therapy, Discontinue therapy or Repeat the test. 
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Pharmaceuticals, 2011), and finally, with decision inputs from the survey described (made with 
and without CI).  For decision inputs according to AASLD Guidelines, no entries were made to 
the Repeat test input, and the Continue and Discontinue therapy inputs were made using the 
percent distribution of the population VLs at that level (based on the imprecision used in the 
survey of 1SD =0.15 log10).  For example, at 560 IU/ml, based on the imprecision of the test, 
approximately 4.8% of results would be expected to fall at or above 1000 IU/ml. Therefore for 
the guideline- dictated decision, 4.8% were placed in the Discontinue therapy arm.  For 31,620 
IU/ml, all were placed in the Discontinue therapy arm.  For decision inputs according to the 
proportions from the survey, only responses from the first presentation of HCV results to the 
respondents were used.  The data were used in this manner (as opposed to combining all 
responses) because the presentation of HCV VL results twice (with and without CI) does not 
reflect common clinical practice.  When using Repeat test decisions, those proportions were first 
combined with the Continue therapy decisions for entry into the model.  After an initial step of 
“two weeks” the proportion of Repeat test responses was re-distributed among the Discontinue 
therapy and Continue therapy arms according to the original proportions of those two decisions, 
adjusted for no repeat testing.  For example, if the original decision inputs were 40% Discontinue 
therapy, 40% Continue therapy and 20% Repeat test, the 20% Repeat test would be combined 
with the 40% Continue therapy decisions for initial input.  After the first two week cycle, the 
20% would be redistributed with half (10%) going to the Discontinue therapy arm and the other 
half (10%) remaining in the Continue therapy arm. 
     The resulting total costs and the average QoL ratio for each of the model inputs were 
recorded.  The total costs of the survey-guided decisions with and without CI were compared 
against the total costs of the decisions according to guidelines at each viral load level.  Since the 
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survey respondents were primarily specialists, their recorded decisions and the guideline-dictated 
decisions were close for most of the viral load levels; with the exception of Repeat test decisions. 
This was reflected in the comparisons of the total costs between the guideline decisions, those 
made viewing HCV VLs with CI, and those made viewing HCV VLs without CI.  For most 
comparisons, there was less than a 10% difference in total costs.  As expected, the greatest 
differences were seen at or near the decision point.  For those VLs above the 1000 IU/ml 
threshold, deviations from guidelines were associated with higher costs as a result of keeping 
patients on therapy.  Notably, at 1950 IU/ml the decisions made using results with CI were 
associated with 16% greater costs than the guideline-dictated decisions and 12% higher costs 
than those decisions made using results without CI.  The impact to the QoL values between the 
three types of decision inputs was negligible.  
     Table 23 displays the decision model inputs and outputs for each VL using the 12-week 
decision point inputs defined by guidelines and from the survey data.  From the survey data the 
input decisions are further split to those made with CI and those made without CI presentation.  
The first column in the table lists the five viral load levels in IU/ml. For each of the decision 
inputs (guideline-directed or survey-directed), the actual percentages of each decision are stated 
with the output total costs from the model and the output QoL value.  Using the guideline 
directed decision percentages as a benchmark, the total cost outputs from decisions made by 
respondents in the survey using results without and with precision information are compared 
(labeled in the table as “% Change from Guide”).  Additionally, total costs outputs from the 
survey-directed decision inputs with CI are compared to those made without CI (labeled as 
“%Change from NoCI”).     
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Table 23 
Total Costs / QoL Comparisons from Guideline-Directed Decisions and Survey Decisions Made 
with and without CI 
 
 
VL= Viral load levels. RX= therapy.  NoCI= Without Confidence Intervals.  With CI= With 
Confidence Intervals. 
 
     Using the data from Table 23, the total costs at each VL resulting from guideline-directed 
decisions versus decisions made by survey respondents using results with and without CI 
presentation are shown in Figure 9. 
 
 
Figure 9. Total costs resulting from guideline-dictated decisions and survey-guided decisions. 
Guideline Survey No CI Survey with CI
HCV VL
(IU/ml)
Model Inputs
%R/%DC RX/%ContRX
Total 
costs $
(60 Wks) Av QOL
Model Inputs
%R/%DC RX/%ContRX
Total 
costs $
(60 Wks) Av QOL
%Change 
from Guide
Model Inputs
%R/%DC RX/%ContRX
Total 
costs $
(60 Wks) Av QOL
%Change 
from Guide
 %Change 
from NoCI
31620 0/100/0 7813 0.82 0/98.5/1.5 8000 0.82 2 0/95/5 8436 0.82 8 5
1950 0/97.3/2.7 8147 0.82 10.8/86.2/3.1 8377 0.82 3 12.1/77.6/10.3 9421 0.82 16 12
1000 0/50/50 13424 0.86 32.3/43.1/24.6 12461 0.87 -7 43.1/32.8/24.1 13590 0.87 1 9
560 0/4.8/95.2 17414 0.97 13.8/23.1/63.1 15171 0.94 -13 6.8/16.9/76.3 16051 0.95 -8 6
100 0/0/100 17778 0.99 15.4/10.8/73.8 16494 0.97 -7 5.1/8.5/86.4 16877 0.97 -5 2
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     Figure 10 displays a graphical representation of the percent change in total costs of the 
survey-directed decisions made with and without CI from the guideline directed decisions.   
 
Figure 10. Percent change in total costs from survey decisions made with and with CI compared 
to guideline-dictated decisions. 
 
 
     The value of HCV VL test information. To determine the value in cost differences per 
patient that the HCV test information brings to the 12-week therapy decision, analyses were 
performed with 100% of the decisions in the Continue therapy arm for each viral load level.   
This provided a base case at each VL level reflecting all patients on therapy regimens without a 
test to help manage the decision to remove non-responders. The all-on-therapy analyses were 
followed by using inputs to the Discontinue and Continue therapy arms for each VL according  
to the AASLD guidelines (guideline-directed).  Finally, inputs according to the decisions made 
in the survey were used.  Since the value of the test at this specific point in the therapy 
management course is demonstrated by removing non-responders from inappropriate therapy, it 
was measured in the cost differences by subtracting the costs of the decisions made with the test 
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information from the costs of continuing all patients on therapy.  Table 24 shows the costs of the 
base case (all patients continuing therapy) compared to costs using the test according to 
guidelines, and according to the combined responses on the survey as well as with those 
responses using HCV VL with CI and those using HCV VL without CI.  As expected, the 
highest cost differences are among those that have high viral load levels. For those at the 100 
IU/ml level, any differences seen as “cost savings” that are greater than the decision-directed 
savings are inappropriate, as removing a potential responder from therapy is incorrect. (The 
calculation of the guideline-directed value at 100 IU/ml is appropriately $95 due to the removal 
Table 24 
Value of Test Information: Average Differences in Total Costs Realized as Savings per Patient 
 
 
 
1
Based on the difference in costs of leaving all patients all on therapy and removing non-
responders per guideline-dictated and survey response decisions.  
 
 
of the proportion of patients that show the presence of HCV RNA at 12 weeks post dual-
combination therapy. This proportion, derived from literature, is coded into the model.  At 560 
IU/ml, due to the distribution of the population of VLs with the imprecision stated, 
approximately 4.8% cross the 1000 IU/ml threshold.  Figure 11 shows the cost differences, 
realized as savings at each VL level from Table 24. 
Guideline Directed Survey  - All Responses Survey - NoCI only Survey - With CI Only
VL Result:
HCV RNA 
IU/mL 
Total Costs $: 
All Continue 
Therapy
Total 
Costs $
Value of test 
information
Costs savings $
1
Total 
Costs $
Value of test 
information
Costs savings $
1
Total 
Costs $
Value of test 
information
Costs savings $
1
Total 
Costs $
Value of test 
information
Costs savings $
1
31620 24976 7813 17163 8125 16851 8000 16976 8436 16540
1950 24900 8147 16753 8888 16012 8377 16523 9421 15479
1000 21424 13423 8001 12713 8711 12461 8963 13590 7834
560 18726 17414 1312 15431 3295 15171 3555 16051 2675
100 17873 17778 95 16569 1304 16494 1379 16877 996
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Figure 11. Cost differences realized as cost savings per patient at each VL due to the 
contribution of the HCV VL test in removing non-responders. 
 
     From this evaluation, it was demonstrated that there were some differences in total cost 
savings per patient based on clinicians use.  When compared to decisions made on the basis of 
HCV VL according to the AASLD guidelines, the different decisions by clinicians produced up 
to 16% increase in average total costs per patient in VLs at 1000 IU/ml and above.  Below 1000 
IU/ml, cost differences seen as “savings” greater than those realized by the guidance directed 
decisions are not valid as these savings are associated with patients who were inappropriately 
removed from therapy.  QoL values did decrease in these cases, but only by one to two percent.  
The time horizon of the model may be too short to show a more dramatic effect.  Interestingly, 
decisions made with the presentation of CI’s resulted in an increase of costs per patient at all 
viral load levels (from 1 to12%).  Since the economic contribution of the HCV VL is to produce 
cost savings in the treatment management of non-responders, the presentation of CIs diminished 
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the value of the test information.  QoL values at each VL were not affected by presentation of CI 
when compared within a VL level. 
     Analysis of a representative population with several VLs.  To simulate decisions for a 
population of patients having a distribution of VLs at the 12-week test point, initial inputs 
designed to produce therapeutic outcomes relatively consistent with the population in the 
telaprevir clinical trial were used (Jacobson, et al., 2011).  During the trial, all patients were on 
therapy throughout the course, unless there was a clinical reason for removal.  Seventy-three 
percent of patients had an SVR, while 17% relapsed. At the start of triple combination therapy 
(12 weeks prior to the starting point of this model), 77% of patients had greater than 800,000 
IU/ml HCV RNA.  In addition, approximately 6% already had cirrhosis.  To represent the 
population in the relatively simple model that was developed for this work, 86% were entered 
into the Continue therapy arm in the Response health state with 14% in the Discontinue therapy 
arm, splitting the Discontinue therapy proportion further with half in the Chronic HCV health 
state and half in the Cirrhosis health state.  The final response percent at week 60 was 73%, 
consistent with the response outcome of the trial.   
     The output of the model simulating this population was used to determine the total costs of all 
patients continuing therapy, a scenario without a test available.  Inputs were then adjusted to 
enter the proportion of non-responders stated in the trial into the discontinue therapy arm to 
assess the cost differences of removing them at week 12 based on their HCV VL.  The results 
($2633 in average cost savings per patient) are shown in Table 25. 
     Impact of repeat-testing on test value. The impact of repeat-testing on the costs was 
examined using this clinical study population.  For this purpose, adjustments were made to the 
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Table 25 
Average Cost Savings per Patient in Removing Non-responders for Telaprevir Clinical Trial 
Population 
 
 
 
model to maintain the ratios of responders and non-responders as close to the final outcome as 
possible.  Table 26 shows the different combination of inputs with repeat testing occurring in 
eventual non-responders as well as responders.  In this model, changes in repeat testing up to 
50% had 6% or less impact on the total costs.  This may be due to the fact that repeat-testing was 
handled by keeping the patient in the Continue therapy arm for the two weeks while “waiting” 
for the test result.  Following the two-week step, those who would have been removed from 
therapy were sent back to the Discontinue therapy arm of the model.  In this situation, where the 
response rate is high, at most only 14% of those retested had the extra two weeks of therapy.  For 
these analyses, the HCV RNA test cost is only $58.88 and two weeks of therapy is $953.  Per 
patient, this is about $1000 in costs.  This small impact on costs, even in high repeat testing 
scenarios may give insight to the robustness of the test value.  
     Analyzing model-outputs’ sensitivity to variation in parameters. The model developed for 
this research was not complex and had a short time horizon (60 weeks).  Inputs and parameters 
were based on literature and on survey data.  In the analyses described, several different levels of 
inputs were tested with variances based on the data received, and the outputs directly reflected 
them.  To determine the sensitivity of the model outputs to variances in the cost and QoL 
 
Telaprevir Study "Population"
Total 
Costs $
Av QoL 
Value
All patients Continue therapy 19472 0.95
Pts who would not have responded: off  therapy at 12 and 24 wks 16839 0.96
Cost Savings per Patient 2633
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Table 26 
Impact of Repeat Testing on Total Costs 
 
 
parameters, those values were varied and the model was run with each change using the 
telaprevir clinical trial population inputs.  Total costs were changed in 10% increments from 
minus 50% of the parameter value used in the analyses to plus 50% of the value.  Additionally, 
treatment costs and the HCV RNA test costs were tested separately for their contribution to 
model output sensitivity.  Table 27 and Figure 12 are tabular and graphical representations of the 
outputs of this deterministic sensitivity analysis. 
Inputs Outputs
Repeat 
Rate
Discontinue 
Therapy
Continue  
Therapy Costs ($)
% Change 
from Index
0* 0.14* 0.86* 16831 Index
0.05 0.09 0.86 17166 2
0.1 0.04 0.86 17501 4
0.15 0 0.85 17769 6
0.15 0.05 0.8 17434 4
0.2 0.05 0.75 17434 4
0.2 0.1 0.7 17099 2
0.25 0.1 0.65 17099 2
0.3 0.1 0.6 17099 2
0.35 0.1 0.55 17099 2
0.4 0.05 0.55 17434 4
0.4 0.1 0.5 17099 2
0.45 0.05 0.5 17434 4
0.45 0.1 0.45 17099 2
0.5 0.05 0.45 17434 4
0.5 0.1 0.4 17099 2
0.5 0.14 0.36 16781 0
* Index
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Table 27  
Model Output Sensitivity to Costs and QoL Parameter Values 
 
 
 
     For total costs, the increases or decreases resulted in similar changes of magnitude in the 
output.  Table 27 shows the variation of the parameter values and resulting change in the model 
outputs.  Treatment costs were about 87% of the total costs, and the model was demonstrated to 
be sensitive to them.  HCV RNA test costs had very little impact on the model outputs, even  
%Change 
from 
Baseline
New Total 
Costs ( $)
%Change
From 
Baseline 
New Total 
Costs ( $)
%Change
From 
Baseline 
New Total 
Costs ( $)
%Change
From 
Baseline 
New 
Average 
QoL 
%Change
From 
Baseline 
-50 8420 -50.0 9525 -43.4 16814 -0.1 0.48 -50.0
-40 10104 -40.0 10988 -34.7 0.57 -40.6
-30 11788 -30.0 12450 -26.1 16824 -0.1 0.67 -30.2
-20 13471 -20.0 13914 -17.4 0.77 -19.8
-10 15155 -10.0 15372 -8.7 0.86 -10.4
0* 16839* 0* 16839* 0* 16839* 0* 0.96* 0*
+10 18523 10.0 18202 8.1 0.97 1.0
+20 20207 20.0 19765 17.4 0.99 3.1
+30 21891 30.0 21228 26.1 16854 0.1 1 4.2
+40 23575 40.0 22690 34.7 1 4.2
+50 25259 50.0 24153 43.4 16864 0.1 1 4.2
+100 16890 0.3
+250 16965 0.7
+500 17090 1.5
+750 17215 2.2
+1000 17341 3.0
+2000 17843 6.0
*Baseline
** QoL values not adjusted beyond 1
Total Cost Changes
Therapy Cost Changes 
Only
HCV VL Test Cost 
Changes Only QoL Ratio Changes
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Figure 12. Model sensitivity to costs and QoL parameters values. 
 
 
when increased by 2000% (resulting in a test cost of $1237).  The base case “cost” used was the 
Medicare national limit of $58.88, however the cost of an HCV RNA test does vary widely and 
private-pay patients can pay above $1000.  The analyses in this research demonstrated that even 
at that price, the test maintains its contributory economic value in the decisions being made 
regarding therapy management.   
     QoL ratios were also varied in the manner described for costs, except when each QoL ratio 
reached one, or full health, no further adjustments were made.  For QoL ratios, the changes 
below the base case mirrored the percent change in QoL values. 
     Section summary: determining value. Through decision-analytic modeling, the economic 
contribution of the HCV VL test at week 12 was demonstrated.  In this evaluation, changes in the 
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use of the information were shown to affect the value of the test.  Changes in the use of the 
information from that directed by clinical guidelines could be measured in a simulated 
population with a representative distribution of viral load levels.  Despite variations in use, the 
test held value. 
Summary of Results. 
     The analyses and results in this section described two aspects of the clinical utility of a 
laboratory test, using HCV VL as a model, the interpretation and use of the test information and 
the economic contribution it has to the efficient use of clinical resources.  It was found that 
among the hepatology specialists who responded to the survey, test information use was close to 
clinical guidelines, with the exception of repeat testing.  Although differences were observed, 
there was no statistically significant impact on the use of the information when CIs were present. 
     Through the use of a specifically developed decision analytic model, economic contributions 
in average cost differences per patient could be demonstrated in simulated scenarios. The HCV 
VL test contributed an average of over $2600 in cost differences over all subjects in a 
hypothetical population of HCV patients, with savings up to $17,000 at higher VL levels. 
Varying the cost of the test up to $1200 had little impact on the value of the information 
produced from it.  
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Chapter Five: Discussion and Conclusions  
 
 
 
Summary of the Study  
 
     The goal of this study was to examine the impact of physician awareness of a key 
performance characteristic for a pivotal laboratory test utilized in patient management decisions, 
and the economic contribution of that test to patient care.  Quantitative HCV VL was used as the 
model since it is the principal indicator of the success or failure of current anti-HCV therapies. 
For HCV genotype 1 patients on triple-combination therapy, the HCV VL assessed at several 
time points during the course of therapy determines whether or not the patient should continue 
treatment.  Since the treatment regimen is costly and can be debilitating, removing non-
responders is appropriate when the HCV VL indicates they will not benefit from further therapy. 
Clinicians’ uses of quantitative HCV RNA results to make this decision after 12 weeks of the 
triple-combination-therapy part of the HCV-treatment regimen were studied. 
     The key performance characteristic examined for the HCV VL test was its imprecision, which 
in this study was operationally defined as the 95% CI based on an SD of 0.15 log10 IU/ml. 
Through a survey, decisions made by clinicians after reviewing HCV VL results with and 
without those CIs were compared.  Demographics, practice behaviors, and test presentation 
preferences were also analyzed to determine if they played a role in their decisions.  In addition, 
a decision-analytic model was developed to calculate and evaluate how the value of the HCV VL 
test information was affected by the clinicians’ utilization of the HCV VL results in their clinical 
decision making process.  The hypothesis was that the clinical utility (CU) and the value of the 
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laboratory test information would change if clinicians were aware of the imprecision of the 
results. 
Discussion of Survey Findings and Implications 
     Of the 1491 e-mail invitations to the survey sent, 124 responses were received with usable 
data (8.3%).  The subset was small, however over 90% of those responding were representative 
of the target population, clinicians who manage HCV patients. 
     In an analysis of all responses, there was less than a 10% difference between decisions made 
when viewing quantitative HCV VL results with CIs, and those made without the CIs, at all 
HCV VL levels.  Analysis of responses based solely on the presentation format of the first 
question seen by respondents showed greater differences between the two presentations, 
particularly for those HCV VL levels flanking either side of the decision threshold.  For the HCV 
VL level immediately above the 1000 IU/ml threshold (1950 IU/ml) and immediately below 
(560 IU/ml), the presentation of CIs led to a 7-13% increase in the decision to continue therapy.  
At the 560 IU/ml HCV VL level, the presentation of CIs was also associated with a decrease in 
the decision to repeat the test compared to decisions made without CIs.  These differences were 
not statistically significant, however.  Small response numbers may have had a role: data from 
the first question seen provided only 65 responses to the HCV VL results without CI and 59 from 
the results with CI. 
     When the responses were analyzed to examine the impact that the order of presentation had 
on decisions, those clinicians who viewed results without CIs, and then saw results with CIs, 
were less likely to choose to continue therapy at all VL levels, except the actual threshold level 
of 1000 IU/ml (the decisions were the same).  The VL level demonstrating the highest difference 
between the responses with the two presentations was at 560 IU/ml; just below the threshold.  At 
 122 
 
this level, while most of the assay variance was below the threshold (lower bound = 290 IU/ml) 
the upper bound of the CI crossed the threshold slightly (upper bound = 1,110 IU/ml).  This may 
have influenced the decision not to continue treatment or to repeat the test.  Repeating the test, 
where the greater number of the decisions shifted, delays the decision.  These findings, though 
interesting, do not reflect current practice, as clinicians are not presented with the same results 
twice.  However, they could provoke further discussion regarding the presentation of imprecision 
information to a community not accustomed to seeing it or instructed how to incorporate it into 
their decisions. 
     The tendency to continue the current course when the information is doubtful was 
demonstrated in the decisions made by those respondents who thought the imprecision 
information confused or detracted from the result.  They were more likely to continue therapy 
than even to repeat the test.  The decision to continue therapy is one of no action in this scenario.  
Patients are already on therapy at the decision point; and the action decision would be to remove 
the treatment.  In the HCV triple combination therapy regimen, there is another HCV VL testing 
point 12 weeks after the one addressed in the survey (Ghany et al., 2011).  At that time, the HCV 
VL should be undetectable for the patient to continue the last 24 weeks of therapy, giving the 
clinician and the patient time to revisit the earlier decision and compare the HCV VL results. 
Whether these considerations were part of the thought process for this group of experienced 
respondents was not tested.   
     Behavioral decision research is a field of study having roots in behavioral economics, and has 
grown to several applied areas (Medin & Bazerman, 1999; Thaler, 1991).  Some of the tenets 
discussed in this field may provide insight into the observed tendency to choose no action 
(Continue therapy or Repeat the test) over action when faced with risk or uncertainty.  It was not 
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the aim of this study to explain why clinicians made their choices, but to observe what the 
choices were and assess their impact on the value of the test information.  Questions regarding 
the reason for choices, or the next course of action, might be added in future studies to focus on 
the question of continuing a path for patients when guidelines suggest an opposite action.   
      Repeat testing levels were high, and not surprisingly, most predominately high near the 
decision threshold.  Repeat test rates were not influenced by the presentation of imprecision 
information or the order in which that information was seen.  The Repeat test option was 8.2% of 
all first question responses and 8.5% of all second question responses, indicating that the second 
presentation of results did not fulfill the role of a repeat test for respondents.  If the second 
viewing did fulfill this role, the repeat rate would be expected to be less for the second response. 
     The impact that the HCV VL level had on the actual decisions was anticipated.  The 
therapeutic management of HCV patients hinges on HCV VL testing.  The fact that the 
presentation of CIs had no statistically significant impact on the responses was unexpected, 
especially considering the studies discussed earlier that demonstrated clinicians’ difficulty with 
more complex laboratory data (Bachmann et al., 2003; Bramwell et al., 2006; Cahan et al., 2003; 
Ghosh & Ghosh, 2004; Heller et al., 2004).  The findings in this work could be attributed to 
several factors. 
     The targeted population was one of hepatology specialists; and the returned surveys were 
from the AASLD members, which may account for the strong knowledge of, and intended 
adherence to the treatment guidelines.  It was appropriate to survey this group however, as it 
represents the community of specialists primarily managing HCV disease.  Experienced 
clinicians using quantitative HCV RNA tests in the management of their patients have worked 
with quantitative HCV RNA tests as they have evolved, and the discussions surrounding the 
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relative imprecision in HCV VL testing have been active among them.  An inherent knowledge 
of the test imprecision and having to make treatment decisions while considering the variance in 
test methods and in individual laboratories may already exist.  The presentation of results with 
CIs in the survey may have served to substantiate this knowledge.  It was notable, though, that 
the greatest difference in decisions made with and without CI was for those clinicians that had 
made decisions without CI first and then were presented with CI at the HCV VL level of 560 
IU/ml, which is very near the decision threshold.  If the presentation of CIs with a result that is 
near a threshold impacts this experienced and specialized group, surveying a sample of non-
specialists with a relevant diagnostic/ therapeutic combination could possibly demonstrate 
greater differences in dealing with the presentation of imprecision.   
     The CIs defining the imprecision in this study were conservative, particularly at the lower 
levels where imprecision is greatest in quantitative viral load assays.  Table 2 described 
published studies with these relative values.  The CIs presented with the HCV VL results in the 
in the survey may have illustrated an optimal situation.  A larger imprecision range might have 
produced different findings.  In addition, the decision threshold for telaprevir is 1000 IU/ml, 
which is 40 times the limit of detection for quantitative HCV RNA assays used for these 
decisions and comfortably within a reproducible part of the reportable range.  Another protease 
inhibitor (boceprevir), used in a similar manner with interferon and ribavirin, has a decision 
threshold of 100 IU/ml (Ghany et al., 2011).  The imprecision at this point would be expected to 
be much larger, and in some cases cross the lower limits of detection for the tests.  Surveying 
clinicians using this decision threshold and associated imprecision characteristics may also have 
produced greater differences between groups seeing the results with CI and those seeing results 
without them, particularly at the threshold. 
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     An interesting finding was the frequent choice of the decision to repeat the test.  Respondents 
chose the decision to repeat at all HCV VL levels except the highest (31,620 IU/ml).  The Repeat 
test decision was 17.5% of all decisions.  The decision to repeat tests at the threshold of 1000 
IU/ml and the two immediately flanking levels (560 and 1950 IU/ml) was 19.8% of all decisions, 
and at the decision threshold (1000 IU/ml) it was 36.1% of all decisions.  At these three HCV VL 
levels, the decision to repeat was 2-6% higher when the results were presented with CIs.  The 
presentation of CIs had a consistent and small, but non-statistically significant impact. 
     Though there were no statistically significant associations with the decision to repeat the 
HCV RNA test, the frequency of this decision among respondents is an important consideration.  
The Repeat test decision had little impact on the economic value of the test; however, indications 
for repeat testing are not part of the labeling for quantitative HCV RNA tests, the therapeutics for 
which they are companions, nor is repeat testing considered in the guidance documents.  The 
inherent imprecision of the quantitative HCV RNA test is already a factor in the establishment of 
decision thresholds by means of the therapeutic clinical trials; at least for the specific test used in 
those trials.  As such, a repeat test may be considered medically unnecessary by reimbursement 
policy makers; and the patient or the institution may be required to bear the cost when the 
clinician makes this decision.  Adding information about the imprecision of the test to the result, 
which, in this study, was demonstrated to increase repeat testing behavior, may have 
economically adverse consequences.   
     Repeat testing is not uncommon in clinical laboratory medicine, within the laboratory and at 
clinicians’ requests.  Several publications discuss the reasons for and the implications of this 
practice (Deetz, Nolan, & Scott, 2012; Hawkins, 2005; van Walraven et al., 2003).  However, the 
tests studied in these publications were typically chemistry and hematology tests, which have 
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lower cost, turn-around time and resource impact than molecular tests for viral load.  As tests 
with more expensive technology, time and resource impact are implemented, examining this 
tendency further or outlining in guidelines where repeat testing is appropriate may be necessary. 
     The manner in which the imprecision information was presented to the clinicians may also 
have had an impact on their decisions.  In this survey, the imprecision information was presented 
numerically and consistent with the visual format of the test result.  No additional explanation 
accompanied the 95% CI range.  Presentation in words, graphically, or with interpretive 
language may have led to different decisions.  An explanation of how to apply the imprecision 
information or a graphical representation of the odds of the value crossing the decision threshold 
might have had an impact on the Repeat test decisions or those decisions that were inconsistent 
with the clinical guideline recommendations.  Bachmann and colleagues noted that among the 
different presentation of results they provided to their participants, the most effective way of 
presenting complex laboratory information was with an explanatory statement of the odds of the 
patient having the disease in question (2003). 
     Limitations of the survey research.  Assessing the impact of a laboratory test in a healthcare 
setting necessitates the mitigation of as many variables as possible.  One way to accomplish this 
is to choose a clinical path where a specific decision employs a prescribed laboratory test, and 
then use that in a setting with a single patient.  The scenario chosen for this research was based 
on professional guidelines of treatment and assessment; and the description of the simulated 
patient was intended to present one with an average burden of therapeutic-associated adverse 
events.  However, a single patient scenario in one specific clinical path limits the ability to 
generalize the findings, or to assess if the bias towards patient types exists among respondents. 
Since patient-treatment biases were not the focus of this research, the single simulated patient 
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scenario provided the opportunity to hold a greater number of variables constant to assess the 
effect of the HCV RNA test variables and interpretation.  The situation presented in this study 
may have a seemingly narrow focus, but the approach used can serve as a basis for research 
questions in other disease management areas, or for other questions regarding viral disease 
management.  
     There are no publicly available, validated instruments measuring clinicians’ experiences with 
test result imprecision.  The survey, through which the hypotheses in this study were tested, was 
developed specifically for this work.  The questions presented were designed to be consistent 
with standard practice guidelines and the HCV VL numbers and imprecision budget used for the 
test results were calculated using published studies and recommendations of minimum 
performance standards by expert groups.  Patient management for HCV disease is evolving 
quickly.  Even during the development phase of this research, the treatment protocols changed 
affecting the patient scenario and the survey design (Ghany, et al., 2009; Ghany et al., 2011).  
However the reliance on the clinicians’ interpretations of quantitative HCV RNA results as a 
critical component of the therapeutic management of the patient remained constant and will 
continue to be used for this purpose for the foreseeable future. 
     Relying on a survey as a surrogate for clinicians’ decision also has limitations.  It is possible 
that the participants chose their answers according to how they believed they should answer.  A 
survey cannot represent the full complexity of the authentic medical situation.  Further, there are 
no consequences for a wrong decision.  A more robust way of gathering data would be to review 
patient records.  The HCV VL result and the continuance or removal of therapy would be 
apparent information in the patient record, and easily extractable.  However, a multi-site or 
multi-system study would have to be done in order to access a significant number of clinicians.  
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Patients would have to be matched by disease severity, viral load, adverse events and 
demographics.  A small study to verify or dispute the findings in this study may be justified but 
the larger one may not be a priority until the use of electronic health records across systems is 
more established and easily accessed by legitimate researchers.  
Discussion of Economic Model Findings and Implications 
      A Markov decision-tree model was developed to determine the value of the HCV VL test 
information.  Transition probabilities, costs, and QoL values for health states were populated 
from published literature.  Clinicians’ actual use of the HCV VL information was represented by 
the survey data and used as inputs to the model.  The definition of value for this study was the 
potential average differences in costs per patient obtained by removing non-responders from 
inappropriate therapy.  This would result in potential savings that could be attributed to having 
the HCV VL information.  The HCV VL test information contributes to an average of over 
$2600 in cost savings in a model population of HCV patients, with savings up to $17,000 at 
higher HCV VL levels.  Presentation of CI with the HCV VL results showed a slight decrease in 
the value, as decisions made after reviewing HCV VL with CIs resulted in greater costs than 
guideline-directed decisions made without CIs.  
    Though cost savings of $2,600 to $17,000 may be considered small compared to other health 
economic analyses, when the investment made to facilitate those savings ($58.88 Medicare 
reimbursement rate) is considered, the HCV VL test in the clinical scenario used for this research 
was determined to be economically effective.  Even when the cost of the test was mathematically 
increased to nearly $1200, there was little impact to its value in the model.  The optimal value 
does depend on realizing cost savings through the proper use of the test in patient management.  
It was shown that when decisions were made according to guidelines, the test was most cost 
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effective.  This type of analysis might help demonstrate the importance of investing in programs 
to assure that clinicians interpret and use testing information properly, in addition to the efforts 
spent in the technical considerations of choosing an assay.   
     Limitations of the health economic research.  Mathematical models have advantages as 
well as limitations, and are as robust as the assumptions and data built into them.  The costs, 
disease state transitions, and QoL values in the model developed for this research were sourced 
from a rich literature base and conservative choices were made.  The sensitivity of the model 
outputs to costs was demonstrated; higher or lower treatment or disease associated costs will 
have an impact on the outcome of test value.  With the small investment needed for the current 
HCV laboratory test though, its relative value prevails.  For HCV VL testing at the 12-week 
decision point, testing costs up to $2600 would still realize a net savings, using the assumptions 
made in this model. 
     A limitation of the decision analytic model developed for this study was seen at the lower VL 
levels.  Adverse outcomes for inappropriately choosing to remove a patient from therapy exist 
due to the patient’s disease progression.  However, the full costs of these adverse outcomes could 
not be assessed in this study due to the short time horizon of the model.  Discontinuing 24 weeks 
of therapy for an individual would “save” approximately $11,400 for approximately the first 
half-year; however, depending on the rate of disease progression due to therapy discontinuance, 
the next four-and-a-half years would incur six month costs of $3090 to $42,600.  Liver 
transplant, which could happen after this time period, and which would add considerable cost 
was not included in the model.  Since the proportion of patients that progress through the more 
expensive stages of hepatitis C is small, and those costs do not always outweigh the treatment 
savings in the short run, QoL ratios were also evaluated.  To assess a quality of life penalty, QoL 
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values were calculated at each health state and for some inputs having a greater proportion of 
decisions to discontinue therapy than was appropriate, the QoL value did decrease.  However the 
decrease in QoL was less than 2%.  Again, the measurable change in health state in 60 months 
for the majority of patients is subtle.  Attempts to build economic models to appropriately 
address the scope of influence of diagnostic tests would benefit from inter-disciplinary 
discussions among laboratory professionals, health economists, clinicians and policy makers.  
     The costs of producing and implementing laboratory reports with CIs on each result were not 
considered.  It was assumed that they would be minimal in relation to the overall costs of the 
treatments and disease management.  However they could be significant with respect to the 
current cost of generating a billable laboratory result.  Costs to be considered are: the cost of 
performing studies to determine the imprecision of the results within the laboratory, changes to 
the laboratory information systems which generate the reports, education and training of 
clinicians, and of laboratory staff to answer clinicians’ questions.  The value of the information 
in the population of HCV patients was calculated to be an average of $2600 per patient.  The cost 
of implementing CIs, as well as the true costs of performing the test (instead of the Medicare 
reimbursement used in this study), could be used to determine the cost/benefit of including CIs 
with laboratory test results for HCV VL. 
Conclusions and Recommendations for Future Research 
     The results of this research led to the following conclusions: 
 The presentation of test imprecision with HCV VL results had little impact on clinicians’ 
treatment management choices at the 12-week decision point for HCV patients. 
 There was a high percent of repeat testing as the HCV VL test result neared the decision 
threshold.  Presentation of imprecision information did not influence this rate. 
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 When treatment management decisions changed from viewing results with and without 
CIs, they were most often associated with not having imprecision information first, 
followed by seeing results with imprecision information. 
 Most clinicians surveyed preferred not to have imprecision information presented with 
HCV VL test results. 
 The monetary value of HCV VL information at the 12 week decision point for triple 
combination therapy could be calculated through a decision analytic model. The 
monetary value of the test information prevailed despite knowledge of imprecision and 
high rates of repeat testing. 
     Recommendations for future research in the context of these conclusions are discussed below. 
    The responses to the survey showed that the presentation of test imprecision with the HCV VL 
results had little impact on the clinicians’ treatment management choices.  As noted, this was 
unexpected and inconsistent with predictions modeled by laboratory professionals (Pisani et al., 
2009).  The high percent of the Repeat test choice, though not entirely unexpected, was also 
notable.  Since many clinical path recommendations are developed without reference to test 
specifications, and the conditions for repeat testing are not usually discussed, these findings 
underscore the importance of conducting research in the interpretation and employment of 
laboratory test results by the actual users of the information. 
     The clinicians surveyed in this study were an elite group of specialists.  By the number of 
years in practice, it can be assumed that their professional experience had developed with the 
development of the quantitative molecular HCV RNA tests.  Their responses provide a 
benchmark for appropriate interpretation and use of complex quantitative test information.  
Laboratory test results, however, are available to and used by many types of providers: general 
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practice physicians, nurses, pharmacists, other non-provider professionals and patients.  
Coincidently, with the advances in research and technology, laboratory test information is 
becoming more complex.    
     Future research in test interpretation and clinical use should study test results for complex 
specialty areas, which highly impact medical decisions and are used by non-specialists.  A 
relevant example is cardiac marker testing to determine and predict myocardial events.  
Mathematical models demonstrating the impact of test imprecision on those decisions have been 
performed and the recommendations of useable assays include a tolerance for imprecision (Wu 
& Christensen, 2013).  However, the determination of a cardiac event is not always made by a 
specialist who is familiar with the latest studies in this field regarding the biological variation 
and assay imprecision of standard and ultra sensitive tests.  Research presenting emergency 
department physicians with results of these tests that include their imprecision could illustrate the 
impact of this additional information on high risk, high impact decisions.  Another example is 
quantitative CMV testing for transplant patients.  In this case, specialists from different fields 
(transplantation and infectious diseases) use quantitative CMV VL to discriminate between graft 
rejection, infection, clearance of infection or viral resistance (Bienek, Kirby, Cheng, 
Eichelberger, & Qian, 2011; Perrottet et al., 2010).  CMV VL results inform very different 
management strategies for each of these indications.  Research on the clarity of the result at the 
decision point considering the test imprecision could help refine the precision specifications 
needed for these tests.  A third area is in disease prediction tests, which are being used to 
persuade patients to make behavioral and lifestyle changes to avert them.  Research in the 
interpretation, use and the actual impact of that information on the intended outcome is critically 
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important in the current heath care environment where resource prioritization must be supported 
by data. 
     Clinicians’ knowledge and use of imprecision information is also an important topic for 
developing clinical laboratory policy.  Laboratory guidelines exist that articulate the 
determination and reporting of imprecision with laboratory test results (CLSI C51A, 2011& IS0, 
2012).  In this study, it was shown that most changed decisions occurred when respondents 
viewed results with imprecision after having viewed the same results without it.  Further, the 
most frequent response to the question of whether or not respondents wanted imprecision 
information with laboratory test results was negative.  It is currently mandated that test 
imprecision information be available on request, and it is anticipated that future guidance will 
require it.  Standardization of how it is to be calculated and portrayed; and an understanding of 
how users of the information will respond have not been studied.  Further research to help guide 
policy in this area is warranted. 
     Another area for future research is in methods development for the value of laboratory test 
information analyses.  The value of the HCV VL test information at the 12-week decision point 
for triple combination therapy was determined through a decision analytic model evaluating the 
monetary value of the information provided for that specific decision.  Typically, health 
economic analyses examine the extension of life or increased quality of life facilitated though 
service or therapeutic interventions where incremental cost effectiveness ratios are measured and 
compared.  When applied to evaluate diagnostic tests, these methods presume that the primary 
intended use of the diagnostic test is to extend life and quality.  While those are the ultimate 
outcomes, evaluating diagnostic information in this manner and comparing its contribution to 
interventions and services with direct impact on them, can obscure the primary contribution of 
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the diagnostic test.  Examining the value of the test information that directs a decision along that 
ultimate path may more clearly represent the contribution of the laboratory test.  The analysis 
presented in this study demonstrated this strategy and is one way the value of the test result could 
be calculated.  Development of the decision analytic model revealed several issues to be 
considered such as: the required complexity of the model, the aspects of the outcome to be 
measured, the appropriate time horizon of the model, the representation of actual decisions made 
by users, and the impact of decisions made as a result of incorrect results.     
     The value of information is a concept already gaining use in clinical trial decisions for 
extending or truncating arms of trials, determining the value of additional research, and adding 
different indications (Meltzer, Hoomans, Chung, & Basu, 2011).  Though the value of 
information in a decision path can be calculated, it has not been used as a tool to measure or 
compare laboratory tests as was presented here.  The field of companion diagnostics is growing, 
where more laboratory tests will have direct roles in deciding treatment paths.  Further 
development and consideration of this type of analysis will be useful to guide investment in the 
diagnostic tests that will be necessary to realize personalized medicine.  Interdisciplinary work is 
critical to define the acceptable perspective and scope of economic analyses specifically relevant 
to clinical laboratory diagnostics.  Information derived from such analyses may help support 
policy decisions needed to make available those diagnostics for which clinical and economic 
utility can be demonstrated. 
     The predicted economic burden of HCV disease has catalyzed a strong pipeline of HCV 
therapeutics currently in trials (Cox, 2013).  Health economic literature on the cost effectiveness 
of new therapeutics is now available shortly after their approval for use (Camma et al., 2012).  
However, there are no economic analyses for the laboratory tests which are integral to the 
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clinical trials and which determine the efficacy of the drugs; the same tests that will be used to 
triage patients to therapies and manage their therapy for response, compliance and drug 
resistance.  As new therapies in hepatitis C and hepatitis B are developed, the viral load assays 
will be critical in assessing outcomes and then managing patients.  Knowing the technical 
limitations of the assays only answers part of the question of their clinical utility.  Whether or not 
clinicians accurately account for those technical limitations when using the information is also 
important.  To be able to communicate the value that those assays bring to patient management 
decisions will also help secure development support and future access to these tests for the 
patients who need them. 
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Appendix A: HCV VL Survey  
 
 
 
Text of Survey: HCV-1 Triple Combination Therapy- Incivek. 
 
Consent 
 
We are conducting a study of laboratory tests and their impact on medical decisions. If you are 
willing to participate, we would like you to complete a brief, confidential survey.  The principal 
investigator on this survey is William Korzun, PhD, Associate Professor, Department of Clinical 
Laboratory Sciences, Virginia Commonwealth University. 
 
Time Required: We expect the survey will take less than 10 minutes. 
 
Risks: This is a confidential, individual based survey. There are no reasonably foreseeable risks 
or discomforts involved in taking part in this survey. 
 
Compensation: There is no compensation for completing this survey.  However if you would like 
a summary of the results, please send a separate email with the title “HCV Survey Summary” to 
madejrm@mymail.vcu.edu. A summary will be sent to you in 2013. 
 
Confidentiality: Your responses are anonymous and you cannot be identified.  Individual 
responses to the survey questions will be kept confidential, and the output of the study will be 
based on aggregation of the data collected from participants. 
 
Participation: In the event you choose not to participate, you will not be penalized. 
 
Study contact for questions: If you have questions, concerns, or complaints, please feel free to 
email Dr. William Korzun: 
 
WJKORZUN@VCU.EDU or Roberta Madej at madejrm@mymail.vcu.edu. 
 
If you have any questions about your rights as a participant in this study, you may contact: 
Office for Research 
Virginia Commonwealth University 
800 East Leigh Street, Suite 113 
P.O. Box 980568 
Richmond, VA 23298 
To proceed with the survey please, choose “I consent and agree to participate”. If you do not 
wish to take the survey, please choose “I do not wish to take this survey”. 
Thank you for your time. 
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Please choose one of the following: 
 
○ I consent and agree to participate 
 
○ I do not wish to take this survey 
 
Introduction: HCV Triple Combination Therapy with Incivek (Telaprevir) 
 
Welcome to the Survey. Thank you for your participation. There are no correct or incorrect 
answers. The best estimate of what your decision would be in the following scenario is 
requested. 
 
The purpose of this survey is to evaluate responses to quantitative lab test results presented in 
different ways by the clinical laboratory, using quantitative HCV RNA (HCV viral load) as a 
model. You will be presented with a description of a patient followed by laboratory results and 
will be asked to choose the responses closest to what your decisions would be for each result 
presented. The results will be presented to you twice – each in a different way. 
 
The decision for this “patient” is the treatment management decision made at Treatment Week 
(TW) 12 for patients with HCV genotype 1 disease who have been on triple combination therapy 
with Incivek (telaprevir), peginterferon alpha and ribavirin therapy.  According to the AASLD 
guidelines published in October 2011, the recommended course is to treat with the three drugs 
for 12 weeks, then to continue with peginterferon alfa and ribavirin for an additional 12- 36 
weeks, or discontinue all therapy. Important to this decision are the results of quantitative HCV 
Viral Load (HCV VL) testing at TW 12. 
 
At the 12week decision point, the AASLD guidelines recommend the following: 
 
“Patients without cirrhosis treated with telaprevir, peginterferon, and ribavirin, whose HCV RNA 
level at weeks 4 and 12 is undetectable should be considered for a shortened duration of therapy 
of 24 weeks (Class 2a, Level A). 
Treatment with all three drugs (telaprevir, peginterferon alfa, and ribavirin) should be stopped if 
the HCV RNA level is >1,000 IU/mL {3Log10 IU/ml} at treatment weeks 4 or 12 and/or 
detectable at treatment week 24 (Class 2a, Level B).” 
 
Ghany et al. (2011) Hepatology, 54, 1433-1444. 
 
Description of case and results – Integers 
 
Patient: middle aged with chronic HCV genotype 1a. No cirrhosis. 
Your previously untreated (for HCV) patient has been on triple combination therapy for 12 
weeks with: Incivek (telaprevir) 750mg three times a day, together with peg interferon alfa 
weekly and weight based ribavirin. Over the 12 weeks your patient has experienced the 
following side effects: nausea, moderate to severe fatigue, joint and muscle aches, irritability and 
headaches. Hemoglobin has gone from 12.3 to 9.1 gm/dl. The patient is employed fulltime and 
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has missed approximately 10 days of work in the last 12 weeks due to the fatigue, nausea and 
headaches. 
 
     You are reviewing the Treatment Week 12 HCV viral load results in order to make a 
decision regarding the continuing management of this patient. The quantitative HCV RNA 
test result for this patient performed before the start of therapy (week zero, baseline) was 
560,000 IU/ml. 
 
     Consider each of the following 12 week HCV RNA results individually with regards to 
this patient. For each, please indicate what your most likely decision would be regarding 
this patient’s therapy? 
 
 
 Continue Rx with 
dual therapy 
Discontinue Rx Repeat the HCV viral 
load test 
 
31,620 IU/ml ○ ○ ○ 
1,950 IU/ml  ○ ○ ○ 
1,000 IU/ml ○ ○ ○ 
560 IU/ml ○ ○ ○ 
100 IU/ml ○ ○ ○ 
 
 
Description of case and results – Integers with CI 
 
Patient: middle aged with chronic HCV genotype 1a. No cirrhosis. 
Your previously untreated (for HCV) patient has been on triple combination therapy for 12 
weeks with: Incivek (telaprevir) 750mg three times a day, together with peg interferon alfa 
weekly and weight based ribavirin. Over the 12 weeks your patient has experienced the 
following side effects: nausea, moderate to severe fatigue, joint and muscle aches, irritability and 
headaches. Hemoglobin has gone from 12.3 to 9.1 gm/dl. The patient is employed fulltime and 
has missed approximately 10 days of work in the last 12 weeks due to the fatigue, nausea and 
headaches. 
 
     You are reviewing the Treatment Week 12 HCV viral load results in order to make a 
decision regarding the continuing management of this patient. The quantitative HCV RNA 
test result for this patient performed before the start of therapy (week zero, baseline) was 
560,000 IU/ml (95% CI: 286,000 - 1,107,000 IU/ml). 
 
     Consider each of the following 12 week HCV RNA results individually with regards to 
this patient. For each, please indicate what your most likely decision would be regarding 
this patient’s therapy? 
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 Continue Rx with 
dual therapy 
Discontinue Rx Repeat the HCV 
viral load test 
 
31,620 IU/ml (95% CI: 16,060 
-  62,230 
IU/ml) 
○ ○ ○ 
1,950 IU/ml (95% CI: 990 - 
3,800 IU/ml) 
○ ○ ○ 
1,000 IU/ml (95% CI: 510 - 
1,970 IU/ml) 
○ ○ ○ 
560 IU/ml (95% CI: 290 - 
1,110 
IU/ml) 
○ ○ ○ 
100 IU/ml  (95% CI: 50 – 200 
IU/ml) 
○ ○ ○ 
 
Question regarding the utility of the test results with CI 
 
      One set of test results you reviewed contained the measurement uncertainty of the 
result expressed as the 95% confidence interval (CI). The test results with the 95% 
confidence intervals: 
 
○ Provided relevant added information to the test result.  
 
○ Detracted from or confused the test result. 
 
○ Neither added to nor detracted from the test result.  
 
Participant demographics 
 
Please answer the following questions regarding your professional demographics and practice. 
 
Where do you currently practice/ work? 
 
○ Africa 
 
○ Australia/ New Zealand 
 
○ Canada 
 
○ Europe  
 
○ Latin America/ South America 
 
○ United States 
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Do you manage the treatment of Hepatitis C patients? 
 
○ Yes 
 
○ No 
 
 
HCV patient managing professionals (For those choosing “Yes” to the  question “Do you 
manage the treatment of HCV patients?) 
 
Which of the following best describes your profession? 
 
○ Physician 
 
○ Physician Assistant 
 
○ Nurse Practitioner 
 
○ Nurse 
 
○ Other (please specify) 
 
How many YEARS have you been practicing medicine? _____ 
 
Approximately how many Hepatitis C patients do you see per MONTH?  _____ 
 
Which most appropriately describes your practice field? 
 
○ General Medicine 
 
○ Internal Medicine 
 
○ Infectious Diseases 
 
○ Hepatology 
 
○ Gastroenterology 
 
○ Urology 
 
○ Pathology 
 
○ Family Medicine 
 
○ Pediatrics 
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○ Oncology 
 
○ Other (please specify) 
 
 
Please select the guidelines that you use when managing Hepatitis C patients (select 
all that apply): 
 
○ American Association for the Study of Liver Diseases (AASLD) 
 
○ American College of Gastroenterology (ACG) 
 
○ American Gastroenterological Association (AGA) 
 
○ CDC 
 
○ EASL 
 
○ Information from the pharmaceutical company 
 
○ Institutional guidelines 
 
○ Other (please specify) 
 
 
Would you like to receive the 95% confidence intervals of laboratory values reported with 
patient results? 
 
○ Yes 
 
○ No 
 
○ I already receive 95% confidence intervals from my testing laboratory 
 
○ I don’t know 
 
Do you use quantitative HCV RNA test results (HCV viral load tests) in the treatment 
management of your patients with Hepatitis C? 
 
○ Yes 
 
○ No 
(For “No”) Why not? ___ 
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( For “Yes” to the use of quantitative HCV RNA results) Do you send patients / samples to the 
same testing laboratory for the pretreatment and 12 week quantitative HCV RNA ? 
 
○ Sometimes, 
 
○ Most of the time, 
 
○ Not at all 
 
○ It is not within my control 
 
 
( For “Yes” to the use of quantitative HCV RNA results)   Do you specify that the identical test 
method be used for the pretreatment and 12 week quantitative HCV RNA tests? 
 
○ Sometimes, 
 
○ Most of the time, 
 
○ Not at all 
 
○ It is not within my control 
 
 
( For “Yes” to the use of quantitative HCV RNA results) Please choose the type of HCV viral 
load results that are closest to the test results you receive from your testing laboratory: 
 
○ Integers (i.e. 1,000,000 IU/ml) 
 
○ Log10 (i.e. 6.0 Log10 IU/ml) 
 
○ Both integers and Log10 values are provided 
 
○ I am not sure 
 
 
Non HCV Managing professionals (For those choosing “No” to the question, “Do you manage 
the treatment of HCV patients?) 
 
Which of the following best describes your profession? 
 
○ Physician 
 
○ Pathologist 
 
○ Non-Pathologist Laboratory Director 
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○ Laboratory Professional (Non Pathologist/ Non Director) 
 
○ Pharmacist 
 
○ Other (please specify) 
 
 
     Thank you for the time that you have spent in taking this survey. If you would like a copy of 
the results please send a separate email with the title “HCV Survey Summary” to 
madejrm@mymail.vcu.edu. 
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